Обзоры, лекции
Reviews, Lectures

Фармакогнозия, ботаника
Pharmacognosy, Botany

Фармацевтическая технология
и биотехнология
Pharmaceutical Technology
and Biotechnology

Фармацевтическая
и токсикологическая химия
Pharmaceutical and Toxicological
Chemistry

Фармакология и клиническая
фармакология
Pharmacology and Clinical
Pharmacology

Информационные технологии
в фармации
Information Technologies in Pharmacy

Организация и экономика
фармацевтического дела
Organization and Economy
of Pharmacy

Экономика и менеджмент
медицины
Economy and Management
of Medicine

Фармацевтическое образование
Pharmaceutical Education

Дискуссии, рецензии, юбилеи,
научные школы, история
фармации и фармакологии
Discussions, Referee Reports,
Anniversaries, Schools
of Thought, History
of Pharmacy and
Pharmacology

CONTENS / СОДЕРЖАНИЕ

REVIEWS / ОБЗОРЫ

RESEARCH ARTICLE / ОРИГИНАЛЬНЫЕ СТАТЬИ

Organization and Economy of Pharmacy / Организация и экономика фармацевтического дела

Pharmacology and Clinical Pharmacology / Фармакология и клиническая фармакология

MOLECULAR MECHANISMS DEFINING APPLICATION OF GLYCINE AND ZINC COMBINATION IN CORRECTION OF STRESS AND ANXIETY MAIN MANIFESTATIONS

V.N. Shishkova[1,2], Y.R. Nartsissov[3,4], V.Y. Titova[3], E.V. Sheshegova[3]

[1] National Medical Research Center for Therapy and Preventive Medicine,
Bld. 3, 10, Petroverigsky Ln., Moscow, Russia, 101000

[2] Evdokimov Moscow State Medical and Dental University,
Bld. 1, 20, Delegatskaya St., Moscow, Russia, 127473

[3] Institute of Cytochemistry and Molecular Pharmacology,
Bldg 14, 24, 6th Radial'naya St., Moscow, Russia, 115404

[4] Biomedical Research Group, BiDiPharma GmbH,
5, Bültbek, Siek, Germany, 22962

E-mail: yarosl@biotic.dol.ru

The aim of the work was to carry out a systematic analysis of the molecular mechanisms that determine the possibility of a combined use of amino acid glycine and zinc compounds for the treatment of patients with manifestations of stress and anxiety.

Materials and methods. Information retrieval (Scopus, PubMed) and library (eLibrary) databases were used as research tools. In some cases, the ResearchGate application was applied for a semantic search. The analysis and generalization of references was carried out on the research topic, covering the period from 2000 to the present time.

Results. It has been shown that amino acid glycine, along with gamma-aminobutyric acid (GABA), is a key neurotransmitter that regulates physiological inhibition processes in the central nervous system (CNS) by increasing transmembrane conductance in specific pentameric ligand-gated ion channels. The introduction of zinc ions can potentiate the opening of these receptors by increasing their affinity for glycine, resulting in an inhibitory processes increase in CNS neurons. The replenishment of the glycine and zinc combined deficiency is an important element in the correction of a post-stress dysfunction of the central nervous system. A balanced intake of zinc and glycine is essential for most people who experience daily effects of multiple stresses and anxiety. This combination is especially useful for the people experiencing a state of chronic psycho-emotional stress and maladaptation, including those who have a difficulty in falling asleep.

Conclusion. A balanced maintenance of the zinc and glycine concentration in the body of a healthy person leads to the development of a stable anti-anxiety effect, which is accompanied by the normalization of the sleep-wake rhythm, which makes it possible to have a good rest without any loss of working efficiency after waking up.

Keywords: glycine; zinc; anxiolytic agents; brake action; anxiety states

Abbreviations: GABA – gamma-aminobutyric acid; pLGICs – pentameric ligand-gated ion channels; CNS – central nervous system; GlyR – glycine receptor; MT – metallothioneins; ROS – reactive oxygen species; RNS – reactive nitrogen species; SHMT – serine hydroxymethyltransferase; GCS – glycine cleavage system; VIAAT – vesicular inhibitory amino acid transporter; BBB – blood-brain barrier.

МОЛЕКУЛЯРНЫЕ МЕХАНИЗМЫ, ОПРЕДЕЛЯЮЩИЕ ПРИМЕНЕНИЕ КОМБИНАЦИИ ГЛИЦИНА И ЦИНКА В КОРРЕКЦИИ ОСНОВНЫХ ПРОЯВЛЕНИЙ СТРЕССА И ТРЕВОГИ

В.Н. Шишкова[1,2]**, Я.Р. Нарциссов**[3,4]**, В.Ю. Титова**[3]**, Е.В. Шешегова**[3]

[1] Федеральное государственное бюджетное учреждение
«Национальный медицинский исследовательский центр терапии и профилактической медицины»
Министерства здравоохранения Российской Федерации,
101990, Россия, г. Москва, Петроверигский пер., д. 10, стр. 3

[2] Федеральное государственное бюджетное образовательное учреждение высшего образования
«Московский государственный медико-стоматологический университет имени А.И. Евдокимова»
Министерства здравоохранения Российской Федерации,
127437, Россия, г. Москва, ул. Делегатская, д. 20, стр. 1

[3] Научно-исследовательский институт цитохимии и молекулярной фармакологии,
115404, Россия, г. Москва, ул. 6-я Радиальная, д. 24, стр. 14

[4] Группа биомедицинских исследований (BiDiPharma GmbH),
22962, Германия, Зик, Бюльтбек, 5

E-mail: yarosl@biotic.dol.ru

Цель. Работа посвящена системному анализу молекулярных механизмов, определяющих возможность комбинированного использования аминокислоты глицин и соединений цинка для лечения пациентов с проявлениями стресса и тревоги.

Материалы и методы. В качестве инструментов проведения исследования использовались информационно-поисковые (Scopus, PubMed) и библиотечные (eLibrary) базы данных. В ряде случаев для семантического поиска использовалось приложение ResearchGate. В работе осуществлялся анализ и обобщение научной литературы по теме исследования, охватывающей период с 2000 по настоящее время.

Результаты. Показано, что аминокислота глицин, наравне с гамма-аминомасляной кислотой (ГАМК) является ключевым нейромедиатором, регулирующим процессы физиологического торможения в центральной нервной системы (ЦНС) путем увеличения трансмембранной проводимости в специфических гетеропентамерных лигандзависимых хлорных каналах. Введение ионов цинка способно потенцировать открытие данных рецепторов путем увеличения их сродства к глицину, в результате чего происходит усиление процессов торможения в нейронах ЦНС. Восполнение сочетанного дефицита глицина и цинка является важным элементом коррекции постстрессорной дисфункции ЦНС. Сбалансированное потребление цинка и глицина имеет важное значение для большинства людей, ежедневно испытывающих последствия многочисленных стрессов и находящихся в тревожном состоянии. Особенно полезна данная комбинация для лиц, испытывающих состояние хронического психоэмоционального напряжения и дезадаптации, в том числе имеющих сложности с засыпанием.

Заключение. Сбалансированное поддержание концентрации цинка и глицина в организме здорового человека приводит к развитию стойкого противотревожного эффекта, который сопровождается нормализацией ритма сон-бодрствование, что дает возможность полноценного отдыха без потерь работоспособности после пробуждения.

Ключевые слова: глицин; цинк; анксиолитические средства; торможение; тревожные состояния

Список сокращений: ГАМК – гамма-аминомасляная кислота; pLGICs – гетеропентомерные лиганд-зависимые хлорные каналы; ЦНС – центральная нервная система; GlyR – глициновый рецептор; МТ – металлотонеины; ROS – реактивные формы кислорода; RNS – реактивные формы азота; SHMT – серин гидроксиметилтрансфераза; GCS – митохондриальная система расщепления глицина; VIAAT (vesicular inhibitory amino acid transporter) – везикулярный переносчик тормозных аминокислот; ГЭБ – гематоэнцефалический барьер.

INTRODUCTION

A negative impact of stress and anxiety is experienced by an increasing number of people in the modern world, regardless of age and gender [1]. It is known that stress is also called a state of acute or chronic psycho-emotional tension. It should be also notified that anxiety disorders are significant psychosocial risk factors for the development of many chronic noncommunicable diseases [2]. Taking into account the growing need for timely therapy and prevention of disorders associated with the development of stress and anxiety, the search and development of safe and effective means for their correction are becoming increasingly important.

Treatment regimens for anxiety states of various

origins are based on the use of a number of anxiolytic psychotropic drugs [3]. The molecular mechanism of their anti-anxiety action is based on a long-term increase in the activity of subclass A gamma-aminobutyric acid (GABA) receptors [4]. This class of membrane receptors responsible for the inhibition in neurons belongs to the family of pentameric ligand-gated ion channels (pLGICs) [5, 6]. The interaction of the agonist with the receptor, leading to the opening of a selective anion channel on the surface of the excitable membrane, leads to an increase in the Cl⁻ flux, which causes hyperpolarization of the neuron [7]. This activation of the transmembrane anionic current through the GABA receptors makes it possible to consider GABA as the main inhibitory neurotransmitter in the central nervous system (CNS) in the classical approach to neurophysiological processes [8]. Along with this, the second most physiologically important mediator that causes inhibition in the neurons of the spinal cord and brainstem is amino acid glycine [9]. This neurotransmitter, along with GABA, is present both in specific glycinergic and mixed synapses and is widely distributed in different parts of the brain. It also activates the transmembrane conductivity of chloride ions in the glycine receptor (GlyR), which belongs to the already mentioned pLGICs family [10, 11] (Fig. 1).

It is noteworthy that the structures of transmembrane proteins are isolated together with zinc ions, which are present in the analyzed recombinant proteins [12, 13]. Zinc belongs to the group of the most significant trace elements in the body along with iron, magnesium, and iodine. A decrease in the content of this divalent cation leads to significant problems for patients in both developing and developed countries [14, 15].

Zinc is the second most common micronutrient in the body after iron. On average, the body of an adult contains 2–3 grams of zinc [16]. In the body, it is distributed according to the skeletal type – 63% in the skeletal muscles, 22% in the skeletal system. The maximum concentration of zinc is also observed in the muscles and bones, as well as in the prostate gland in men. The concentration of zinc in the brain is estimated at 150 μmol/l, which, in turn, is 10 times higher than the content of zinc in blood serum [17]. Zinc is involved in all types of metabolism: it is assumed that it binds to about 3000 enzymes *in vivo*, which corresponds to about 10% of the human proteome [18]; regulates the cell stability and permeability and participates in membrane transport [19]; it has a pronounced immunomodulatory effect on hematopoiesis, osteogenesis, respiration processes and programmed cell death (apoptosis) [16, 20]. The role of Zn^{2+} as a neurotransmitter and modulator of the neurons state has been experimentally proven, since this ion is able to accumulate in presynaptic vesicles with a subsequent release into the synaptic cleft [21]. In addition, the level of zinc affects the susceptibility to learning and memory [22]. These results show that zinc ions, along with well-known neurotransmitters, can directly affect the state of neurons and participate in the regulation processes of CNS excitation and inhibition.

THE AIM of the work was to carry out a possible combined application of glycine and zinc compounds to change the metabolism and correct the conditions of patients with anxiety disorders and manifestations of stress.

MATERIALS AND METHODS

Information retrieval (Scopus, PubMed) and library (eLibrary) databases were used as research tools. In some cases, the ResearchGate application was used for a semantic search.

The analysis and synthesis of the scientific literature on the research topic, was carried out covering the period from 2000 to September 2022.

The following keywords and word combinations were used in the search: anxiety, anxiolytic properties, neuron metabolism, a synaptic cleft, inhibitory mediators, glycine metabolism, glycine receptor, GABA, GABA receptors, glycine transporters, chloride ion properties, chloride connectivity, zinc metabolism, tissue zinc levels, zinc levels, zinc transport, zinc effects, allosteric regulation, reactive oxygen species, antioxidant effects, metabolic levels of glycine, metabolic level of zinc, blood-brain barrier, vasodilatation, cerebral blood flow, anti-anxiety effects of glycine, glycine effects on stress, clinical trials of glycine.

Visualization of membrane receptors was carried out using the data from the Protein Data Bank (PDB) (https://www.rcsb.org/). To make up chemical formulas and illustrations, the libraries of the ACD/ChemSketch 2020.2.0 software package were used.

RESULTS AND DISCUSSION

A feature of the molecular mechanisms underlying the therapeutic effect of glycine and zinc ions on patients suffering from anxiety disorders is the combined effect of these metabolites on various biochemical and signaling systems. In fact, it is necessary to discuss a complex effect touching upon several systems at once.

In the context of accumulation and transformation, in neurons and other types of human cells, there are fundamental differences between glycine and zinc due to their chemical nature. Glycine is a non-essential amino acid that is actively involved in many metabolic processes, while Zn^{2+} is a part of the trace elements, the level of which is always regulated by an influx from an external source.

Processes of zinc transport and storage in human cells and tissues

In enterocytes of the small intestine, zinc buffer proteins determine the process of this ion transfer into the bloodstream. Further, Zn^{2+} is redistributed between albumin (the main zinc carrier, binds up to 80% in blood), α-microglobulin and transferrin [22, 24]. The protein content of food, as well as the condition of the mucosal layer of the small intestine, determine the absorption of zinc. Only 10% of zinc is excreted from the body with sweat and urine, the rest – with fecal masses [25].

Figure 1 – Pentamers activation of pLGICs family by CNS inhibitory neurotransmitters
Note: Structural images of membrane proteins are presented based on the Protein Data Bank (PDB) (https://www.rcsb.org) in parallel planes (GABA$_A$ receptor, 7PBZ, [12]; glycine receptor, 6VM3, [23]) and perpendicular (glycine receptor, 5VDI, [13]) plane of the membrane.

Figure 2 – Main ways of zinc ions transport and deposition in human cells
Note: Intracellular compartments are: endoplasmic reticulum (ZnT1, ZIP7), Golgi apparatus (ZnT5-7, ZIP13), endosomes (ZnT4), lysosomes (ZnT2), insulin granules (ZnT5, ZnT8) and synaptic vesicles (ZnT3).

Figure 3 – Schematic representation of glycinergic synapse

Note: A neurotransmitter release from synaptic vesicles is accompanied by a subsequent diffusion into the synaptic cleft and the activation of structured GlyR and gephyrin clusters on the postsynaptic membrane. The increasing concentration of chloride ions in the postsynaptic terminal is regulated by transport through the KCC2 transporter. Structural plasticity of the synapse is mediated by the interaction of α-neurexin (presynaptic membrane) and the neuroligin-2 complex with the structural network of gephyrin trimers in the postsynaptic terminal [43].

At the cellular level, 30–40% of zinc is localized in the nucleus, 50% in the cytoplasm and organelles, and the rest – in the cell membrane. Cellular zinc homeostasis is mediated by three main mechanisms [26]. First, this is transport across the plasma membrane by importer proteins from the ZIP and ZnT families (Fig. 2). Second, this is due to the sequestration mediated by the transporter into intracellular organelles, including endoplasmic reticulum, a Golgi complex and lysosomes. To maintain the cell viability, a strict control of zinc homeostasis is necessary, since dysregulation leads to the cell death. The third mechanism for maintaining homeostasis is the metallothionein/thionein system [18]. Metallothioneins (MTs) form complexes with about 20% of intracellular zinc. MTs are ubiquitous proteins characterized by a low molecular weight, a high cysteine content and the ability to form complexes with metal ions.

One MT molecule can bind up to seven zinc ions. Due to the different affinity of metal ion binding sites, Zn can act as a powerful cellular zinc buffer. Free and weakly bound zinc ions interact with the apoprotein thionein (T_{red}) to form MTs [27]. An increase in the level of free zinc ions triggers the transcription factor-1 (MTF), thus inducing the expression of thionein [18]. In addition, oxidation of thiols by reactive oxygen species (ROS) or nitrogen (RNS) triggers the formation of oxidized protein thionine (Tox) with a concomitant zinc release [28].

Since there is no zinc storage system in the body, its level in cells must be constantly maintained. Both vegetable (mushrooms, nuts, cereals, legumes) and animal (meat, liver, seafood, cheese) products can be used as sources to maintain the normal level of this ion [25, 29].

In accordance with the norms of physiological needs for energy and nutrients for various population groups in the Russian Federation (Methodological recommendations MP 2.3.1.0253-21), the recommended daily allowance is from 3 to 12 mg of zinc for children and 12 mg for adults. In the US, the daily allowance of zinc for men is 11 mg, for women – 8 mg. In Germany, it is 10 mg for men and 7 mg for women [26].

Glycine metabolism in human cells

As mentioned above, unlike zinc, amino acid glycine, being both a substrate and a product of enzymatic reactions, is actively involved in the metabolic processes

of human cells. In most cases, glycine is synthesized by serine hydroxymethyltransferase (SHMT), which uses serine supplied with food or obtained as a product of anabolic reactions from glucose and glutamate, as a substrate [30]. SHMT is a pyridoxal phosphate and a tetrahydrofolate dependent protein that is present in both the cytoplasm (SHMT1) and mitochondria (SHMT2), with the mitochondrial enzyme being more active [31]. Alternative metabolic pathways are the synthesis of glycine from threonine (with the participation of threonine aldolase and threonine dehydrogenase), choline (initiated by choline oxidase), and glyoxylate (catalyzed by alanine glyoxylate aminotransferase) [32, 33]. In general, the balance and dominance of these anabolic pathways is highly dependent on conditions, diet, and a body state. As catabolic reactions, one can consider the reversibility of the SHMT reaction, as well as the mitochondrial glycine cleavage system (GCS), which is a combination of four proteins (glycine decarboxylase (P-protein), aminomethyltransferase (T-protein), dihydrolipoamide dehydrogenase (L-protein) and a protein containing lipoic acid (H-protein) [34]. It should be notified that despite the complexity of the process, GCS is considered as a reversible system and its activity is unevenly distributed in human tissues: the glycine cleavage system is more represented in the liver and kidneys and, to a lesser extent, in the brain, testicles, and the small intestine [30].

Role of glycine as neurotransmitter in neurons

Synthesized glycine is pumped into vesicles *via* the vesicular inhibitory amino acid transporter (VIAAT), which is associated with the transport of chloride ions into synaptic particles [35]. Such an activity is typical for both glycinergic and GABAergic neurons, as well as for terminal endings of a mixed type [36]. Exocytosis of synaptic vesicles leads to the diffusion of glycine into the postsynaptic membrane with a subsequent activation of GlyR, which, in turn, leads to the depletion of the chloride ion gradient [37, 38]. For most mature CNS neurons, the intracellular concentration of chloride ions is maintained at a low level (about 5 mM) [39], which is achieved due to the activity of K^+/Cl^- carriers known as KCC2 [40, 41], which function along with $Na^+/K^+/Cl^-$ transporter (NKCC1), as well as glycine transporters – GlyT1 and GlyT2 [42] (Fig. 3).

It should be emphasized that a distinctive structure feature of the postsynaptic region containing glycine and GABAA receptors is their cluster organization on the membrane surface. A similar effect is achieved due to the interaction of GlyR with a specific protein, gephyrin [44], which consists of three subunits [43] and forms trimers associated with cytoskeleton (Fig. 3). This protein is a part of a multistage system that ensures the formation and development of neuroplasticity of the neurons postsynaptic membrane containing receptors activated by inhibitory neurotransmitters (glycine and GABA) [45]. This process is dynamic and can be regulated in various ways, in particular, by the level of a specific brain-derived neurotrophic factor [46]. Glycine released into the synaptic cleft is subsequently captured back into neurons and glial cells through the already mentioned GlyT carriers, and some of the neurotransmitter molecules are carried away by convection diffusion into the interstitial fluid. This process is important for the formation of spatial heterogeneity in the distribution of glycine and the explanation of the molecular mechanisms of its effects in neurons [33].

Other concomitant and metabolic effects of glycine

The considered molecular activation mechanism of chlorine ions transmembrane currents indicates the direct participation of glycine in the formation of inhibitory processes in CNS neurons and is the basis for the formation of various treatment regimens aimed at reducing anxiety and reducing the manifestation of stress. Thus, it has been experimentally shown that high doses of glycine when taken orally (3 g once before falling asleep) improve the subjective and objective assessment of the quality of sleep in the group of patients under consideration [47]. The oral intake of glycine reduces metabolic disorders in patients with cardiovascular diseases, inflammation of various origins in a number of cancers, as well as in obesity and diabetes [48]. Glycine protects against oxidative stress caused by a wide range of toxic compounds (including drugs) at the level of cells or an entire organ in the liver, kidneys, intestines, and a vascular system [49]. It is noteworthy that glycine has a direct effect on the arteriole dilatation [50, 51], which is the most important aspect of this amino acid overall effect on the CNS state [52]. The impact on the blood flow system in microvessels and capillaries leads to a theoretically substantiated [53–55] and experimentally confirmed increase in the glucose content in tissues [56].

Allosteric regulation of GlyR by zinc ions

A number of experimental works have shown the allosteric regulation of GlyR by zinc ions [57, 58]. The effect of zinc on the activity of glycine receptors depends on the level of the ion content and has a biphasic form. At low concentrations of Zn^{2+} (<10 μM), the receptor is activated, while at high concentrations (>10 μM), it is inhibited. These multidirectional processes involve different sites on the receptor and have different molecular mechanisms. Potentiation is achieved by increasing the affinity of the receptor for glycine, while inhibition is achieved by decreasing its efficiency [57]. These effects should be considered as a consequence of zinc physicochemical properties; zinc is the only ion among transition metals that does not have a biological redox activity. It is the lack of the zinc redox activity, along with its relatively strong affinity for proteins that has made zinc a suitable ion to play the role of a

structural cofactor that modulates the activity of the glycine receptor.

Antioxidant effects of glycine and zinc

In addition to the immediate direct combined effect on the state of the neuron membrane polarization, glycine and Zn^{2+} have many effects on metabolic processes that directly affect the condition of patients with anxiety disorders. In particular, it has been experimentally shown that an increase in the concentration of glycine has a protective effect on the oxidative phosphorylation system in the mitochondria of neurons under anoxia and hypoxia conditions [59–61], which is a part of the global regulatory mechanism of the metabolism switching state depending on the level of the tissue amino acids [62]. In addition, a direct increase in the content of glycine reduces the generation level of reactive oxygen species initiated by glutamate excitotoxicity [63]. The antioxidant effect is supported by the mediated participation of glycine in the glutathione tripeptide in the system of protection against the oxidative stress, which is the basis of this amino acid protective effect in various ischemic conditions and acute cerebrovascular accidents [64]. Under normal physiological conditions, Zn^{2+} is redox-inactive; therefore, it takes part in the processes of receiving and transmitting electrons indirectly. The antioxidant properties of zinc are the result of several indirect mechanisms, i.e. the inhibition of ROS formation by transition metals and sulfhydryl stabilization [65, 66].

The above-mentioned molecular mechanisms of the glycine and zinc effect on the cellular and subcellular systems of the brain tissue indicate the need for the combined use of these metabolites to achieve a more pronounced effect in patients suffering from anxiety disorders. At the same time, both the ability to maintain the concentration of the amino acid and microelement in question, as well as their effectiveness and bioavailability, are important.

Bioavailability and maintenance of glycine and zinc levels in human body

Despite the fact that glycine is a non-essential amino acid, Melendes-Hevia E. et al. point at the need for its supply from outside as a source to meet the biological needs of the cells [67]. It should be notified that to date, the ability of glycine to penetrate the BBB with the help of nonspecific amino acid carriers when administered orally has been experimentally proven [47]. Nevertheless, the doses used in this method of administration are quite high [68] and, therefore, it is necessary to take into account the specificity of local changes in the concentration of glycine, which is achieved by an effective choice of this metabolite route of delivery.

To maintain full zinc homeostasis, a sufficient daily intake is necessary, because the systems of the intracellular zinc ions localization discussed above, are rather dynamically filled compartments and traps, which ultimately can lead to the absence of a deposition system for this microelement in the body.

Unfortunately, zinc deficiency does not show any specific symptoms. With its deficiency, such nonspecific conditions as sleep disturbances, deterioration of the skin, hair and nails, decreased appetite, increased hair loss, impaired night vision, decreased mood, increased duration of wound healing, and others can be observed [69].

Zinc deficiency is more common among people on the diet high in phytates [15]. Most often, they are residents of developing countries. Phytates are found in grains, seeds, nuts, legumes, cocoa beans and cocoa powder, and coffee beans. Phytates bind to zinc, thereby reducing its bioavailability [25, 26]. It is worth noting that zinc derived from animal products has a higher bioavailability compared to plant foods. Therefore, vegetarians are usually recommended to increase the zinc norm by 1.5 times [26].

To increase its bioavailability in vegetarian diets, legumes should be used in the sprouted form, or grains and legumes should be soaked in water for several hours before cooking.

According to the unified sanitary-epidemiological and hygienic requirements for goods subject to sanitary-epidemiological supervision (control), the recommended adequate level of the daily zinc intake for an adult is 12 mg; the upper allowable intake level is 25 mg [70]. The physiological need for children is from 3 to 12 mg/day (depending on age). Breastfeeding until at least 6 months of age provides an adequate level of zinc intake in the child's body [71].

Interestingly, some authors point at the need for sublingual zinc in the treatment of colds [14]. A slow drug dissolution in the mouth will allow zinc ions to be released, absorbed and transported to the nose – the source of infection. The chemical composition of the preparation is also important so that zinc can be ionized in the oral cavity at pH 7.4: citric acid, glycine and tartrate prevent zinc ionization [14].

In biologically active food supplements, zinc can be present in the form of compounds: acetate, sulfate, chloride, citrate, gluconate, lactate, oxide, carbonate, L-ascorbate, L-aspartate, bisglycinate, L-lysinate, malate, mono-L-methionine sulfate, picolinate, L-pyroglutamate, as well as amino acid complexes (in accordance with the Unified Sanitary-Epidemiological and Hygienic Requirements). Biological zinc supplements have a varying bioavailability. Zinc bound to amino acids such as aspartate, cysteine and histidine, has the highest absorption concentration, followed by zinc chloride, sulfate and acetate, while zinc oxide has the lowest bioavailability [14, 26, 72]. A comparison of various saccharides and their combinations effect on the zinc uptake by vesicles with brush border membranes showed that the addition of maltose and a mixture of galactose

with glucose did not significantly reduce the level of the zinc uptake compared with the control. The addition of a glucose polymer or lactose significantly increased the bioavailability of zinc [73]. The addition of glucose to lactose or mannitol to the glucose polymer had the same effect as lactose or polymer alone, respectively. The galactose-only buffer had no effect on zinc binding. In another study, a low molecular weight lactose-zinc complex was found out to have a higher bioavailability *in vitro* [74].

The use of Zn^{2+} together with glycine will allow the formation of chelated forms of zinc, the undeniable advantages of which include a maximum bioavailability even under the conditions where the assimilation of the components is impaired (the lack of interaction with food, other minerals and gastric hydrochloric acid, the absence of adverse reactions) [75].

It has been established that zinc, as one of the most important trace elements, plays an important role in various pathological conditions. Various diseases of the gastrointestinal tract, such as malabsorption, cirrhosis of the liver, a celiac disease, Crohn's disease and chronic diarrhea, can also lead to zinc deficiency, due to the impaired absorption [19, 26].

Low zinc levels have been shown to be associated with metabolic syndrome and diabetes [76, 77], as well as decreased immunity [26, 78, 79]. Large amounts of iron from supplements can interfere with the zinc absorption. Disruption of zinc homeostasis, leading to either depletion or excess zinc, causes severe damage to neurons [80]. Zinc-induced cell death and changes in brain zinc status are associated with a wide range of diseases, including many neurodegenerative disorders, such as Alzheimer's disease, and mood disorders, including depression, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and prion diseases, as well as autism spectrum disorders. [66, 81–83].

The considered molecular mechanisms of the metabolites action are reflected in the clinical practice of the anxiety states treatment. In particular, it was shown that such anxiety symptoms as anxious mood, tension, and sleep disturbances were subjected to the greatest reverse dynamics during glycine therapy [85]. In addition, a randomized placebo-controlled study demonstrated the effectiveness of glycine in the treatment of mild anxiety in patients with an adjustment disorder with a predominance of disturbance of other emotions [86].

All major metabolic pathways are regulated by zinc metalloenzymes. The functions of these enzymes include catalytic, structural and regulatory roles. The status of zinc, whether deficient or abundant, is able of influencing each of this element's diverse roles in human biology.

CONCLUSION

Thus, deficiencies of certain essential trace elements and amino acids, such as glycine and zinc, especially their combined deficiencies, are one of the frequent causes of various adverse effects, including post-stress CNS dysfunctions. Given the accumulated experience of these micronutrients positive impact on the processes of recovery and maintenance of the central nervous system normal functioning, an adequate intake of zinc and glycine may be important for most people who experience the consequences of numerous stresses and anxiety on a daily basis. This combination can be especially useful for the people experiencing a state of chronic psycho-emotional stress and maladaptation, including those who have difficulty in falling asleep. Replenishment of zinc and glycine deficiency in the body of a healthy person is manifested by the development of a persistent anti-anxiety effect, which is accompanied by the normalization of the sleep-wake rhythm, which makes it possible to have a good rest without any loss of working efficiency after waking up.

CONFLICT OF INTERESTS
The authors declare no conflict of interest.

AUTHORS' CONTRIBUTION
VNS – writing and editing the text, analyzing literary sources and interpreting the results, analyzing glycine and zinc clinical effects, approval of the text; YRN – writing and editing the text, analyzing literary sources and interpreting the results, conducting a database search in the Protein Data Bank (PDB) (https://www.rcsb.org/), selecting material on the glycine action, developing design and making illustrations using graphic tools and the library of the ACD/ChemSketch 2020.2.0 software package, approval of the article final version for publication; VYT – writing and editing the text, analyzing literary sources and interpreting the results, selecting material on the metabolic zinc action; EVS – writing and editing the text, analyzing literary sources and interpreting the results, analyzing pharmaceutically acceptable zinc compounds and bioavailability of combinations, approval of the text.

REFERENCES

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789–1858. DOI: 10.1016/S0140-6736(18)32279-7

2. Drapkina OM, Kontsevaya AV, Kalinina AM, Avdeev SM, Agaltsov MV, Alexandrova LM, Antsiferova AA, Aronov DM, Akhmedzhanov NM, Balanova YuA, Balakhonova TV, Berns SA, Bochkarev MV, Bochkareva EV, Bubnova MV, Budnevsky AV, Gambaryan MG, Gorbunov VM, Gorny BE, Gorshkov AYu, Gumanova NG, Dadaeva VA, Drozdova LYu, Egorov VA, Eliashevich SO, Ershova AI, Ivanova ES, Imaeva AE, Ipatov PV, Kaprin AD, Karamnova NS, Kobalava ZD, Konradi AO, Kopylova OV, Korostovtseva LS, Kotova MB, Kulikova MS, Lavrenova EA, Lischenko OV, Lopatina MV, Lukina YuV, Lukyanov MM, Mayev IV, Mamedov MN, Markelova SV, Martsevich SYu, Metelskaya VA, Meshkov AN, Milushkina OYu, Mukaneeva DK, Myrzamatova AO, Nebieridze DV, Orlov DO, Poddubskaya EA, Popovich MV, Popovkina OE, Potievskaya VI, Prozorova GG, Rakovskaya YuS, Rotar OP, Rybakov IA, Sviryaev YuV, Skripnikova IA, Skoblina NA, Smirnova MI, Starinsky VV, Tolpygina SN, Usova EV, Khailova ZV, Shalnova SA, Shepel RN, Shishkova VN, Yavelov IS, Mardanov BU. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. DOI: 10.15829/1728-8800-2022-3235. Russian

3. Beune T, Absalom A. Anxiolytics, sedatives and hypnotics. Anaesthesia & Intensive Care Medicine. 2022;23(8):481–6. DOI: 10.1016/j.mpaic.2022.04.013

4. Sinclair L, Nutt D. Anxiolytics. Psychiatry. 2007;6(7):284–8. DOI: 10.1016/j.mppsy.2007.04.007

5. Amundarain MJ, Ribeiro RP, Costabel MD, Giorgetti A. GABA$_A$ receptor family: overview on structural characterization. Future Med Chem. 2019 Feb 25. DOI: 10.4155/fmc-2018-0336

6. Kim JJ, Hibbs RE. Direct Structural Insights into GABA$_A$ Receptor Pharmacology. Trends Biochem Sci. 2021 Jun;46(6):502–17. DOI: 10.1016/j.tibs.2021.01.011

7. Knoflach F, Bertrand D. Pharmacological modulation of GABA$_A$ receptors. Curr Opin Pharmacol. 2021;59:3–10. DOI: 10.1016/j.coph.2021.04.003

8. Avoli M, Krnjević K. The Long and Winding Road to Gamma-Amino-Butyric Acid as Neurotransmitter. Can J Neurol Sci. 2016 Mar;43(2):219–26. DOI: 10.1017/cjn.2015.333

9. Benarroch EE. Glycine and its synaptic interactions: functional and clinical implications. Neurology. 2011 Aug 16;77(7):677–83. DOI: 10.1212/WNL.0b013e31822a2791

10. Betz H, Laube B. Glycine receptors: recent insights into their structural organization and functional diversity. J Neurochem. 2006 Jun;97(6):1600–10. DOI: 10.1111/j.1471-4159.2006.03908.x

11. Beato M. The time course of transmitter at glycinergic synapses onto motoneurons. J Neurosci. 2008 Jul 16;28(29):7412–25. DOI: 10.1523/JNEUROSCI.0581-08.2008

12. Kasaragod VB, Mortensen M, Hardwick SW, Wahid AA, Dorovykh V, Chirgadze DY, Smart TG, Miller PS. Mechanisms of inhibition and activation of extrasynaptic αβ GABA$_A$ receptors. Nature. 2022;602(7897):529–33. DOI: 10.1038/s41586-022-04402-z

13. Huang X, Chen H, Shaffer PL. Crystal Structures of Human GlyRα3 Bound to Ivermectin. Structure. 2017 Jun 6;25(6):945-950.e2. DOI: 10.1016/j.str.2017.04.007

14. Prasad AS. Discovery of human zinc deficiency: its impact on human health and disease. Adv Nutr. 2013 Mar 1;4(2):176–90. DOI: 10.3945/an.112.003210

15. Wessells KR, Brown KH. Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. PLoS One. 2012;7(11):e50568. DOI: 10.1371/journal.pone.0050568

16. Asl SH, Nikfarjam S, Majidi Zolbanin N, Nassiri R, Jafari R. Immunopharmacological perspective on zinc in SARS-CoV-2 infection. Int Immunopharmacol. 2021 Jul;96:107630. DOI: 10.1016/j.intimp.2021.107630

17. Portbury SD, Adlard PA. Zinc Signal in Brain Diseases. Int J Mol Sci. 2017 Nov 23;18(12):2506. DOI: 10.3390/ijms18122506

18. Kimura T, Kambe T. The Functions of Metallothionein and ZIP and ZnT Transporters: An Overview and Perspective. Int J Mol Sci. 2016 Mar 4;17(3):336. DOI: 10.3390/ijms17030336

19. Wang S, Liu GC, Wintergerst KA, Cai L. Chapter 14 – Metals in Diabetes: Zinc Homeostasis in the Metabolic Syndrome and Diabetes. In: Mauricio D, editor. Molecular Nutrition and Diabetes. Academic Press; 2016. p. 169–182. DOI: 10.1016/B978-0-12-801585-8.00014-2

20. Daaboul D, Rosenkranz E, Uciechowski P, Rink L. Repletion of zinc in zinc-deficient cells strongly up-regulates IL-1β-induced IL-2 production in T-cells. Metallomics. 2012 Oct;4(10):1088–97. DOI: 10.1039/c2mt20118f

21. Li Y, Hough CJ, Suh SW, Sarvey JM, Frederickson CJ. Rapid translocation of Zn$^{(2+)}$ from presynaptic terminals into postsynaptic hippocampal neurons after physiological stimulation. J Neurophysiol. 2001 Nov;86(5):2597–604. DOI: 10.1152/jn.2001.86.5.2597

22. Tamano H, Koike Y, Nakada H, Shakushi Y, Takeda A. Significance of synaptic Zn^{2+} signaling in zincergic and non-zincergic synapses in the hippocampus in cognition. J Trace Element Medic Biolog. 2016;38:93–8. DOI: 10.1016/j.jtemb.2016.03.003

23. Kumar A, Basak S, Rao S, Gicheru Y, Mayer ML, Sansom MSP, Chakrapani S. Mechanisms of activation and desensitization of full-length glycine receptor in lipid nanodiscs. Nat Commun. 2020 Jul 27;11(1):3752. DOI: 10.1038/s41467-020-17364-5

24. Lu J, Stewart AJ, Sadler PJ, Pinheiro TJ, Blindauer CA. Albumin as a zinc carrier: properties of its high-affinity zinc-binding site. Biochem Soc Trans. 2008 Dec;36 (Pt 6):1317–21. DOI: 10.1042/BST0361317

25. Sandstead HH, Freeland-Graves JH. Dietary phytate, zinc and hidden zinc deficiency. J Trace Elem Med Biol. 2014 Oct;28(4):414–7. DOI: 10.1016/j.jtemb.2014.08.011

26. Gammoh NZ, Rink L. Zinc in Infection and Inflammation. Nutrients. 2017 Jun 17;9(6):624. DOI: 10.3390/nu9060624

27. Maret W. The function of zinc metallothionein: a link between cellular zinc and redox state. J Nutr. 2000 May;130(5S Suppl):1455S–8S. DOI: 10.1093/jn/130.5.1455S

28. Plum LM, Rink L, Haase H. The essential toxin: impact of zinc on human health. Int J Environ Res Public Health. 2010 Apr;7(4):1342–65. DOI: 10.3390/ijerph7041342

29. Drapkina OM, Karamnova NS, Kontsevaya AV, Gorny BE,

Dadaeva VA, Drozdova LYu, Yeganyan RA, Eliashevich SO, Izmailova OV, Lavrenova EA, Lischenko OV, Skripnikova IA, Shvabskaya OB, Shishkova VN. Russian Society for the Prevention of Noncommunicable Diseases (ROPNIZ). Alimentary-dependent risk factors for chronic non-communicable diseases and eating habits: dietary correction within the framework of preventive counseling. Methodological Guidelines. Cardiovascular Therapy and Prevention. 2021;20(5):2952. DOI: 10.15829/1728-8800-2021-2952. Russian

30. Wu G. Amino Acids: Biochemistry and Nutrition, 2nd Edition. CRC Print: Boca Raton; 2021. 816 p. DOI: 10.1201/9781003092742

31. Wang W, Wu Z, Dai Z, Yang Y, Wang J, Wu G. Glycine metabolism in animals and humans: implications for nutrition and health. Amino Acids. 2013 Sep;45(3):463–77. DOI: 10.1007/s00726-013-1493-1

32. Wu G. Functional amino acids in growth, reproduction, and health. Adv Nutr. 2010 Nov;1(1):31–7. DOI: 10.3945/an.110.1008

33. Nartsissov YR. Amino Acids as Neurotransmitters. The Balance between Excitation and Inhibition as a Background for Future Clinical Applications. COVID-19, Neuroimmunology and Neural Function, edited by Thomas Heinbockel, Robert Weissert, IntechOpen; 2022. DOI: 10.5772/intechopen.103760

34. Kikuchi G, Motokawa Y, Yoshida T, Hiraga K. Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia. Proc Jpn Acad Ser B Phys Biol Sci. 2008;84(7):246–63. DOI: 10.2183/pjab.84.246

35. Juge N, Muroyama A, Hiasa M, Omote H, Moriyama Y. Vesicular inhibitory amino acid transporter is a Cl⁻/gamma-aminobutyrate Co-transporter. J Biol Chem. 2009 Dec 11;284(50):35073–8. DOI: 10.1074/jbc.M109.062414

36. Ito T, Bishop DC, Oliver DL. Expression of glutamate and inhibitory amino acid vesicular transporters in the rodent auditory brainstem. J Comp Neurol. 2011 Feb 1;519(2):316–40. DOI: 10.1002/cne.22521

37. Berndt N, Hoffmann S, Benda J, Holzhütter HG. The influence of the chloride currents on action potential firing and volume regulation of excitable cells studied by a kinetic model. J Theor Biol. 2011;276(1):42–9. DOI: 10.1016/j.jtbi.2011.01.022

38. Doyon N, Prescott SA, Castonguay A, Godin AG, Kröger H, De Koninck Y. Efficacy of synaptic inhibition depends on multiple, dynamically interacting mechanisms implicated in chloride homeostasis. PLoS Comput Biol. 2011 Sep;7(9):e1002149. DOI: 10.1371/journal.pcbi.1002149

39. Raimondo JV, Richards BA, Woodin MA. Neuronal chloride and excitability – the big impact of small changes. Curr Opin Neurobiol. 2017 Apr;43:35–42. DOI: 10.1016/j.conb.2016.11.012

40. Chamma I, Chevy Q, Poncer JC, Lévi S. Role of the neuronal K-Cl co-transporter KCC2 in inhibitory and excitatory neurotransmission. Front Cell Neurosci. 2012 Feb 21;6:5. DOI: 10.3389/fncel.2012.00005

41. Kaila K, Price TJ, Payne JA, Puskarjov M, Voipio J. Cation-chloride cotransporters in neuronal development, plasticity and disease. Nat Rev Neurosci. 2014 Oct;15(10):637–54. DOI: 10.1038/nrn3819

42. Zaytsev KS, Mashkovtseva EV, Nartsissov YR. [Membrane Transporters of Glycine Amino Acid in Nervous Tissue: Structure, Localization, Functions and Regulation]. Uspekhi sovremennoj biologii. 2012;132(4):391–400. Russian

43. Choii G, Ko J. Gephyrin: a central GABAergic synapse organizer. Exp Mol Med. 2015 Apr 17;47:e158. DOI:10.1038/emm.2015.5

44. Baer K, Waldvogel HJ, During MJ, Snell RG, Faull RL, Rees MI. Association of gephyrin and glycine receptors in the human brainstem and spinal cord: an immunohistochemical analysis. Neuroscience. 2003;122(3):773–84. DOI: 10.1016/s0306-4522(03)00543-8

45. Luscher B, Fuchs T, Kilpatrick CL. GABA_A receptor trafficking-mediated plasticity of inhibitory synapses. Neuron. 2011 May 12;70(3):385–409. DOI: 10.1016/j.neuron.2011.03.024

46. González MI. Brain-derived neurotrophic factor promotes gephyrin protein expression and GABA_A receptor clustering in immature cultured hippocampal cells. Neurochem Int. 2014 Jun;72:14–21. DOI: 10.1016/j.neuint.2014.04.006

47. Bannai M, Kawai N. New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep. J Pharmacol Sci. 2012;118(2):145–8. DOI: 10.1254/jphs.11r04fm

48. Razak MA, Begum PS, Viswanath B, Rajagopal S. Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. Oxid Med Cell Longev. 2017;2017:1716701. DOI: 10.1155/2017/1716701

49. Pérez-Torres I, Zuniga-Munoz AM, Guarner-Lans V. Beneficial Effects of the Amino Acid Glycine. Mini Rev Med Chem. 2017;17(1):15–32. DOI: 10.2174/1389557516666160609081602

50. Podoprigora GI, Nartsissov YR, Aleksandrov PN. Effect of glycine on microcirculation in pial vessels of rat brain. Bull Experiment Biol Med. 2005;139(6):675–7. DOI: 10.1007/s10517-005-0375-2

51. Podoprigora GI, Nartsissov YR. Effect of glycine on the microcirculation in rat mesenteric vessels. Bull Experiment Biol Med. 2009;147(3):308–11. DOI: 10.1007/s10517-009-0498-y

52. Podoprigora GI, Blagosklonov O, Angoué O, Boulahdour H, Nartsissov YR. Assessment of microcirculatory effects of glycine by intravital microscopy in rats. Annu Int Conf IEEE Eng Med Biol Soc. 2012;2012:2651–4. DOI: 10.1109/EMBC.2012.6346509

53. Nartsissov YR, Tyukina ES, Boronovsky SE, Sheshegova EV. Computer modeling of spatial-time distribution of metabolite concentrations in phantoms of biological objects by example of rat brain pial. Biophysics. 2013;58(5):703–11. DOI: 10.1134/S0006350913050102

54. Nartsissov YR. The Effect of Flux Dysconnectivity Functions on Concentration Gradients Changes in a Multicomponent Model of Convectional Reaction-Diffusion by the Example of a Neurovascular Unit. Defect and Diffusion Forum. 2021;413:19–28. DOI: 10.4028/www.scientific.net/DDF.413.19

55. Nartsissov YR. Application of a multicomponent model of convectional reaction-diffusion to description of glucose gradients in a neurovascular unit. Front Physiol. 2022 Aug 22;13:843473. DOI: 10.3389/fphys.2022.843473

56. Blagosklonov O, Podoprigora GI, Davani S, Nartsissov YR, Comas L., Boulahdour H, Cardot JC. FDG-PET scan shows increased cerebral blood flow in rat after sublingual glycine application. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 2007;571(1–2):30–2. DOI: 10.1016/j.nima.2006.10.022

57. Yevenes GE, Zeilhofer HU. Allosteric modulation of glycine receptors. Br J Pharmacol. 2011 Sep;164(2): 224-36. DOI: 10.1111/j.1476–5381.2011.01471.x

58. Burgos CF, Yévenes GE, Aguayo LG. Structure and Pharmacologic Modulation of Inhibitory Glycine Receptors. Mol Pharmacol. 2016 Sep;90(3):318–25. DOI: 10.1124/mol.116.105726

59. Tonshin AA, Lobysheva NV, Yaguzhinsky LS, Bezgina EN, Moshkov DA, Nartsissov YR. Effect of the inhibitory neurotransmitter glycine on slow destructive processes in brain cortex slices under anoxic conditions. Biochemistry (Mosc). 2007 May;72(5):509–17. DOI: 10.1134/s0006297907050070

60. Lobysheva NV, Tonshin AA, Selin AA, Yaguzhinsky LS, Nartsissov YR. Diversity of neurodegenerative processes in the model of brain cortex tissue ischemia. Neurochem Int. 2009 May–Jun;54(5–6):322–9. DOI: 10.1016/j.neuint.2008.12.015

61. Selin AA, Lobysheva NV, Vorontsova ON, Tonshin AA, Yaguzhinsky LS, Narcissov YR. [The mechanism of action of glycine as a protector of brain tissue energy disorders in hypoxia]. Bulletin of Experimental Biology and Medicine. 2012;48(1):91–6. Russian

62. Nesterov SV, Yaguzhinsky LS, Podoprigora GI, Nartsissov YR. Amino Acids as Regulators of Cell Metabolism. Biochemistry (Mosc). 2020 Apr;85(4):393–408. DOI: 10.1134/S000629792004001X

63. Lobysheva NV, Selin AA, Vangeli IM, Byvshev IM, Yaguzhinsky LS, Nartsissov YR. Glutamate induces H2O2 synthesis in nonsynaptic brain mitochondria. Free Radic Biol Med. 2013 Dec;65:428–435. DOI: 10.1016/j.freeradbiomed.2013.07.030

64. Skvortsova VI, Nartsissov YR, Bodykhov MK, Kichuk IV, Prianikova NA, Gudkova IuV, Sodatenkova TD, Kondrashova TT, Kalinina EV, Novichkova MD, Shut'eva AB, Kerbikov OB. [Oxidative stress and oxygen status in ischemic stroke]. Zh Nevrol Psikhiatr Im SS Korsakova. 2007;107(1):30–6. Russian

65. Singh TA, Sharma A, Tejwan N, Ghosh N, Das J, Sil PC. A state of the art review on the synthesis, antibacterial, antioxidant, antidiabetic and tissue regeneration activities of zinc oxide nanoparticles. Advan Colloid Interface Sci. 2021;295:102495. DOI: 10.1016/j.cis.2021.102495

66. Faghfouri AH, Zarezadeh M, Aghapour B, Izadi A, Rostamkhani H, Majnouni A, Abu-Zaid A, Kord Varkaneh H, Ghoreishi Z, Ostadrahimi A. Clinical efficacy of zinc supplementation in improving antioxidant defense system: A comprehensive systematic review and time-response meta-analysis of controlled clinical trials. Europ J Pharmacol. 2021;907:174243. DOI: 10.1016/j.ejphar.2021.174243

67. Meléndez-Hevia E, De Paz-Lugo P, Cornish-Bowden A, Cárdenas ML. A weak link in metabolism: the metabolic capacity for glycine biosynthesis does not satisfy the need for collagen synthesis. J Biosci. 2009 Dec;34(6):853–72. DOI: 10.1007/s12038-009-0100-9

68. Leung S, Croft RJ, O'Neill BV, Nathan PJ. Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls. Psychopharmacology (Berl). 2008 Feb;196(3):451–60. DOI: 10.1007/s00213-007-0976-8

69. Rebrov VG, Gromova OA. [Vitamins, macro- and microelements]. Moscow: GEOTAR-Media; 2008, 960 p. Russian

70. Popova AY, Tutelyan VA, Nikityuk DB. [On the new (2021) Norms of physiological requirements in energy and nutrients of various groups of the population of the Russian Federation]. Problems of Nutrition. 2021; 90(4): 6-19. DOI:10.33029/0042-8833-2021-90-4-6-19. Russian

71. Salgueiro MJ, Zubillaga MB, Lysionek AE, Caro RA, Weill R, Boccio JR. The role of zinc in the growth and development of children. Nutrition. 2002 Jun;18(6):510-9. DOI: 10.1016/s0899-9007(01)00812-7

72. Reiber C, Brieger A, Engelhardt G, Hebel S, Rink L, Haase H. Zinc chelation decreases IFN-β-induced STAT1 upregulation and iNOS expression in RAW 264.7 macrophages. J Trace Elem Med Biol. 2017 Dec;44:76–82. DOI: 10.1016/j.jtemb.2017.05.011

73. Bertolo RF, Bettger WJ, Atkinson SA. Divalent metals inhibit and lactose stimulates zinc transport across brush border membrane vesicles from piglets. J Nutr Biochem. 2001 Feb;12(2):73–80. DOI: 10.1016/s0955-2863(00)00126-1

74. Sharma A, Shilpa Shree BG, Arora S, Tomar SK. Lactose–Zinc complex preparation and evaluation of acceptability of complex in milk. LWT – Food Science and Technology. 2015;64(Issue 1):275–81. DOI: 10.1016/j.lwt.2015.05.056

75. Beketova H, Horiacheva I. [Zinc and its impact on human health in conditions of COVID-19 pandemic: what's new?] Pediatrics. Eastern Europe. 2021;9(1):8–20. DOI: 10.34883/PI.2021.9.1.001. Russian

76. Fathi M, Alavinejad P, Haidari Z, Amani R. The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. J Trace Elem Med Biol. 2020 Dec;62:126635. DOI: 10.1016/j.jtemb.2020.126635

77. Barbara M, Mindikoglu AL. The role of zinc in the prevention and treatment of nonalcoholic fatty liver disease. Metabol Open. 2021 Jun 29;11:100105. DOI: 10.1016/j.metop.2021.100105

78. Osuna-Padilla IA, Briceño O, Aguilar-Vargas A, Rodríguez-Moguel NC, Villazon-De la Rosa A, Pinto-Cardoso S, Flores-Murrieta FJ, Perichart-Perera O, Tolentino-Dolores M, Vargas-Infante Y, Reyes-Terán G. Zinc and selenium indicators and their relation to immunologic and metabolic parameters in male patients with human immunodeficiency virus. Nutrition. 2020 Feb;70:110585. DOI: 10.1016/j.nut.2019.110585

79. Koo SI, Turk DE. Effect of zinc deficiency on the ultrastructure of the pancreatic acinar cell and intestinal epithelium in the rat. J Nutr. 1977 May;107(5):896–908. DOI: 10.1093/jn/107.5.896

80. Pang W, Leng X, Lu H, Yang H, Song N, Tan L, Jiang Y, Guo C. Depletion of intracellular zinc induces apoptosis of cultured hippocampal neurons through suppression of ERK signaling pathway and activation of caspase-3. Neurosci Lett. 2013 Sep 27;552:140–5. DOI: 10.1016/j.neulet.2013.07.057

81. Faber S, Zinn GM, Kern JC 2nd, Kingston HM. The plasma zinc/serum copper ratio as a biomarker in children with autism spectrum disorders. Biomarkers. 2009 May;14(3):171–80. DOI: 10.1080/13547500902783747

82. Vela G, Stark P, Socha M, Sauer AK, Hagmeyer S, Grabrucker AM. Zinc in gut-brain interaction in autism and neurological disorders. Neural Plast. 2015;2015:972791. DOI: 10.1155/2015/972791

83. Grabrucker S, Jannetti L, Eckert M, Gaub S, Chhabra R,

Pfaender S, Mangus K, Reddy PP, Rankovic V, Schmeisser MJ, Kreutz MR, Ehret G, Boeckers TM, Grabrucker AM. Zinc deficiency dysregulates the synaptic ProSAP/Shank scaffold and might contribute to autism spectrum disorders. Brain. 2014 Jan;137(Pt 1):137–52. DOI: 10.1093/brain/awt303

84. Gromova OA, Pronin AV, Torshin IYu, Kalacheva AG, Grishina TR. Neurotrophic and antioxidant potential of neuropeptides and trace elements. Neurology, Neuropsychiatry, Psychosomatics. – 2015. – Vol. 7, No. 4. – P. 92–100. DOI: 10.14412/2074-2711-2015-4-92-100. Russian

85. Grigorova OV, Romasenko LV, Vazagaeva T., Maksimova LN, Nartsissov YR. [Therapy efficiency of anxiety at patients with adjustment disorder, on glycine therapy model with placebosensibility]. Russ J Psychiatry. 2012;(4):45–52. Russian

86. Grigorova OV, Romasenko LV, Faizulloev AZ, Vazagaeva TI, Maksimova LN, Nartsissov YR. [The use of glycine in the treatment of patients suffering from adjustment disorder]. Practical Medicine J. 2012;57(2):178–82. Russian

AUTHORS

Veronika N. Shishkova – Doctor of Sciences (Medicine), Leading Researcher, Head of the Department for the Prevention of Cognitive and Psychoemotional Disorders, National Medical Research Center for Therapy and Preventive Medicine; Associate Professor of the Department of Therapy and Preventive Medicine, Evdokimov Moscow State Medical and Dental University. ORCID ID: 0000-0002-1042-4275. E-mail: veronika-1306@mail.ru

Yaroslav R. Nartcissov – Candidate of Sciences (Physics and Mathematics), Associate Professor in Biophysics, Head of the Department of Mathematical Modeling and Statistical Processing of Results, Institute of Cytochemistry and Molecular Pharmacology; Head of Biomedical Research Group, BiDiPharma GmbH, Germany. ORCID ID: 0000-0001-9020-7686. E-mail: yarosl@biotic.dol.ru

Victoria Y. Titova – Junior Researcher, Department of Mathematical Modeling and Statistical Processing of Results, Institute of Cytochemistry and Molecular Pharmacology. ORCID ID: 0000-0002-4741-2331. E-mail: victorinchik@gmail.com

Elena V. Sheshegova – Candidate of Sciences (Pharmacy), Head of the Department of Experimental Pharmacology, Institute of Cytochemistry and Molecular Pharmacology. ORCID ID: 0000-0003-1796-3017. E-mail: elshesh@yandex.ru

CONVENTIONAL APPROACHES TO THE THERAPY OF HEREDITARY MYOPATHIES

M.V. Pokrovsky[1], M.V. Korokin[1], A.M. Krayushkina[1], N.S. Zhunusov[1], K.N. Lapin[2],
M.O. Soldatova[3], E.A. Kuzmin[4], O.S. Gudyrev[1], I.S. Kochkarova[1], A.V. Deikin[1]

[1] Belgorod State National Research University,
85, Pobeda Str., Belgorod, Russia, 308015
[2] V.A. Negovsky Research Institute of General Reanimatology,
Federal Scientific and Clinical Center for Resuscitation and Rehabilitology,
Bld. 2, 25, Petrovka Str., Moscow, Russia, 107031
[3] Kursk State Medical University,
3, Karl Marx Str., Kursk, Russia, 305041
[4] Sechenov First Moscow State Medical University (Sechenov University),
Bld. 2, 8, Trubetskaya Str., Moscow, Russia, 119991

E-mail: mkorokin@mail.ru

The aim of the work was to analyze the available therapeutic options for the conventional therapy of hereditary myopathies.
Materials and methods. When searching for the material for writing a review article, such abstract databases as PubMed and Google Scholar were used. The search was carried out on the publications during the period from 1980 to September 2022. The following words and their combinations were selected as parameters for the literature selection: "myopathy", "Duchenne", "myodystrophy", "metabolic", "mitochondrial", "congenital", "symptoms", "replacement", "recombinant", "corticosteroids", "vitamins", "tirasemtiv", "therapy", "treatment", "evidence", "clinical trials", "patients", "dichloracetate".
Results. Congenital myopathies are a heterogeneous group of pathologies that are caused by atrophy and degeneration of muscle fibers due to mutations in genes. Based on a number of clinical and pathogenetic features, hereditary myopathies are divided into: 1) congenital myopathies; 2) muscular dystrophy; 3) mitochondrial and 4) metabolic myopathies. At the same time, treatment approaches vary significantly depending on the type of myopathy and can be based on 1) substitution of the mutant protein; 2) an increase in its expression; 3) stimulation of the internal compensatory pathways expression; 4) restoration of the compounds balance associated with the mutant protein function (for enzymes); 5) impact on the mitochondrial function (with metabolic and mitochondrial myopathies); 6) reduction of inflammation and fibrosis (with muscular dystrophies); as well as 7) an increase in muscle mass and strength. The current review presents current data on each of the listed approaches, as well as specific pharmacological agents with a description of their action mechanisms.
Conclusion. Currently, the following pharmacological groups are used or undergoing clinical trials for the treatment of various myopathies types: inotropic, anti-inflammatory and antifibrotic drugs, antimyostatin therapy and the drugs that promote translation through stop codons (applicable for nonsense mutations). In addition, metabolic drugs, metabolic enzyme cofactors, mitochondrial biogenesis stimulators, and antioxidants can be used to treat myopathies. Finally, the recombinant drugs alglucosidase and avalglucosidase have been clinically approved for the replacement therapy of metabolic myopathies (Pompe's disease).
Keywords: hereditary myopathies; Duchenne's muscle dystrophy; metabolic therapy; pharmacological correction
Abbreviations: ETC – electronic transport chain; mRNA – matrix ribonucleic acid; tRNA – transport ribonucleic acid; siRNAs – small interfering ribonucleic acids; NAD, nicotineamide-adenine dinucleotide; FAD – flavin adenine dinucleotide; NADP – nicotinamide adenine dinucleotide phosphate; ATP – adenosine triphosphate; ADP – adenosine diphosphate; CTGF – connective tissue growth factor; TGFβ – transforming growth factor-beta; NSAIDs – non-steroidal anti-inflammatory drugs; XLMTM – X-linked myotubular myopathy; TCA – tricarboxylic acid cycle; TNF-α – tumor necrosis factor-alpha; CTGF/CCN2 – connective tissue growth factor.

КОНВЕНЦИОНАЛЬНЫЕ ПОДХОДЫ К ТЕРАПИИ НАСЛЕДСТВЕННЫХ МИОПАТИЙ

М.В. Покровский[1], М.В. Корокин[1], А.М. Краюшкина[1], Н.С. Жунусов[1], К.Н. Лапин[2], М.О. Солдатова[3], Е.А. Кузьмин[4], О.С. Гудырев[1], И.С. Кочкарова[1], А.В. Дейкин[1]

[1] Федеральное государственное автономное образовательное учреждение высшего образования «Белгородский государственный национальный исследовательский университет»
308015, Россия, г. Белгород, ул. Победы, д. 85

[2] Научно-исследовательский институт общей реаниматологии имени В.А. Неговского
Федерального научно-клинического центра реаниматологии и реабилитологии
107031, Россия, г. Москва, ул. Петровка, д. 25, стр. 2

[3] Федеральное государственное бюджетное образовательное учреждение высшего образования «Курский государственный медицинский университет»
Министерства здравоохранения Российской Федерации
305041, Россия, г. Курск, ул. Карла Маркса, д. 3

[4] Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова»
Министерства здравоохранения Российской Федерации (Сеченовский Университет)
11999, Россия, г. Москва, ул. Трубецкая, д. 8, стр. 2

E-mail: mkorokin@mail.ru

Цель. Проанализировать доступные терапевтические опции для конвенциональной терапии наследственных миопатий.

Материалы и методы. При поиске материала для написания обзорной статьи использовали такие реферативные базы данных, как PubMed и Google Scholar. Поиск осуществлялся по публикациям за период с 1980 г. по сентябрь 2022 г. Параметрами для отбора литературы были выбраны следующие слова и их сочетания: "myopathy", "Duchenne", "myodystrophy", "metabolic", "mitochondrial", "congenital", "symptoms", "replacement", "recombinant", "corticosteroids", "vitamins", "tirasemtiv", "therapy", "treatment", "evidence", "clinical trials", "patients", "dichloracetate".

Результаты. Врожденные миопатии представляют собой гетерогенную группу патологий, которые вызваны атрофией и дегенерацией мышечных волокон вследствие мутаций в генах. На основании ряда клинических и патогенетических особенностей наследственные миопатии разделяют на: 1) врожденные миопатии; 2) мышечные дистрофии; 3) митохондриальные и 4) метаболические миопатии. При этом, подходы к лечению значительно варьируют в зависимости от типа миопатии и могут быть основаны на 1) замещении мутантного белка; 2) увеличении его экспрессии 3) стимуляции экспрессии внутренних компенсаторных путей; 4) восстановлении баланса соединений, связанных с функцией мутантного белка (для ферментов); 5) воздействии на функцию митохондрий (при метаболических и митохондриальных миопатиях); 6) снижении воспаления и фиброза (при мышечных дистрофиях); а также на 7) увеличении мышечной массы и силы. В текущем обзоре представлены современные данные о каждом из перечисленных подходов, а также конкретные фармакологические агенты с описанием их механизмов действия.

Заключение. В настоящее время для лечения разных типов миопатий используются или проходят клинические исследования следующие фармакологические группы: инотропные, противовоспалительные и антифибротические препараты, антимиостатиновая терапия и препараты, способствующие трансляции через стоп-кодоны (применима при нонсенс-мутациях). Кроме того, для лечения миопатий могут быть применены метаболические препараты, кофакторы метаболических ферментов, стимуляторы митохондриального биогенеза и антиоксиданты. Наконец, клинически одобрены рекомбинантные препараты алглюкозидаза и авалглюкозидаза для заместительной терапии метаболических миопатий (болезнь Помпе).

Ключевые слова: наследственные миопатии; миодистрофия Дюшенна; метаболическая терапия; фармакологическая коррекция

Список сокращений: ЭТЦ — электронно-транспортная цепь; мРНК — матричная рибонуклеиновая кислота; тРНК — транспортная рибонуклеиновая кислота; миРНК — малая интерферирующая рибонуклеиновая кислота; НАД — никотинамидадениндинуклеотид; ФАД — флавинадениндинуклеотид; НАДФ — никотинамидадениндинуклеотидфосфат; АТФ — аденозинтрифосфат; АДФ — аденозиндифосфат; CTGF — фактор роста соединительной ткани; TGFβ — трансформирующий фактор роста-бета; НПВП — нестероидные противовоспалительные препараты; XLMTM — X-сцепленная миотубулярная миопатия; ЦТК — цикл трикарбоновых кислот; ФНО-α — фактор некроза опухоли-альфа; CTGF/CCN2 — фактор роста соединительной ткани.

INTRODUCTION

Hereditary myopathies are a clinically, histologically and genetically heterogeneous group of muscle pathologies that are caused by atrophy and degeneration of striated muscles due to mutations in genes whose role is closely related to the functioning of myocytes. Most often, the proteins encoded by these genes are involved in the formation or maintenance of the structural integrity of the cytoskeleton and plasma membrane. At the same time, myopathies associated with the pathology of cytoskeletal proteins are characterized by a progressive course (muscular dystrophies), and myopathies caused by a function loss of membrane proteins are fully manifested from birth (congenital myopathies). In addition, hereditary myopathies can be caused by mutations in the genes associated with the work of mitochondria (mitochondrial myopathies), or the genes encoding enzymes of intracellular metabolism (metabolic myopathies) [1].

Initially, classifications of hereditary myopathies were based on the clinical presentation or typical histological features found in muscle biopsy specimens. However, according to the current recommendations, the diagnosis of myopathy should be accompanied by the data from molecular genetic studies. In addition to precision diagnostics, this approach leads to an expansion list of the nosological group genetic correlates [2].

THE AIM of the work was to analyze the available therapeutic options for the conventional therapy of hereditary myopathies.

MATERIALS AND METHODS

When searching for the material for writing a review article, such abstract databases as PubMed and Google Scholar were used. The search was carried out on the publications during the period from 1980 to September 2022. The following words and their combinations were selected as parameters for the literature selection: "myopathy", "Duchenne", "myodystrophy", "metabolic", "mitochondrial", "congenital", "symptoms", "replacement", "recombinant", "corticosteroids", "vitamins", "tirasemtiv", "therapy", "treatment", "evidence", "clinical trials", "patients", "dichloracetate".

RESULTS AND DISCUSSION

1. General characteristics of hereditary myopathies

The most typical symptoms of myopathies are muscle weakness, myalgia, myopenia, and exercise intolerance. The clinical picture of myopathies can vary from asymptomatic forms with an increase in serum creatine kinase values and an increased tendency to hyperthermia to severe forms leading to skeletal deformities, as well as respiratory and heart failures. The groups of affected muscles can differ significantly –

from an isolated lesion of the oculomotor muscles [3] to a systemic muscle atrophy involving myocardium and diaphragm. The variability of clinical signs is associated both with the diversity of causative genes and with the degree of their function loss. For example, a severe muscle phenotype in Duchenne's muscle dystrophy is associated with neuropsychiatric disorders [4], and muscle symptoms in the phosphofructokinase deficiency (Tarui disease) are accompanied by hemolytic anemia and hyperuricemia [5]. Mitochondrial myopathies are characterized by especially high clinical heterogeneity [6]. Since multisystem disorders, nervous, digestive, urinary, cardiovascular, endocrine and reproductive systems, as well as the organs of vision and hearing often accompany a mitochondrial dysfunction, they can be involved in the pathological process (Table 1).

1.1. Muscular dystrophies

More than 30 muscular dystrophies have been identified, the most common of which are as follows: Duchenne's muscle dystrophy, facioscapulohumeral muscular dystrophy, Becker muscular dystrophy, limb-girdle and myotonic kinds of muscular dystrophy. Etiologically, these diseases are very heterogeneous. For example, Duchenne's muscle dystrophy and Becker dystrophy are caused by dystrophin mutations, while lumbar-limb muscular dystrophies can be caused by an impaired function of calpain, dysferlin, sarcoglycan, lamin, anoctamine, etc. [7]. In all cases, early signs of degeneration and then regeneration of some muscle fibers are usually found. The fibers that regenerate become larger than usual, and eventually the muscle is almost completely replaced by a fibrous scar tissue and fat.

The most classic type of such muscle disorders is Duchenne's dystrophy. It is caused by frameshift mutations in the MDD gene encoding the dystrophin protein, which is a plasma membrane-associated protein that plays a critical role in sarcolemma stabilizing in mechanical shifts during the muscle contraction or stretching [8, 9]. The dystrophin absence leads to a decrease in the resistance of sarcolemma and the subsequent necrosis of the muscle fibers [10]. The muscle fibers destruction is exacerbated by a mechanical stress and improves while the muscle immobilization [11, 12]. Thus, the accumulation of the damaged muscle fibers is the cause of the progressive course of Duchenne's myodystrophy. At the same time, the exact molecular mechanisms by which dystrophin plays the role of a mechanical stabilizer, are still unclear [13].

1.2. Congenital myopathies

Unlike muscular dystrophies, congenital myopathies are already manifested in the neonatal period [14]. This is due to the fact that the function of defective proteins is not associated with maintaining the integrity of already differentiated myocytes, but with

the structural organization of the muscle tissue even at the stage of histogenesis. Basically, these are the proteins involved in the formation of the cytoskeleton or intercellular substance. At the same time, these can be such multifunctional proteins as myotubularin, which is involved in the transfer of endosomes, coupling of excitation and contraction, the organization of intermediate filaments, and apoptosis.

Although the exact epidemiology of congenital myopathies is unknown, researchers estimate their incidence to be around 1:25 000 [15]. The classification of congenital myopathy is constantly being revised as more genes that are associated with its various phenotypic and histological manifestations, are identified. At the moment, it continues to be based mainly on the features observed in muscle biopsy [16]. Accordingly, congenital myopathy can be divided into the following five forms: rod myopathy; cardiac myopathy; centronuclear myopathy; congenital myopathy of a fiber type imbalance; myosin storage myopathy.

Clinically, congenital myopathies are manifested by muscle hypotonia and weakness, present at birth or appearing in infancy and not progressive during life. Depending on the causative gene and the nature of the mutation, the clinical spectrum varies from severe neonatal forms with congenital arthrogryposis to mild forms with isolated hyposthenia [14, 16]. In the neonatal period, symptoms tend to be more pronounced and may include reduced fetal movement and a subsequent development of arthrogryposis and clubfoot. Severe muscular hypotonia is often present at birth and in the first months of life (a sign of a lethargic baby) along with a frog-like posture, difficulty sucking, and a respiratory failure [17].

1.3. Metabolic myopathies

Metabolic myopathies are associated with mutations in the genes encoding energy metabolism enzymes. Biochemical disorders include disorders of fatty acids, glucose, or glycogen oxidation. As a result, the functional reserves of the muscle tissue are reduced, which is manifested by hypotension, increased fatigue, myalgia, convulsions, episodes of rhabdomyolysis, etc. [18]. At the same time, fatty acids utilization defects are characterized by a low tolerance to long-term endurance exercises, while disorders of glucose and glycogen metabolism are manifested by an intolerance to fast high-intensity exercises [19]. A separate feature of myopathies also associated with mutations of glycogenolysis enzymes, is the accumulation of intracellular glycogen inclusions [20].

1.4. Mitochondrial myopathies

The pathogenetic basis of mitochondrial myopathies is a violation of energy metabolism processes due to defects in the oxidative phosphorylation. In this regard, some authors consider mitochondrial myopathies as a subtype of metabolic ones. Nevertheless, a number of features of inheritance and pathogenesis, as well as some clinical characteristics, make it possible to distinguish them into a separate group. Thus, mitochondrial myopathies are always associated with impaired functioning of the electronic transport chain (ETC), most often with defects in complex 1 [21–23]. In addition, mitochondrial myopathies can be caused by mutations in both nuclear and mitochondrial genes. In case of mitochondrial DNA mutations, inheritance occurs almost exclusively maternally [24]. The severity of symptoms is determined not only by the pathogenicity of the mutation, but also by the number of the mutant mitochondrial DNA copies that the body has inherited from the mother [25]. The fact is that the mitochondrial genome is heterogeneous (the phenomenon of heteroplasmy) and, along with mutant ones, healthy mitochondria are always present in the cell. Thus, the proportion of defective mitochondria is determined randomly with a random distribution of mitochondria between the daughter cells, which is called the "bottleneck" phenomenon [26].

In general terms, mitochondrial myopathies are mitochondrial diseases, in the spectrum of clinical manifestations of which there are pronounced symptoms from the muscle tissue. Mitochondrial myopathies are characterized by a progressive course and a wide range of associated symptoms, including epilepsy, neuropathy, sensory impairments, etc. [27].

2. Treatment of hereditary myopathy

Treatment of hereditary myopathies varies widely depending on the type and specific disease. A significant proportion of therapeutic interventions in the treatment of myopathies patients are the approaches based on diet, exercise therapy and massage. For example, in metabolic myopathies associated with impaired glucose utilization, the most important therapeutic approach is a low-carbohydrate ketogenic diet [53]. When correcting congenital myopathies, patients are recommended a controlled physical activity, as well as the use of special corsets to prevent the development of bone deformities.

Pharmacological approaches occupy an important place in symptomatic, supportive, and pathogenetic-oriented kinds of therapy. In addition, high rates development of antisense and gene therapy have recently made it possible to focus on etiotropic approaches in the treatment of myopathies patients.

As with most monogenic diseases associated with the gene function loss, conventional specific therapy can be aimed at: 1) replacement of the mutant protein; 2) increase in its expression; 3) stimulation of the expression of internal compensatory pathways; 4) restoration of the balance of compounds associated with the function of the mutant protein (for enzymes).

Table 1 – General clinical characteristics of hereditary myopathies

Group of congenital myopathies	Examples of diseases	Clinical manifestations	Proteins with impaired function	Pathogenesis
Muscular dystrophies	Miyoshi myopathy	Distal skeletal muscle weakness Elevated levels of creatine kinase in the blood First symptoms occur during adolescence [28, 29]	Dysferlin [30]	Dysferlin is a membrane-associated linker protein; its function is to mediate calcium-dependent regeneration of mechanical damage to sarcolemma. With mutations that disrupt the dysferlin function; the accumulation of damage to sarcolemma occurs, which leads to progressive dystrophy of skeletal muscles [31].
	Limb-girdle muscular dystrophy type 2B (LGMD2B)	Proximal skeletal muscle weakness Elevated levels of creatine blood kinase Manifestation at the age from 10 to 30 years [32, 33]		
	Duchenne's myodystrophy	Muscular hypotension Heart failure Respiratory distress Debut in early postnatal or postnatal age Death before age of 20 [34, 35]	Dystrophin [36]	Dystrophin is involved in the mechanical stabilization of sarcolemma. In case of loss of the protein product dysferlin due to large deletions or a shift in the reading frame, sarcolemma becomes vulnerable to mechanical deformations that occur during muscle contraction or stretching [37]. Since dystrophin plays an important role in the processes of mitotic division, Duchenne's disease disrupts cell polarity and myogenic differentiation of stem cells. Stem cells lacking functional dystrophin undergo aberrant asymmetric division with centrosome amplification, spindle orientation errors, and an extended cell cycle [38, 39].
Congenital myopathies	Myosin storage myopathy	Muscular hypotension Hypertrophic or dilated cardiomyopathy Manifestation in the neonatal or postnatal period	MYH7 (heavy chain of slow/β-cardiac myosin)	MYH7 is the main myosin isoform in slow oxidative type 1 muscle fibers of skeletal muscles and myocardium. Numerous missense mutations in the MYH7 globular head lead to disruption of the structural protein function and the formation of large inclusions consisting of myosin chains.
	Bethlem muscular dystrophy	Weakness of proximal muscles Joints contracture Hypotension progresses slowly, and more than two-thirds of patients older than 50, continue to move independently. Possible damage to the respiratory muscles [40].	Type VI collagen	Collagen VI is an extracellular matrix protein that forms a microfibrillar network. The protein consists of three different α-chains encoded by separate genes named COL6A1, COL6A2 and COL6A3 in humans. Potential effects on muscles include progressive dystrophic changes, fibrosis, and signs of increased apoptosis [41].
Metabolic myopathies	Pompe's disease	Muscular hypotension Hepatomegaly Heart failure Neurological disorders Debut at any age (an early debut correlates with a more severe course) [42]	Acid maltase [43]	After entering the lysosomes, acid maltase mediates the catalytic breakdown of glycogen by interacting with the mannose-6-phosphate receptor [44]. More than 500 mutations including insertions, deletions, splicing site mutations, nonsense and missense mutations, have been found. They disrupt the functional activity of acid maltase, leading to glycogenosis and energy deficiency of the muscle tissue [45, 46].
	Tarui disease	Muscle weakness Muscle cramps Encephalopathy Hemolytic anemia Rhabdomyolysis risk Debut at any age [47]	Phosphofructokinase [48]	Phosphofructokinase catalyzes the transfer of a phosphate group from ATP to fructose-6-phosphate, which is one of the key elements of glycolysis. In humans, three isozymes named M (muscle), L (liver), and P (platelets), have been identified, Mutations in phosphofructokinase-M lead to muscle weakness due to an energy deficiency in working muscles [49].
Mitochondrial myopathies	Myoclonus epilepsy with myopathy and sensory ataxia (MEMSA)	Proximal and/or distal myopathy Muscular hypotension Myoclonic epilepsy Encephalopathy Sensory ataxia Debut at any age [50]	Polymerase gamma (POLG) [51]	Gamma polymerase is a key enzyme of a mitochondrial DNA replication Mutations in the POLG gene lead to the energy deficiency due to the accumulation of defective mitochondria and a decrease in the number of mtDNA copies (mtDNA depletion), especially in muscle, brain, or liver cells [52].

Figure 1 – Classical pharmacological methods to compensate for inadequate functioning of mitochondria

Figure 2 – Varies of existing pharmacological methods for hereditary myopathies correction depending on disease type

2.1. Mutant protein substitution

Currently, a number of recombinant enzymes have been approved for the specific myopathies therapy. One of the approved approaches is the enzyme replacement therapy for type II glycogenosis (Pompe's disease) with recombinant human alglucosidase alfa (rhGAA; Myozyme© (ex-US) and Lumizyme© (USA), which has been available since 2006, or with avalglucosidase alfa (NEXVIAZYME™; avalglucosidase alfa-ngpt) available since 2021 [54, 55].

Obviously, replacement therapy with recombinant forms of proteins is not the main strategy, since most exogenous proteins cannot penetrate intracellularly to carry out their functions. However, the approaches to directly modify proteins and peptides to enhance cytosolic translocation, continue to be a promising method for improving the delivery efficiency and extending the viability of intracellular protein therapeutics. Among the proposed approaches to improve the cytosolic delivery of exogenous proteins, there have been such as chemical recharging or the inclusion of intracellular internalization motifs [56]. For example, the enzyme replacement therapy with a modified recombinant protein has been proposed for the treatment of X-linked myotubular myopathy. In the preclinical study on Mtm1 δ4 mice with a myotubularin gene knockout, the replacement therapy with recombinant 3E10Fv-MTM1 protein (0.1 mg/kg) into the tibialis anterior muscle twice a week significantly improved the muscle function [57].

2.2. Increase in expression

Some nucleotide substitutions called nonsense mutations, lead to the formation of a stop codon in the coding gene region, resulting in the premature termination of the desired protein synthesis. In addition, mRNA resulting from nonsense mutations is destabilized by a nonsense-mediated decay [58]. Similar mutations are often the cause of hereditary myopathies. Such mutations are found in approximately 10% of Duchenne's patients [59] and in 20% of individuals with X-linked myotubular myopathy (XLMTM) [60].

To restore the expression of the full amino acid sequence, the drugs that force the reading of termination codons were proposed [61]. For example, these were aminoglycosides containing a 2-deoxystreptamine ring bind to the small ribosomal RNA subunit, reducing the accuracy of translation [62]. This property made it possible to propose the use of aminoglycosides for the treatment of Duchenne's myodystrophy [63] and a number of other monogenic diseases caused by premature stop codon mutations [64, 65].

However, serious side effects of aminoglycosides, such as nephrotoxicity and ototoxicity, limit their long-term use. In this regard, alternative agents have been proposed, including suppressor tRNAs and small interfering RNAs (siRNAS) [66] and ataluren [67]. However, only ataluren is currently approved for a clinical use [68].

Theoretically, the termination forcing approach could help treat all hereditary myopathies associated with premature stop codons. Restoration of translation does not always lead to the formation of a functional protein, which, apparently, is associated with impaired intracellular traffic and post-translational modifications of the product [69]. To date, the termination-forcing strategy has been approved for only use with nonsense mutations that cause Duchenne's muscular dystrophy. In addition, despite a high proportion of nonsense mutations in myopathies, their heterogeneity and a low prevalence of each specific disease in the general population make it difficult to conduct full-fledged clinical studies [57].

2.3. Stimulation of internal compensatory pathways expression

In some cases, a decrease or absence of protein expression can be partially compensated for hyperactivation of internal pathways that can functionally mitigate the defect. For example, the severity of muscle pathology in dystrophin defects can be reduced due to the myogenic stimulation, which leads to an increase in the expression of myocyte structural proteins. Non-clinical studies demonstrate that inhibitors of histone deacetylases have a pronounced therapeutic effect in some myopathies. Apparently, due to the regulatory activity in relation to epigenetic modifications, such compounds increase the activity of myogenic differentiation of myocyte precursors. *In vitro* studies have found out that inhibitors of histone deacetylases enhance myogenesis and the formation of enlarged skeletal myotubes [70, 71]. When administered to the dystrophy mice, the drugs had similar beneficial effects. In the mdx mice, the inhibitors increased the cross-sectional area of myofibrils, reducing the histological signs of inflammation and remodeling [72]. Interestingly, among the compounds with an inhibitory activity against histone deacetylases, such well-known drugs as trichostatin A and valproic acid can be distinguished. Herewith, computational biology methods have shown that trichostatin A has the ability to weaken the posttranscriptional repression of utrophin, which has a significant similarity in sequence and functional motifs with dystrophin, including the ability to bind the same dystrophin-associated glycoprotein complex [73, 74]. Utrophin is expressed in fetal tissues at high levels and is inhibited during its development in adults. It was found out that in mice, a decrease in the level of utrophin programmed in embryogenesis corresponds to the onset of muscle necrosis [75]. At the same time, the gene therapy approaches aimed at the

delivery of utrophin, significantly improve the condition of Duchenne's myodystrophy mice [76]. Trichostatin A is currently undergoing clinical trials for the treatment of Duchenne's muscular dystrophy. At the same time, the specific utrophin modulator ezutromid/SMT C1100 demonstrated unsatisfactory results in phase II clinical trials and was withdrawn [77]. At present, the search for an optimal candidate for increasing utrophin expression continues [78].

2.4. Restoring Balance of Compounds Associated with Mutant Protein Function

In some cases, in addition to repairing the deficiency of the protein itself, a strategy for the delivery of compounds related to its catalytic function can be used (Fig. 1). Obviously, such an approach can be implemented in only metabolic and mitochondrial myopathies, where the cause of the disease is the metabolic enzyme deprivation function, and not the one of structural protein or kinase. The main principle of this approach is based on the fact that the use of an exogenous metabolite compensates for its endogenous deficiency, restoring the efficiency of the entire biochemical chain. For example, it has been known since the 1960s that intravenous glucose improves the exercise tolerance in patients with McArdle's disease, which is associated with a defect in the conversion of glycogen to glucose [79]. Glucose therapy is also effective in some other diseases associated with mutations in the proximal enzymes of glycogen catabolism [80–82]. Another example is the use of triheptanoin, a synthetic medium-length triglyceride that restores the energy efficiency of long-chain fatty acid oxidation in the presence of mutations in proximal catabolism enzymes [83]. Triheptanoin has demonstrated a significant improvement in cardiac and muscle symptoms in VLCAD syndrome patients and in patients with carnitine palmitoyltransferase 2 deficiency [84, 85]. In some cases, an effective strategy to increase the concentration of compounds that serve as substrates for the bypass or an alternative biochemical cascade is also used. Thus, for example, in case of a defect in the formation of ATP along the pathway of fatty acid oxidation, an increase in glucose concentration can compensate for the total energy deficiency due to glycolysis [86]. A similar effect can be achieved with the use of creatine. Creatine is a skeletal muscle amino acid that serves as a substrate for the formation of creatine phosphate, a phosphate group donor for the conversion of ADP to ATP by the enzyme creatine kinase. In a number of studies, the administration of exogenous creatine has shown a therapeutic effect on the muscle symptoms in metabolic myopathies [62, 63].

2.5. Mitotropic drugs

Various cofactors, including riboflavin, coenzyme Q10, vitamins B6 and B3, can be used to partially compensate for the disorders caused by a dysfunction of one of the metabolic pathways (Fig. 1). These drugs can partially increase the energy efficiency of cells due to a positive effect on oxidative phosphorylation in mitochondria [88]. It is known that vitamin B3 (nicotinic acid) serves as a substrate for the formation of NAD and NADP, thereby facilitating the transfer of hydrogen from the tricarboxylic acid cycle to complex 1. Coenzyme Q10 (ubiquinone), in turn, is directly involved in the transfer of electrons from the NADH dehydrogenase complex (complex I) and succinate dehydrogenase complex (II) to complex III.

The use of cofactors is one of the main therapeutic options for mitochondrial myopathies. However, due to the lack of full-fledged clinical studies, it is impossible to judge the effectiveness of this approach in terms of evidence-based medicine. Moreover, the vast majority of these compounds are registered as food additives [89]. Obviously, the approaches based on the use of cofactors do not have a dramatic clinical effect due to e thweak mitochondrial transport, nonselectivity of the action, and a weak overlap with the pathogenetic mechanisms of the disease [90, 91]. The use of vitamin and cofactor cocktails is more justified when the number of factors considered is reduced due to their deficiency or transport defect now when this approach can be considered as replacement therapy [42, 68, 69].

In general, there are still not so many effective methods for restoring a mitochondrial function in mitochondrial mutations from the point of view of evidence-based medicine. In addition to cofactors, mitotropic compounds are represented by antioxidants, mitoprotectors, incl. dichloroacetate, arginine, coenzyme Q10, idebenone, etc. [70, 71]. Pharmacological approaches aimed at improving the function of mitochondria are based on the use of a very wide range of drugs [89, 90, 94]. Some of the most requested connections are shown in Fig. 1.

Classical pharmacological methods of compensating for inadequate functioning of mitochondria are based on increasing the activity of mitochondrial metabolic cascades and reducing the content of toxic agents such as lactate and reactive oxygen species (ROS). E.g., bezafibrate has been shown to stimulate mitochondrial biogenesis by activating the PGC-1a/PPAR pathway. In addition, acipimox, nicotinamide and riboside restore the content of NAD$^+$, increasing the efficiency of electron transfer to the ETC.

Thiamine, lipoic acid and dichloroacetate activate pyruvate dehydrogenase, which leads to a decrease in the lactate accumulation due to the conversion of pyruvate to another metabolite, acetyl-CoA. Succinate, riboflavin, and CoQ10 promote the ETC electron transfer or restore the function of complexes I and II. Some

compounds, such as idebenone, N-acetylcysteine, and lipoic acid, have the ability to reduce or inactivate the ROS production. Elamepritide stabilizes mitochondrial membrane lipids, preventing a mitochondrial destruction.

In case of a deficiency of certain lipid or carbohydrate metabolism enzymes, the deficiency replenishing strategy of compounds in the biochemical chain after the reaction catalyzed by the mutant enzyme, has a therapeutic efficacy. E.g., with a defect in the utilization of long-chain fatty acids, the use of heptanoin, a more proximal component included in the tricarboxylic acid (TCA) cycle, is justified. Similarly, in case of glycogen cleavage defects, the therapeutic potential is the use of exogenous glucose. Finally, the defects in the oxidative phosphorylation and mitochondrial function can be partially compensated for by the use of creatine, which acts in muscles as an alternative carrier of the high-energy phosphate bond in the formation of creatine phosphate.

2.6. Anti-inflammatory therapy

Anti-inflammatory therapy is one of the key approaches to the treatment of muscular dystrophies [96]. Inflammatory changes may accompany other types of myopathies, but this is extremely rare [97].

Currently, the only approved approach aimed at suppressing the inflammatory process in myodystrophy is corticosteroid therapy. However, it is important to emphasize that, despite the progressive death of muscle fibers, anti-inflammatory therapy is not necessary for all muscular dystrophies. E.g., treatment with deflazacort in dysferlinopathies patients neither improved nor showed any trend towards a decrease in muscle strength [98].

Corticosteroids have been shown in clinical trials to improve muscle strength and function without clinically serious side effects [99, 100]. Moreover, glucocorticoids have been shown to increase the utrophin expression [101].

In view of the serious side effects developed during a long-term use of corticosteroids, the search for other anti-inflammatory therapy strategies continues. For example, among the strategies tested in myodystrophy, inhibitors of cyclooxygenase (COX), tumor necrosis factor-alpha (TNF-α) and its receptor, as well as TRPV2 channels, can be distinguished.

Non-steroidal anti-inflammatory drugs (NSAIDs) have shown a relatively modest efficacy in a mouse model of Duchenne's dystrophy. Despite the fact that the use of aspirin and ibuprofen improved the morphological picture of muscles and reduced the inflammatory infiltration and necrosis, the percentage of regenerating myofibrils and isometric tension did not change significantly [102].

The spectrum of the pharmacological activity of the antiallergic drug tranilast includes blockade of TRPV2 [103], therefor its use led to a decrease in fibrosis in skeletal muscles and an increase in the exercise tolerance [104, 105].

Inhibitors of TNF-α have shown some potential in the treatment of myodystrophy. The use of etanercept or an anti-TNF-α antibody slowed down the course of the disease and also reduced the inflammation and destruction of dystrophic muscles in mdx mice without the development of pronounced side effects [106, 107].

2.7. Antifibrotic therapy

An extracellular matrix is an important component of skeletal muscles. It provides a scaffold structure that holds the myofibrils and vessels. In addition, it plays a major role in the processes of biomechanical contraction, as well as in maintaining the integrity and repair of muscle fibers. An excessive accumulation of extracellular matrix components, especially collagen, is defined as fibrosis. An excess formation of the connective tissue as a result of death and defect in muscle cells proliferation is the most important distinguishing feature of muscular dystrophies. Since the dynamics of fibrotic replacement in myodystrophy strongly correlates with the development of muscle symptoms, antifibrotic therapy is one of the main approaches to treating such patients [108].

Tamoxifen is a prodrug, and some of its metabolites interact with the nuclear estrogen receptor, mediating antifibrotic and myoprotective effects. A multicenter, prospective study in 13 outpatient boys aged 6–14 years with genetically confirmed Duchenne's muscular dystrophy demonstrated that patients treated with tamoxifen 20 mg/daily maintained a motor and respiratory functions, compared with a significant deterioration in the patients of the same history of age who had been administrated with only corticosteroids [109].

A similar approach has also shown off its efficacy in a mouse model of dystroglycanopathy. In the studies by Wu B. et al. it has been demonstrated that tamoxifen and raloxifene significantly alleviate a disease progression in the animals with the c.1343C>T mutation of the FKRP gene, demonstrating a pronounced phenotype of a limb-girdle muscular dystrophy [110].

A primary profibrotic signal in skeletal muscles, as in other tissues, is a transforming growth factor-beta (TGFβ) [111]. A high expression of TGFβ is a characteristic feature of dystrophic muscles [112] and is considered one of the main therapeutic targets for reducing fibrosis. It has been shown that Wnt-TGFβ2 is one of the key factors mediating the differentiation of dystrophin-deficient muscle cell precursors in the fibrogenic direction. Antibodies stabilizing LTBP4, which is a TGFβ binding factor, demonstrated a high efficiency.

Anti-LTBP4 treatment also reduced muscle fibrosis and increased muscle strength, including the ones in the diaphragm muscles [113].

The renin-angiotensin system plays an important role in the transmission of profibrotic signals. In particular, the activation of the angiotensin 1 receptor stimulates fibrosis. At the same time, it has been shown that the antihypertensive drug with an inhibitory activity against TGFβ2 losartan led to an increase in the level of myogenic factors with a reduced expression of fibrogenic genes in mdx mice (Duchenne's myodystrophy model) [112].

Interestingly, another drug that blocks the renin-angiotensin-aldosterone axis, enalapril, also exhibits inhibitory effects on the connective tissue growth factor (CTGF/CCN2) [114] and is another regulator of profibrotic signaling [115, 116]. Pharmacological blockade of CTGF has been shown to slow the progression of fibrosis and improve a muscle function in mdx mice [114]. Moreover, anti-muscle CTGF therapy is currently undergoing clinical trials for the treatment of Duchenne's muscular dystrophy [117].

2.8. Means with a positive effect on muscle strength

A decreased muscle strength is the main symptom of myopathies. In this regard, in addition to other approaches, strategies have been developed to increase the effectiveness of the muscle contraction or the prevention of myopenia.

For example, tirasemtiv, fast skeletal troponin activator acting on thin filaments, has been shown to be effective as an agent that increases muscle strength, and can be used to compensate for hypotension in the muscle dysfunction. In the studies on genetically modified mice and cells from a patient with rod myopathy carrying an actin mutation (ACTA1H40Y), treatment with tirasemtiv increased inotropic parameters to those comparable to healthy controls [118].

One of the most popular targets for regulating a muscle mass is myostatin. A decrease in signaling of this myokine leads to a sharp increase in the muscle mass due to the intensification of the muscle fiber growth [119]. The first similar drug, domagruzumab (PF-06252616, Pfizer), which is a recombinant humanized antibody to myostatin, was withdrawn during the second phase of clinical trials, despite the fact that in the first phase, a 6.1% increase in the muscle mass after treatment was shown compared with a placebo group [120]. Another antimyostatin drug, BMS-986089, has demonstrated its high efficacy in preclinical test systems in mice and cynomolgus monkeys, and is currently undergoing clinical trials. However, in general, despite the theoretical promise of the approach and positive

initial results, the recent clinical data demonstrate that antimyostatin therapy is less effective than expected. In addition, the long-term effects of antimyostatin therapy require a particularly close study, due to the possible negative impact on the pool of myosatellite cells [121].

CONCLUSION

Hereditary myopathies are a group of incurable diseases with a wide range of symptoms and a high variability in the clinical course. Currently, a large number of therapeutic approaches have been developed and approved for the use in various types of myopathies (Fig. 2). The most developed are the methods for the correction of muscular dystrophies, which, due to the progressive nature of the course, have the largest number of pathogenetic pathways that can be targets for therapy. At the same time, the smallest number of therapeutic options is available for the treatment of congenital myopathies, where the hereditary defect is permanently manifested throughout life, and there are no secondary alteration factors, such as inflammation and fibrosis. In addition, with the exception of some nosologies, there are no effective approaches to correct metabolic and mitochondrial myopathies.

In the treatment of all myopathies, an important role is played by symptomatic and supportive therapy aimed at treating pain and symptoms from other organs and systems. Osteoporosis [122] and pneumonia are regular consequences arising from hypodynamia myopathies, which are treated according to standard schemes.

It should be notified that in recent years, gene therapy approaches that correct or compensate for a defect at the gene level have become increasingly important. These approaches were not been covered in the work, the aim of which was to analyze the existing conventional strategies. However, to date, it is gene and cell therapy that constitute the most growing and promising layer of pharmacological agents for the treatment of hereditary myopathies.

In congenital myopathies, tirasemtiv, rapid skeletal troponin activator acting on thin filaments, has been shown to be effective. Theoretically, this approach can be effective in other types of myopathies. For the treatment of muscular dystrophies, anti-inflammatory and antifibrotic drugs, as well as antimyostatin therapy and a strategy aimed at translation through stop codons (applicable for nonsense mutations), can be used. In addition, metabolic drugs, metabolic enzyme cofactors, mitochondrial biogenesis stimulants, and antioxidants can be used to treat mitochondrial and metabolic myopathies. Finally, the recombinant drugs alglucosidase and avalglucosidase have been clinically approved for the replacement therapy of metabolic myopathies (Pompe's disease).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHORS' CONTRIBUTION

MVP – idea creating, article concept planning, advising on writing of individual manuscript sections; MVK – idea development, article writing; AMK –literature analysis, article writing; NSZ – literature analysis, article writing; KNL – article writing, graphic material preparing; MOS – literature analysis, article writing; EAK– literature analysis, article writing; OSG – literature analysis, article writing; ISK – literature analysis, article writing; AVD – article concept planning, article writing.

REFERENCES

1. Cardamone M, Darras BT, Ryan MM. Inherited myopathies and muscular dystrophies. Semin Neurol. 2008 Apr;28(2):250–9. DOI: 10.1055/s-2008-1062269
2. Butterfield RJ. Congenital Muscular Dystrophy and Congenital Myopathy. Continuum (Minneap Minn). 2019 Dec;25(6):1640–61. DOI: 10.1212/CON.0000000000000792
3. Yu Wai Man CY, Smith T, Chinnery PF, Turnbull DM, Griffiths PG. Assessment of visual function in chronic progressive external ophthalmoplegia. Eye (Lond). 2006 May;20(5):564–8. DOI: 10.1038/sj.eye.6701924
4. Naidoo M, Anthony K. Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy. Mol Neurobiol. 2020 Mar;57(3):1748–67. DOI: 10.1007/s12035-019-01845-w
5. Toscano A, Musumeci O. Tarui disease and distal glycogenoses: clinical and genetic update. Acta Myol. 2007 Oct;26(2):105–7.
6. Pfeffer G, Chinnery PF. Diagnosis and treatment of mitochondrial myopathies. Ann Med. 2013 Feb;45(1):4–16. DOI: 10.3109/07853890.2011.605389
7. Isabekova PS, Alekseeva TM. [The hereditary progressive limb-girdle muscular dystrophy type 2l (anoctominopathy)]. Modern problems of science and education. 2020;(4):62. Russian
8. Ervasti JM, Campbell KP. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol. 1993 Aug;122(4):809–23. DOI: 10.1083/jcb.122.4.809
9. Vilquin JT, Brussee V, Asselin I, Kinoshita I, Gingras M, Tremblay JP. Evidence of mdx mouse skeletal muscle fragility in vivo by eccentric running exercise. Muscle Nerve. 1998 May;21(5):567–76. DOI: 10.1002/(sici)1097-4598(199805)21:5<567::aid-mus2>3.0.co;2-6
10. Weller B, Karpati G, Carpenter S. Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J Neurol Sci. 1990 Dec;100(1–2):9–13. DOI: 10.1016/0022-510x(90)90005-8
11. Mizuno Y. Prevention of myonecrosis in mdx mice: Effect of immobilization by the local tetanus method. Brain and Development. 1992;14 (Issue 5):319–22. DOI: 10.1016/S0387-7604(12)80151-3
12. Mokhtarian A, Lefaucheur JP, Even PC, Sebille A. Hindlimb immobilization applied to 21-day-old mdx mice prevents the occurrence of muscle degeneration. J Appl Physiol (1985). 1999 Mar;86(3):924–31. DOI: 10.1152/jappl.1999.86.3.924
13. Le S, Yu M, Hovan L, Zhao Z, Ervasti J, Yan J. Dystrophin As a Molecular Shock Absorber. ACS Nano. 2018 Dec 26;12(12):12140–8. DOI: 10.1021/acsnano.8b05721
14. North KN, Wang CH, Clarke N, Jungbluth H, Vainzof M, Dowling JJ, Amburgey K, Quijano-Roy S, Beggs AH, Sewry C, Laing NG, Bönnemann CG; International Standard of Care Committee for Congenital Myopathies. Approach to the diagnosis of congenital myopathies. Neuromuscul Disord. 2014 Feb;24(2):97–116. DOI: 10.1016/j.nmd.2013.11.003
15. Tubridy N, Fontaine B, Eymard B. Congenital myopathies and congenital muscular dystrophies. Curr Opin Neurol. 2001 Oct;14(5):575–82. DOI: 10.1097/00019052-200110000-00005
16. Jungbluth H, Voermans NC. Congenital myopathies: not only a paediatric topic. Curr Opin Neurol. 2016 Oct;29(5):642–50. DOI: 10.1097/WCO.0000000000000372
17. Cassandrini D, Trovato R, Rubegni A, Lenzi S, Fiorillo C, Baldacci J, Minetti C, Astrea G, Bruno C, Santorelli FM; Italian Network on Congenital Myopathies. Congenital myopathies: clinical phenotypes and new diagnostic tools. Ital J Pediatr. 2017 Nov 15;43(1):101. DOI: 10.1186/s13052-017-0419-z
18. Olpin SE, Murphy E, Kirk RJ, Taylor RW, Quinlivan R. The investigation and management of metabolic myopathies. J Clin Pathol. 2015 Jun;68(6):410–7. DOI: 10.1136/jclinpath-2014-202808
19. Tein I. Metabolic myopathies. Semin Pediatr Neurol. 1996 Jun;3(2):59–98. DOI: 10.1016/s1071-9091(96)80038-6
20. Tarnopolsky MA. Metabolic Myopathies. Continuum (Minneap Minn). 2016 Dec;22(6, Muscle and Neuromuscular Junction Disorders):1829–51. DOI: 10.1212/CON.0000000000000403
21. Kirby DM, Crawford M, Cleary MA, Dahl HH, Dennett X, Thorburn DR. Respiratory chain complex I deficiency: an underdiagnosed energy generation disorder. Neurology. 1999 Apr 12;52(6):1255–64. DOI: 10.1212/wnl.52.6.1255
22. Fassone E, Rahman S. Complex I deficiency: clinical features, biochemistry and molecular genetics. J Med Genet. 2012 Sep;49(9):578–90. DOI: 10.1136/jmedgenet-2012-101159. Erratum in: J Med Genet. 2012 Oct;49(10):668.
23. Abramov AY, Angelova PR. Cellular mechanisms of complex I-associated pathology. Biochem Soc Trans. 2019 Dec 20;47(6):1963–9. DOI: 10.1042/BST20191042
24. Chiaratti MR, Macabelli CH, Augusto Neto JD, Grejo MP, Pandey AK, Perecin F, Collado MD. Maternal transmission of mitochondrial diseases. Genet Mol Biol. 2020 Mar 2;43(suppl.1):e20190095. DOI: 10.1590/1678-4685-GMB-2019-0095

25. van den Ameele J, Li AYZ, Ma H, Chinnery PF. Mitochondrial heteroplasmy beyond the oocyte bottleneck. Semin Cell Dev Biol. 2020 Jan;97:156–66. DOI: 10.1016/j.semcdb.2019.10.001

26. Floros VI, Pyle A, Dietmann S, Wei W, Tang WCW, Irie N, Payne B, Capalbo A, Noli L, Coxhead J, Hudson G, Crosier M, Strahl H, Khalaf Y, Saitou M, Ilic D, Surani MA, Chinnery PF. Segregation of mitochondrial DNA heteroplasmy through a developmental genetic bottleneck in human embryos. Nat Cell Biol. 2018 Feb;20(2):144–51. DOI: 10.1038/s41556-017-0017-8

27. Ahmed ST, Craven L, Russell OM, Turnbull DM, Vincent AE. Diagnosis and Treatment of Mitochondrial Myopathies. Neurotherapeutics. 2018 Oct;15(4):943–53. DOI: 10.1007/s13311-018-00674-4

28. Miyoshi K, Kawai H, Iwasa M, Kusaka K, Nishino H. Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy. Seventeen cases in eight families including an autopsied case. Brain. 1986 Feb;109 (Pt 1):31–54. DOI: 10.1093/brain/109.1.31

29. Bushby K, Straub V. One gene, one or many diseases? Simplifying dysferlinopathy. Neurology. 2010 Jul 27;75(4):298–9. DOI: 10.1212/WNL.0b013e3181ea1649

30. Nguyen K, Bassez G, Bernard R, Krahn M, Labelle V, Figarella-Branger D, Pouget J, Hammouda el H, Béroud C, Urtizberea A, Eymard B, Leturcq F, Lévy N. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Hum Mutat. 2005 Aug;26(2):165. DOI: 10.1002/humu.9355

31. Le Rumeur E, Winder SJ, Hubert JF. Dystrophin: more than just the sum of its parts. Biochim Biophys Acta. 2010 Sep;1804(9):1713–22. DOI: 10.1016/j.bbapap.2010.05.001

32. Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB, Bohlega S, Culper EJ, Amato AA, Bossie K, Oeltjen J, Bejaoui K, McKenna-Yasek D, Hosler BA, Schurr E, Arahata K, de Jong PJ, Brown RH Jr. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998 Sep;20(1):31–6. DOI: 10.1038/1682

33. Harris E, Bladen CL, Mayhew A, James M, Bettinson K, Moore U, Smith FE, Rufibach L, Cnaan A, Bharucha-Goebel DX, Blamire AM, Bravver E, Carlier PG, Day JW, Díaz-Manera J, Eagle M, Grieben U, Harms M, Jones KJ, Lochmüller H, Mendell JR, Mori-Yoshimura M, Paradas C, Pegoraro E, Pestronk A, Salort-Campana E, Schreiber-Katz O, Semplicini C, Spuler S, Stojkovic T, Straub V, Takeda S, Rocha CT, Walter MC, Bushby K; Jain COS Consortium. The Clinical Outcome Study for dysferlinopathy: An international multicenter study. Neurol Genet. 2016 Aug 4;2(4):e89. DOI: 10.1212/NXG.0000000000000089

34. Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. Neurol India. 2008;56:236–47. DOI: 10.4103/0028-3886.43441

35. Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health. 2015 Aug;51(8):759–64. DOI: 10.1111/jpc.12868

36. Flanigan KM. Duchenne and Becker muscular dystrophies. Neurol Clin. 2014 Aug;32(3):671–88, viii. DOI: 10.1016/j.ncl.2014.05.002

37. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003 Dec;2(12):731–40. DOI: 10.1016/s1474-4422(03)00585-4

38. Chang NC, Chevalier FP, Rudnicki MA. Satellite Cells in Muscular Dystrophy – Lost in Polarity. Trends Mol Med. 2016 Jun;22(6):479–96. DOI: 10.1016/j.molmed.2016.04.002

39. Dumont NA, Wang YX, von Maltzahn J, Pasut A, Bentzinger CF, Brun CE, Rudnicki MA. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med. 2015 Dec;21(12):1455–63. DOI: 10.1038/nm.3990

40. Bönnemann CG. The collagen VI-related myopathies Ullrich congenital muscular dystrophy and Bethlem myopathy. Handb Clin Neurol. 2011;101:81–96. DOI: 10.1016/B978-0-08-045031-5.00005-0

41. Bönnemann CG. The collagen VI-related myopathies: muscle meets its matrix. Nat Rev Neurol. 2011 Jun 21;7(7):379–90. DOI: 10.1038/nrneurol.2011.81

42. Katzin LW, Amato AA. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy. J Clin Neuromuscul Dis. 2008 Jun;9(4):421–31. DOI: 10.1097/CND.0b013e318176dbe4

43. Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, Zora M, Scalia S, Brando C, Curto AL, Marsana EM, Olivieri R, Vitale S, Duro G. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging (Albany NY). 2020 Aug 3;12(15):15856–74. DOI: 10.18632/aging.103794

44. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol. 2003 Mar;4(3):202–12. DOI: 10.1038/nrm1050

45. Kohler L, Puertollano R, Raben N. Pompe Disease: From Basic Science to Therapy. Neurotherapeutics. 2018 Oct;15(4):928–42. DOI: 10.1007/s13311-018-0655-y

46. Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease: a comprehensive overview. Ann Transl Med. 2019 Jul;7(13):278. DOI: 10.21037/atm.2019.04.13

47. Tarlow MJ, Ellis DA, Pearce GW, Anderson M. Muscle phosphofructokinase deficiency (Tarui's disease). Proc Nutr Soc. 1979 Dec;38(3):110A.

48. Vorgerd M, Zange J, Kley R, Grehl T, Hüsing A, Jäger M, Müller K, Schröder R, Mortier W, Fabian K, Malin JP, Luttmann A. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Arch Neurol. 2002 Jan;59(1):97–101. DOI: 10.1001/archneur.59.1.97

49. Yamasaki T, Nakajima H. [Phosphofructokinase (PFK)]. Nihon Rinsho. 2004 Dec;62 Suppl 12:835-9. Japanese

50. Wong LJ, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, Milone M, Cohen BH, Wical B, Ganesh J, Basinger AA, Burton BK, Swoboda K, Gilbert DL, Vanderver A, Saneto RP, Maranda B, Arnold G, Abdenur JE, Waters PJ, Copeland WC. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat. 2008 Sep;29(9):E150–72. DOI: 10.1002/humu.20824

51. Cohen BH, Chinnery PF, Copeland WC. POLG-Related Disorders. 2010 Mar 16 [Updated 2018 Mar 1]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26471/.

52. Rajakulendran S, Pitceathly RD, Taanman JW, Costello H,

Sweeney MG, Woodward CE, Jaunmuktane Z, Holton JL, Jacques TS, Harding BN, Fratter C, Hanna MG, Rahman S. A Clinical, Neuropathological and Genetic Study of Homozygous A467T POLG-Related Mitochondrial Disease. PLoS One. 2016 Jan 6;11(1):e0145500. DOI: 10.1371/journal.pone.0145500

53. Adler M, Shieh PB. Metabolic Myopathies. Semin Neurol. 2015 Aug;35(4):385–97. DOI: 10.1055/s-0035-1558973

54. Meena NK, Raben N. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder. Biomolecules. 2020 Sep 18;10(9):1339. DOI: 10.3390/biom10091339

55. Dhillon S. Avalglucosidase alfa: First Approval. Drugs. 2021 Oct;81(15):1803–9. DOI: 10.1007/s40265-021-01600-3

56. Horn JM, Obermeyer AC. Genetic and Covalent Protein Modification Strategies to Facilitate Intracellular Delivery. Biomacromolecules. 2021;22:4883–904. DOI: 10.1021/acs.biomac.1c00745

57. Lawlor MW, Armstrong D, Viola MG, Widrick JJ, Meng H, Grange RW, Childers MK, Hsu CP, O'Callaghan M, Pierson CR, Buj-Bello A, Beggs AH. Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy. Hum Mol Genet. 2013 Apr 15;22(8):1525–38. DOI: 10.1093/hmg/ddt003

58. Wu RP, Youngblood DS, Hassinger JN, Lovejoy CE, Nelson MH, Iversen PL, Moulton HM. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res. 2007;35(15):5182–91. DOI: 10.1093/nar/gkm478

59. Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Dai Y, Wang J, Barišić N, Brabec P, Lahdetie J, Walter MC, Schreiber-Katz O, Karcagi V, Garami M, Viswanathan V, Bayat F, Buccella F, Kimura E, Koeks Z, van den Bergen JC, Rodrigues M, Roxburgh R, Lusakowska A, Kostera-Pruszczyk A, Zimowski J, Santos R, Neagu E, Artemieva S, Rasic VM, Vojinovic D, Posada M, Bloetzer C, Jeannet PY, Joncourt F, Díaz-Manera J, Gallardo E, Karaduman AA, Topaloğlu H, El Sherif R, Stringer A, Shatillo AV, Martin AS, Peay HL, Bellgard MI, Kirschner J, Flanigan KM, Straub V, Bushby K, Verschuuren J, Aartsma-Rus A, Béroud C, Lochmüller H. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015 Apr;36(4):395–402. DOI: 10.1002/humu.22758

60. Laporte J, Biancalana V, Tanner SM, Kress W, Schneider V, Wallgren-Pettersson C, Herger F, Buj-Bello A, Blondeau F, Liechti-Gallati S, Mandel JL. MTM1 mutations in X-linked myotubular myopathy. Hum Mutat. 2000;15(5):393–409. DOI: 10.1002/(SICI)1098-1004(200005)15:5<393::AID-HUMU1>3.0.CO;2-R

61. Diop D, Chauvin C, Jean-Jean O. Aminoglycosides and other factors promoting stop codon readthrough in human cells. C R Biol. 2007 Jan;330(1):71–9. DOI: 10.1016/j.crvi.2006.09.001

62. Schroeder R, Waldsich C, Wank H. Modulation of RNA function by aminoglycoside antibiotics. EMBO J. 2000 Jan 4;19(1):1–9. DOI: 10.1093/emboj/19.1.1

63. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest. 1999 Aug;104(4):375–81. DOI: 10.1172/JCI7866

64. Clancy JP, Bebök Z, Ruiz F, King C, Jones J, Walker L, Greer H, Hong J, Wing L, Macaluso M, Lyrene R, Sorscher EJ, Bedwell DM. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001 Jun;163(7):1683–92. DOI: 10.1164/ajrccm.163.7.2004001

65. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med. 1996 Apr;2(4):467–9. DOI: 10.1038/nm0496-467

66. Carnes J, Jacobson M, Leinwand L, Yarus M. Stop codon suppression via inhibition of eRF1 expression. RNA. 2003 Jun;9(6):648–53. DOI: 10.1261/rna.5280103

67. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007 May 3;447(7140):87–91. DOI: 10.1038/nature05756

68. Berger J, Li M, Berger S, Meilak M, Rientjes J, Currie PD. Effect of Ataluren on dystrophin mutations. J Cell Mol Med. 2020 Jun;24(12):6680–9. DOI: 10.1111/jcmm.15319

69. Allamand V, Bidou L, Arakawa M, Floquet C, Shiozuka M, Paturneau-Jouas M, Gartioux C, Butler-Browne GS, Mouly V, Rousset JP, Matsuda R, Ikeda D, Guicheney P. Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes. J Gene Med. 2008 Feb;10(2):217–24. DOI: 10.1002/jgm.1140

70. Iezzi S, Cossu G, Nervi C, Sartorelli V, Puri PL. Stage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases. Proc Natl Acad Sci USA. 2002 May 28;99(11):7757–62. DOI: 10.1073/pnas.112218599

71. Iezzi S, Di Padova M, Serra C, Caretti G, Simone C, Maklan E, Minetti G, Zhao P, Hoffman EP, Puri PL, Sartorelli V. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell. 2004 May;6(5):673–84. DOI: 10.1016/s1534-5807(04)00107-8

72. Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V, Fortuni S, Straino S, Sampaolesi M, Di Padova M, Illi B, Gallinari P, Steinkühler C, Capogrossi MC, Sartorelli V, Bottinelli R, Gaetano C, Puri PL. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med. 2006 Oct;12(10):1147–50. DOI: 10.1038/nm1479

73. Love DR, Hill DF, Dickson G, Spurr NK, Byth BC, Marsden RF, Walsh FS, Edwards YH, Davies KE. An autosomal transcript in skeletal muscle with homology to dystrophin. Nature. 1989 May 4;339(6219):55–8. DOI: 10.1038/339055a0

74. Khurana TS, Hoffman EP, Kunkel LM. Identification of a chromosome 6-encoded dystrophin-related protein. J Biol Chem. 1990 Oct 5;265(28):16717–20.

75. Khurana TS, Watkins SC, Chafey P, Chelly J, Tomé FM, Fardeau M, Kaplan JC, Kunkel LM. Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscul Disord. 1991;1(3):185–94. DOI: 10.1016/0960-8966(91)90023-l

76. Starikova AV, Skopenkova VV, Polikarpova AV,

Reshetov DA, Vassilieva SG, Velyaev OA, Shmidt AA, Savchenko IM, Soldatov VO, Egorova TV, Bardina MV. Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression. Sci Rep. 2022 Jan 17;12(1):848. DOI: 10.1038/s41598-022-04892-x

77. Vuorinen A, Wilkinson IVL, Chatzopoulou M, Edwards B, Squire SE, Fairclough RJ, Bazan NA, Milner JA, Conole D, Donald JR, Shah N, Willis NJ, Martínez RF, Wilson FX, Wynne GM, Davies SG, Davies KE, Russell AJ. Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy. Eur J Med Chem. 2021 Aug 5;220:113431. DOI: 10.1016/j.ejmech.2021.113431

78. Chatzopoulou M, Conole D, Emer E, Rowleya JA, Willisa NJ, Squireb SE, Gillc B, Broughc S, Wilsond FX, Wynnea GM, Daviesa SG, Daviesb KE, Russellae AJ. Structure-activity relationships of 2-pyrimidinecarbohydrazides as utrophin modulators for the potential treatment of Duchenne muscular dystrophy. Bioorg Med Chem. 2022;69:116812. DOI: 10.1016/j.bmc.2022.116812

79. Pearson CM, Rimer DG, Mommaerts WF. A metabolic myopathy due to absence of muscle phosphorylase. Am J Med. 1961 Apr;30:502–17. DOI: 10.1016/0002-9343(61)90075-4

80. Preisler N, Pradel A, Husu E, Madsen KL, Becquemin MH, Mollet A, Labrune P, Petit F, Hogrel JY, Jardel C, Maillot F, Vissing J, Laforêt P. Exercise intolerance in Glycogen Storage Disease Type III: weakness or energy deficiency? Mol Genet Metab. 2013 May;109(1):14–20. DOI: 10.1016/j.ymgme.2013.02.008

81. Preisler N, Laforêt P, Echaniz-Laguna A, Ørngreen MC, Lonsdorfer-Wolf E, Doutreleau S, Geny B, Stojkovic T, Piraud M, Petit FM, Vissing J. Fat and carbohydrate metabolism during exercise in phosphoglucomutase type 1 deficiency. J Clin Endocrinol Metab. 2013 Jul;98(7):E1235–40. DOI: 10.1210/jc.2013-1651

82. Stojkovic T, Vissing J, Petit F, Piraud M, Orngreen MC, Andersen G, Claeys KG, Wary C, Hogrel JY, Laforêt P. Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med. 2009 Jul 23;361(4):425–7. DOI: 10.1056/NEJMc0901158

83. Roe CR, Mochel F. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis. 2006 Apr-Jun;29(2–3):332–40. DOI: 10.1007/s10545-006-0290-3

84. Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002 Jul;110(2):259–69. DOI: 10.1172/JCI15311

85. Roe CR, Yang BZ, Brunengraber H, Roe DS, Wallace M, Garritson BK. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology. 2008 Jul 22;71(4):260–4. DOI: 10.1212/01.wnl.0000318283.42961.e9

86. Laforêt P, Ørngreen M, Preisler N, Andersen G, Vissing J. Blocked muscle fat oxidation during exercise in neutral lipid storage disease. Arch Neurol. 2012 Apr;69(4):530–3. DOI: 10.1001/archneurol.2011.631

87. Farshidfar F, Pinder MA, Myrie SB. Creatine Supplementation and Skeletal Muscle Metabolism for Building Muscle Mass-Review of the Potential Mechanisms of Action. Curr Protein Pept Sci. 2017;18(12):1273–87. DOI: 10.2174/1389203718666170606105108

88. Marriage B, Clandinin MT, Glerum DM. Nutritional cofactor treatment in mitochondrial disorders. J Am Diet Assoc. 2003 Aug;103(8):1029–38. DOI: 10.1016/s0002-8223(03)00476-0

89. Avula S, Parikh S, Demarest S, Kurz J, Gropman A. Treatment of mitochondrial disorders. Curr Treat Options Neurol. 2014 Jun;16(6):292. DOI: 10.1007/s11940-014-0292-7

90. Tinker RJ, Lim AZ, Stefanetti RJ, McFarland R. Current and Emerging Clinical Treatment in Mitochondrial Disease. Mol Diagn Ther. 2021 Mar;25(2):181–206. DOI: 10.1007/s40291-020-00510-6

91. Viscomi C, Bottani E, Zeviani M. Emerging concepts in the therapy of mitochondrial disease. Biochim Biophys Acta. 2015 Jun-Jul;1847(6-7):544–57. DOI: 10.1016/j.bbabio.2015.03.001

92. Barshop BA, Naviaux RK, McGowan KA, Levine F, Nyhan WL, Loupis-Geller A, Haas RH. Chronic treatment of mitochondrial disease patients with dichloroacetate. Mol Genet Metab. 2004 Sep-Oct;83(1–2):138–49. DOI: 10.1016/j.ymgme.2004.06.009

93. Prietsch V, Lindner M, Zschocke J, Nyhan WL, Hoffmann GF. Emergency management of inherited metabolic diseases. J Inherit Metab Dis. 2002 Nov;25(7):531–46. DOI: 10.1023/a:1022040422590

94. Parikh S, Saneto R, Falk MJ, Anselm I, Cohen BH, Haas R, Medicine Society TM. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol. 2009 Nov;11(6):414–30. DOI: 10.1007/s11940-009-0046-0

95. Angelova PR, Esteras N, Abramov AY. Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention. Med Res Rev. 2021 Mar;41(2):770–84. DOI: 10.1002/med.21712

96. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018 Mar;17(3):251–67. DOI: 10.1016/S1474-4422(18)30024-3. Epub 2018 Feb 3. Erratum in: Lancet Neurol. 2018.

97. McNeil SM, Woulfe J, Ross C, Tarnopolsky MA. Congenital inflammatory myopathy: a demonstrative case and proposed diagnostic classification. Muscle Nerve. 2002 Feb;25(2):259–64. DOI: 10.1002/mus.10043

98. Walter MC, Reilich P, Thiele S, Schessl J, Schreiber H, Reiners K, Kress W, Müller-Reible C, Vorgerd M, Urban P, Schrank B, Deschauer M, Schlotter-Weigel B, Kohnen R, Lochmüller H. Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis. 2013 Feb 14;8:26. DOI: 10.1186/1750-1172-8-26

99. Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, Lanzi G, Angelini C. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000 Sep;23(9):1344–7. DOI: 10.1002/1097-4598(200009)23:9<1344::aid-mus4>3.0.co;2-f

100. Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, Kornberg AJ, Bertorini TE, Nevo Y, Lotze T, Pestronk A, Ryan MM, Monasterio E, Day JW, Zimmerman A, Arrieta A, Henricson E, Mayhew J, Florence J, Hu F, Connolly AM. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology. 2011 Aug 2;77(5):444–52. DOI: 10.1212/WNL.0b013e318227b164

101. Pasquini F, Guerin C, Blake D, Davies K, Karpati G, Holland P. The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells. Neuromuscul Disord. 1995 Mar;5(2):105–14. DOI: 10.1016/0960-8966(94)00042-8

102. Serra F, Quarta M, Canato M, Toniolo L, De Arcangelis V, Trotta A, Spath L, Monaco L, Reggiani C, Naro F. Inflammation in muscular dystrophy and the beneficial effects of non-steroidal anti-inflammatory drugs. Muscle Nerve. 2012 Nov;46(5):773–84. DOI: 10.1002/mus.23432

103. Aoyagi K, Ohara-Imaizumi M, Nishiwaki C, Nakamichi Y, Nagamatsu S. Insulin/phosphoinositide 3-kinase pathway accelerates the glucose-induced first-phase insulin secretion through TrpV2 recruitment in pancreatic β-cells. Biochem J. 2010 Dec 1;432(2):375–86. DOI: 10.1042/BJ20100864

104. Iwata Y, Katanosaka Y, Shijun Z, Kobayashi Y, Hanada H, Shigekawa M, Wakabayashi S. Protective effects of Ca^{2+} handling drugs against abnormal Ca^{2+} homeostasis and cell damage in myopathic skeletal muscle cells. Biochem Pharmacol. 2005 Sep 1;70(5):740–51. DOI: 10.1016/j.bcp.2005.05.034

105. Swiderski K, Todorov M, Gehrig SM, Naim T, Chee A, Stapleton DI, Koopman R, Lynch GS. Tranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice. Fibrogenesis Tissue Repair. 2014 Jan 30;7(1):1. DOI: 10.1186/1755-1536-7-1

106. Hodgetts S, Radley H, Davies M, Grounds MD. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul Disord. 2006 Oct;16(9–10):591–602. DOI: 10.1016/j.nmd.2006.06.011

107. Piers AT, Lavin T, Radley-Crabb HG, Bakker AJ, Grounds M, Pinniger GJ. Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice. Neuromuscul Disord. 2011;21(Issue 2): 132–41. DOI: 10.1016/j.nmd.2010.09.013

108. Mahdy MAA. Skeletal muscle fibrosis: an overview. Cell Tissue Res. 2019 Mar;375(3):575–88. DOI: 10.1007/ s00441-018-2955-2

109. Tsabari R, Simchovitz E, Lavi E, Eliav O, Avrahami R, Ben-Sasson S, Do T. Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy. Neuromuscul Disord. 2021;31:803–13. DOI: 10.1016/j.nmd.2021.05.005

110. Wu B, Shah SN, Lu P, Bollinger LE, Blaeser A, Sparks S, Harper AD, Lu QL. Long-Term Treatment of Tamoxifen and Raloxifene Alleviates Dystrophic Phenotype and Enhances Muscle Functions of FKRP Dystroglycanopathy. Am J Pathol. 2018 Apr;188(4):1069–80. DOI: 10.1016/j. ajpath.2017.12.011

111. Ceco E, McNally EM. Modifying muscular dystrophy through transforming growth factor-β. FEBS J. 2013 Sep;280(17):4198–209. DOI: 10.1111/febs.12266

112. Biressi S, Miyabara EH, Gopinath SD, Carlig PM, Rando TA. A Wnt-TGFβ2 axis induces a fibrogenic program in muscle stem cells from dystrophic mice. Sci Transl Med. 2014 Dec 17;6(267):267ra176. DOI: 10.1126/scitranslmed.3008411

113. Demonbreun AR, Fallon KS, Oosterbaan CC, Vaught LA, Reiser NL, Bogdanovic E, Velez MP, Salamone IM, Page PGT, Hadhazy M, Quattrocelli M, Barefield DY, Wood LD, Gonzalez JP, Morris C, McNally EM. Anti-latent TGFβ binding protein 4 antibody improves muscle function and reduces muscle fibrosis in muscular dystrophy. Sci Transl Med. 2021 Sep 8;13(610):eabf0376. DOI: 10.1126/scitranslmed.abf0376

114. Morales MG, Cabrera D, Céspedes C, Vio CP, Vazquez Y, Brandan E, Cabello-Verrugio C. Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2). Cell Tissue Res. 2013 Jul;353(1):173–87. DOI: 10.1007/s00441-013-1642-6

115. Sun G, Haginoya K, Wu Y, Chiba Y, Nakanishi T, Onuma A, Sato Y, Takigawa M, Iinuma K, Tsuchiya S. Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy. J Neurol Sci. 2008 Apr 15;267(1-2): 48–56. DOI: 10.1016/j.jns.2007.09.043

116. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol. 1996 Sep;107(3):404–11. DOI: 10.1111/1523-1747.ep12363389

117. Smith LR, Barton ER. Regulation of fibrosis in muscular dystrophy. Matrix Biol. 2018 Aug;68–69:602–615. DOI: 10.1016/j.matbio.2018.01.014

118. de Winter JM, Gineste C, Minardi E, Brocca L, Rossi M, Borsboom T, Beggs AH, Bernard M, Bendahan D, Hwee DT, Malik FI, Pellegrino MA, Bottinelli R, Gondin J, Ottenheijm CAC. Acute and chronic tirasemtiv treatment improves in vivo and in vitro muscle performance in actin-based nemaline myopathy mice. Hum Mol Genet. 2021 Jun 26;30(14):1305–20. DOI: 10.1093/hmg/ddab112

119. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997 May 1;387(6628):83–90. DOI: 10.1038/387083a0

120. Guiraud S, Davies KE. Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr Opin Pharmacol. 2017 Jun;34:36–48. DOI: 10.1016/j. coph.2017.04.002

121. Rybalka E, Timpani CA, Debruin DA, Bagaric RM, Campelj DG, Hayes A. The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle. Cells. 2020 Dec 10;9(12):2657. DOI: 10.3390/cells9122657

122. Korokin MV, Soldatov VO, Gudyrev OS, Koklin IS, Taran EI, Mishenin MO, Korokina LV, Kochkarov AA, Pokrovskii MV, Varaksin MV, Chupakhin ON. [The role of cortisol metabolism in the realization of pathogenetic links in the development of osteoporosis – the rationale for the search for new pharmacotherapeutic targets (review)]. Research Results in Biomedicine. 2022;8(4):457–473. DOI: 10.18413/2658-6533-2022-8-4-0-5. Russian

AUTHORS

Mikhail V. Pokrovsky – Doctor of Sciences (Medicine), Professor of the Department of Pharmacology and Clinical Pharmacology, Head of the Research Institute of Pharmacology of Living Systems, Belgorod State National Research University. ORCID ID: 0000-0002-2761-6249. E-mail: mpokrovsky@yandex.ru

Mikhail V. Korokin – Doctor of Medical Sciences, Associate Professor, Professor of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University. ORCID ID: 0000-0001-5402-0697. E-mail: mkorokin@mail.ru

Anastasia M. Krayushkina – Assistant of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University. ORCID ID: 0000-0002-6830-3820. E-mail: annkrayushkina98@gmail.com

Nikita S. Zhunusov – Assistant of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University. ORCID ID: 0000-0002-1969-3615. E-mail: nzhunu@mail.ru

Konstantin N. Lapin – Researcher, Laboratory of Experimental Research, V.A. Negovsky Research Institute of General Reanimatology, Federal Scientific and Clinical Center for Resuscitation and Rehabilitology. ORCID ID: 0000-0002-7760-3526. E-mail: k.n.lapin@gmail.com

Maria O. Soldatova – laboratory researcher at the Research Institute of Population Genetics and Epidemiology, Kursk State Medical University. ORCID ID: 0000-0001-6637-1654. E-mail: mar.sold46@gmail.com

Egor A. Kuzmin – laboratory assistant of the Department of Histology, Embryology and Cytology, Sechenov First Moscow State Medical University. ORCID ID: 0000-0003-4098-1125. E-mail: eg.ku@yandex.ru

Oleg S. Gudyrev – Candidate of Sciences (Medicine), Associate Professor, Associate Professor of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University. ORCID ID: 0000-0003-0097-000X. E-mail: gudyrev@mail.ru

Indira S. Kochkarova – Junior Researcher, Research Institute of Pharmacology of Living Systems, Belgorod State National Research University. ORCID ID: 0000-0001-6202-9923. E-mail: kochkarova@bsu.edu.ru

Aleksey V. Deikin – Candidate of Sciences (Biology), Associate Professor of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University. ORCID ID: 0000-0002-8151-6337. E-mail: deykin@bsu.edu.ru

CURRENT ASPECTS OF ETIOTROPIC COVID-19 THERAPY

D.N. Zemskov[1], L.A. Balykova[1], O.A. Radaeva[1], K.Ya. Zaslavskaya[1], P.A. Bely[2],
E.V. Semenova[1], M.V. Shirmankina[1], K.N. Koryanova[3]

[1] National Research Ogarev Mordovia State University,
68, Bol'shevistskaya Str., Saransk, Republic of Mordovia, Russia, 430005
[2] Evdokimov Moscow State Medical and Dental University,
Bld. 1, 20, Delegatskaya Str., Moscow, Russia, 127473
[3] Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University,
11, Kalinin Ave., Pyatigorsk, Russia, 357532

E-mail: dizem1978@gmail.com

Since the beginning of the pandemic, repeated attempts have been made to develop etiotropic therapy for a novel coronavirus infection. Hydroxychloroquine, lopinavir/ritonavir, etc. derivatives were used as antiviral agents, however, they demonstrated a low efficiency and an insufficient safety. In this connection, other groups of drugs with a more effective and safe pharmacological profile are currently being actively used.

The aim of the study was to analyze the literature references on the efficacy and safety of antiviral drugs for the COVID-19 treatment.

Materials and methods. When searching for the materials for the review article writing, such abstract databases as PubMed, Google Scholar, e-Library were used. The search was carried out on publications for the period from January 2020 to September 2022. The key queries were: COVID-19, etiotropic therapy; immunological drugs; antiviral drugs; interferons.

Results. Currently, there are various degrees of effective etiotropic drugs for the treatment of COVID-19 patients. The review has considered a few groups of drugs that are of interest from the point of view of etiotropic therapy: immunological drugs (anticovid plasma, the drugs based on antiviral antibodies, the drugs of recombinant interferons-α2 and -β1, as well as interferon inducers, i.e., the drugs based on double-stranded RNA sodium salt, and others); drugs that block the penetration of the virus into the cell (umifenovir); the drugs that disrupt the process of the viral replication (favipiravir, remdesivir, molnupiravir, nirmatrelvir/ritonavir).

Conclusion. Synthetic antivirals, in particular favipiravir, molnupiravir, remdesivir, and nirmatrelvir/ritonavir, have the largest evidence base for their efficacy and safety. The search for new effective and safe etiotropic drugs for the treatment of COVID-19, as well as the collection and analysis of post-registration data on the drugs already used in clinical practice, continues.

Keywords: COVID-19; interferons; molnupiravir; favipiravir; nirmatrelvir/ritonavir; etiotropic therapy

Abbreviations: IFN – interferon; II – interferon inducers; IVIG – intravenous immunoglobulin; dsRNA – double-stranded ribonucleic acid; siRNA – small interfering RNA; ARDS – acute respiratory distress syndrome; OR – odds ratio; CI – confidence interval; RR – risk ratio; AE - adverse events; ALV – artificial lung ventilation.

АКТУАЛЬНЫЕ АСПЕКТЫ ЭТИОТРОПНОЙ ТЕРАПИИ COVID-19

Д.Н. Земсков[1], Л.А. Балыкова[1], О.А. Радаева[1], К.Я. Заславская[1], П.А. Белый[2],
Е.В. Семенова[1], М.В. Ширманкина[1], К.Н. Корянова[3]

[1] Федеральное государственное бюджетное образовательное учреждение высшего образования
«Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва»,
43005, Россия, г. Саранск, ул. Большевистская, д. 68
[2] Федеральное государственное бюджетное образовательное учреждение высшего образования
«Московский государственный медико-стоматологический университет имени А.И. Евдокимова»,
Министерства здравоохранения Российской Федерации,
127473, Россия, г. Москва, ул. Делегатская, д. 20/1
[3] Пятигорский медико-фармацевтический институт – филиал федерального государственного
бюджетного образовательного учреждения высшего образования «Волгоградский государственный
медицинский университет» Министерства здравоохранения Российской Федерации,
357532, Россия, г. Пятигорск, пр-т Калинина, д. 11

E-mail: dizem1978@gmail.com

С начала пандемии предпринимались неоднократные попытки разработки этиотропной терапии новой коронавирусной инфекции. В качестве противовирусных средств использовались производные гидроксихлорохина, лопинавир/ритонавир и др., однако они продемонстрировали невысокую эффективность и недостаточную безопасность. В связи с чем, в настоящее время активно применяются другие группы препаратов, обладающих более эффективным и безопасным фармакологическим профилем.

Цель. Анализ литературных данных по эффективности и безопасности противовирусных препаратов для лечения COVID-19.

Материалы и методы. При поиске материала для написания обзорной статьи использовали такие реферативные базы данных, как PubMed, Google Scholar, e-Library. Поиск осуществлялся по публикациям за период с января 2020 по сентябрь 2022 гг. Ключевые запросы: COVID-19, этиотропная терапия/etiotropic therapy; иммунологические препараты/immunologic drugs; противовирусные препараты/antiviral drugs; интерфероны/interferons.

Результаты. В настоящее время имеются в разной степени эффективные этиотропные препараты для лечения пациентов с COVID-19. В обзоре рассмотрены несколько групп лекарственных препаратов, представляющих интерес с точки зрения этиотропной терапии: иммунологические препараты (антиковидная плазма, препараты на основе противовирусных антител, препараты рекомбинантных интерферонов-α2 и -β1, а также индукторы интерферона, например, препараты на основе РНК двуспиральной натриевой соли и др.); препараты, блокирующие проникновение вируса в клетку (умифеновир); препараты, нарушающие процесс репликации вируса (фавипиравир, ремдесивир, молнупиравир, нирматрелвир/ритонавир).

Заключение. Наиболее объемную доказательную базу данных по эффективности и безопасности имеют синтетические противовирусные средства, в частности фавипиравир, молнупиравир, ремдесивир и нирматрелвир/ритонавир. Поиск новых эффективных и безопасных этиотропных препаратов для лечения COVID-19 продолжается, также как сбор и анализ пострегистрационных данных об уже применяющихся в клинической практике средствах.

Ключевые слова: COVID-19; интерфероны; молнупиравир; фавипиравир; нирматрелвир/ритонавир; этиотропная терапия

Список сокращений: ИНФ – интерферон; ИИ – индукторы интерферонов; ВВИГ – внутривенный иммуноглобулин; дсРНК – двуспиральная рибонуклеиновая кислота; миРНК – малая интерферирующая рибонуклеиновая кислота; ОРДС – острый респираторный дистресс-синдром; ОШ – отношение шансов; ДИ – доверительный интервал; ОР – отношение рисков; НЯ – нежелательные явления; ИВЛ – искусственная вентиляция легких.

INTRODUCTION

The novel coronavirus infection has challenged all of humanity, showing the global vulnerability of the society to infectious diseases. The main target of SARS-CoV-2 is the respiratory system, however, in addition to the fatal pulmonary complications of COVID-19, the patients have a variety of dangerous extrapulmonary manifestations, including thrombotic complications, an acute kidney injury, and "acute" cardiovascular disorders [1, 2]. The prognosis for COVID-19 is determined by a combination of individual risk factors (age, comorbidities, healthcare organizations).

In the retrospective study by Magleby R. et al., comprising 678 hospitalized COVID-19 patients, it was demonstrated that an independent risk factor for mortality (odds ratio (OR)=6.05; p <0.001) and the crossover to the artificial lung ventilation (ALV) (OR=2.73; p <0.001) is a high viral load [3]. An early initiation of the antiviral therapy contributes to an effective reduction in the viral load, reduces the risk of the disease progression and improves the prognosis [4]. In this regard, in the early phase of the disease, when the maximum replication rate of SARS-CoV-2 is notified, the antiviral therapy is of primary importance, while in later periods, the hyperinflammatory syndrome and coagulopathy take the leading places in the pathogenesis of the disease, respectively, the role of anti-inflammatory drugs (glucocorticosteroids), immunomodulating agents,

anticoagulants and their combinations, increases [5]. However, it should be notified that the antiviral therapy remains a significant even at the late stages of the disease, due to the long-term (from 17 to 27 days) viral shedding in patients, especially those with a severe infection [6].

Since the beginning of the pandemic, repeated attempts have been made to develop etiotropic therapy for a novel coronavirus infection. Hydroxychloroquine, lopinavir/ritonavir, etc. derivatives were used as antiviral agents, however, they demonstrated a low efficiency and an insufficient safety [7–10]. In this connection, other groups of drugs with a more effective and safe pharmacological profile are currently being actively used.

THE AIM of the study was to analyze the literature references on the efficacy and safety of antiviral drugs for the COVID-19 treatment.

MATERIALS AND METHODS

When searching for the materials for the review article writing, such abstract databases as PubMed, Google Scholar, e-Library were used. The search was carried out on publications for the period from Jan 2020 to Sep 2022. The key queries were: COVID-19, etiotropic therapy; immunological drugs; antiviral drugs; interferons. The data from both clinical and *in vitro* trials, were considered as references.

RESULTS AND DISCUSSION

At the moment, the following groups of etiotropic drugs for the treatment of COVID-19 can be distinguished (Table 1):

1) immunological drugs (anticovid plasma, preparations based on antiviral antibodies, preparations of recombinant interferons-α2 and -β1, as well as interferon inducers, i.e., the drugs based on double-stranded RNA sodium salt, and others);

2) drugs that block the penetration of the virus into the cell (umifenovir);

3) drugs that disrupt the process of the viral replication (favipiravir, remdesivir, molnupiravir, nirmatrelvir/ritonavir).

1. Immunological drugs
1.1. Anticovid plasma

Plasma from the patients who have been cured of the COVID-19 infection, is a source of antiviral antibodies and is considered as a treatment option backed by a significant historical experience, but still promising in the context of SARS-CoV-2. In addition to the antiviral (virus-neutralizing) effect, plasma reduces an antibody-dependent cellular cytotoxicity, a complement activation, and phagocytosis [11]. Theoretically, the administration of convalescent plasma at an early stage of the disease is more effective [12], since the peak of viremia is observed in the first week of the infection, and the native primary immune response usually develops on the 10–14th days [13]. In addition to direct antiviral effects, plasma components can also restore the activity of the hemostasis system [14].

Against the background of the conventional therapy and in the controlled study, in patients with severe COVID-19, in the description of individual series of plasma clinical cases, positive results were obtained in 76–90% [15–17]. A donor selection according to the titers or the activity of neutralizing antibodies can further increase the efficacy of anticovid plasma [18]. Clinical and biochemical predictors of the plasma efficacy are lymphopenia, elevated levels of procalcitonin, ferritin, D-dimer and C-reactive protein. It is believed that the preference should be given to the patients who are in a non-critical condition, at the early stage of the disease [19]. A potential danger lies in the intensification of the disease in the presence of certain antibodies – an antibody-dependent increase in the penetration of coronavirus [20]. An analysis of more than 5 000 patients with a severe or life-threatening COVID-19 infection treated with anticovid plasma, showed that serious adverse events (AEs) occurred in <1% of patients in the first 4 h after the infusion [21].

1.2. Intravenous immunoglobulin

Intravenous immunoglobulin (IVIG) can inhibit the complement cascade activation of pro-inflammatory cytokines, differentiation and activation of dendritic cells, as well as the activation of neutrophils and the formation of neutrophil extracellular traps [22]. Considering that these mechanisms can play an important role in the pathogenesis of a novel coronavirus infection, IVIG is one of the options for treating COVID-19 [23]. In a multicenter, double-blind, placebo-controlled (Phase 3) study of 146 patients (69 of whom 69 had received IVIG, 77 – placebo) with an acute respiratory distress syndrome (ARDS) due to COVID-19, the use of IVIG did not improve clinical outcomes (on day 28) and was associated with a slight increase in the incidence of thromboembolic complications [24].

1.3. Interferons

Based on the pathogenetic mechanisms of infection caused by SARS-CoV-2, a possible drug target is the interferon (IFN) system. The SARS-CoV-2 virus can inhibit the induction of type I and type III IFNs [25]. In the study by Contoli M. et al., the hospitalized COVID-19 patients with a respiratory failure had 3.8 times lower levels of IFN-α compared to the controls. Herewith, the improvement in the patients' condition was accompanied by an increase in the blood level of the same IFN-α [26]. In addition, the patients with congenital defects in the type I IFN system (with the presence of autoantibodies) have a predisposition to a severe COVID-19 [27]. In the treatment of COVID-19, the antiviral effect of IFN-α2b is determined by the time of the therapy initiation [28].

1.4. Double-stranded RNA sodium salt

The data accumulated by now, show that interferon inducers (IIs) of double-stranded ribonucleic acid (dsRNA), sodium ribonucleonate, being a multiclonal stimulator, induces the synthesis of IFN by several cell populations (cells of the mononuclear phagocytic system, granulocytes, neutrophils, endothelial cells and fibroblasts), characterized by a high (specific) activity and safety.

By activating a number of Toll-like receptors, dsRNA stimulates the synthesis of endogenous IFNs (α, β, γ), which block the ability of the cells to support a viral reproduction by both activating the synthesis of proteins that inhibit the production of viral copies in affected cells and, possibly, damaging the genetic virus material when interacting with the host cell (similar to siRNA effects). Subsequently, both NK cells and mechanisms of adaptive immunity are activated.

In the Russian Federation, a medicinal product based on the dsRNA sodium salt (Radamin® Viro

LS-000381[1] dated 03 Aug 2010, date of renewal 27 Dec 2021), is registered. When administrated into the body, dsRNA stimulates the formation of endogenous IFN I (IFN-α, IFN-β) and IFN II (IFN-γ) types, which are the most important cytokines of the immune response, induce differentiation of myeloid cells, stimulate phagocytosis of neutrophils and macrophages, activate NK cells, enhance the Th1-type T-helper response, thus triggering the innate and adaptive immune response. The antiviral effect of the drug is associated with the activation of the proteins synthesis inhibiting the production of viral copies in the affected cells [29].

DsRNA belongs to the "early type" of interferon inducers, while the production of IFN occurs within 2-6 hours after the administration of the drug with a return to the background values within 2 days. The drug inhibits the reproduction of viruses and various microorganisms (including chlamydia) at the cellular level, prevents the development of the infectious process by activating the body's nonspecific resistance, optimizing inflammatory reactions. Due to its mechanism of action, the drug provides a high protection of the body at already early stages of viral or bacterial infections, has a pronounced anti-inflammatory effect, and also indirectly stimulates reparative and regenerative processes in the body, has antiviral, antibacterial and immunostimulating effects, and also increases the body's resistance to infections [29].

As an II, dsRNA itself has been known for more than 10 years. However, a new technology for the production of dsRNA sodium salt has made it possible to obtain a highly purified biological product, which significantly increases the safety of the drug and opens up broad prospects for its use in clinical practice [29].

2. Drugs that block virus penetration into cell
2.1. Umifenovir

Since the start of the pandemic, umifenovir has been one of the first widely used synthetic antiviral drugs in our country. It is a broad-spectrum antiviral drug that blocks the entry of viruses into host cells by inhibiting the fusion of the lipid envelope of the virus with the cell membrane. Initially, umifenovir was developed for the prevention of the influenza treatment [30]. It has demonstrated an activity against SARS-CoV-2 *in vitro* [31]. In the meta-analysis assessing the efficacy and safety of umifenovir in COVID-19, it was found out that the use of the drug was associated with a higher incidence of negative PCR results on the 14th day of illness (OR=1.27; 95% CI=1.04–1.55) compared with the control group,

however, was not associated with a reduction in the risk of the COVID-19 progression, a clinical improvement, and a duration reduction in hospital stay [32].

3. Drugs that disrupt viral replication process

Recently, the drugs able of inhibiting RNA-dependent RNA polymerase of direct action, which is an important enzyme of RNA-containing viruses, have been of primary importance in the development of the antiviral therapy strategy for COVID-19 and ensuring their replication [33].

3.1. Favipiravir

Favipiravir, synthesized and patented by Japanese scientists Y. Furuta and H. Egawa in the late 1990s, is a broad-spectrum antiviral drug proposed for the treatment of severe viral infections, including influenza A, B and C, as well as Ebola. [34]. In 2014, this drug was approved in Japan for the treatment of the infection caused by a pandemic variant of the influenza virus or when other drugs had failed. The subsequent studies have shown that favipiravir is highly active against a large group of RNA-containing viruses, such as influenza viruses, bunya-, arena-, flavi-, picoranaviruses, etc. [35]. In an experimental study by Yamada K. et al., favipiravir has been shown to be effective for a post-exposure prophylaxis of rabies and may be a suitable alternative to immunoglobulin [36]. Favipiravir has shown a good inhibitory activity *in vitro* against SARS-CoV-2, but relatively high doses of the drug are required to obtain effective inhibitory concentrations and provide an antiviral activity [35].

Favipiravir is a prodrug, its active form is ribofuranosyl triphosphate. As a nucleoside analogue, it inhibits the SARS-CoV-2 RNA-dependent RNA polymerase complex by binding to its catalytic domain and preventing the incorporation of nucleotides for a viral RNA replication, which leads to an increase in the mutation frequency and a possible lethal mutagenesis. Also important note that RNA-dependent RNA polymerase is absent in human cells, so the drug is active only contrary virus [37, 38].

The Ministry of Health of the Russian Federation has issued an accelerated permission to use favipiravir preparations for the treatment of COVID-19 [37]. Similar approvals have been obtained in China, India and other countries. In phase II/III of the clinical study in sixty patients, favipiravir therapy was well tolerated and safe, resulting in viral clearance in 62.5% of COVID-19 patients after four days. On the fifth day, twice as many patients treated with favipiravir, received a negative PCR result for SARS-CoV-2 compared with the patients in the control group (p <0.05) [39].

A lot of clinical trials and observatory studies which reported on the effectiveness and safety of

---

[1] Russian State Register of Medicines. Instructions for Radamin® Viro. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=27d5a81d-b2e9-49d2-a9eb-1f1c9eacbaa4

Favipiravir in the treatment of COVID-19 patients, have been conducted [38–44]. Alamer A. et al. assessed the effectiveness of Favipiravir in the treatment of COVID-19 (n=457). It has been established that the average time from the onset of the disease to discharge was 10 days (95% CI = 9–10) in the group of patients receiving favipiravir (n=234), versus 15 days (95% CI=14–16) in the comparison group, receiving supporting therapy (n=223) [38]. In the prospective open multicenter clinical study, including 240 COVID-19 patients (120 patients received Favipiravir, 120 – Umifenovir), in the group of favipiravir patients, there was a faster decrease in the temperature and a decrease in the cough severity [40].

According to the results of the open randomized multicenter comparative study (N = 206), the use of favipiravir for the COVID-19 treatment contributed to a more rapid improvement of the condition (6-8 days) compared with the use of the standard therapy (7–12 days), also demonstrating a favorable security profile. According to the PCR, the Elimation of SARS-COV-2 to the 10th day of therapy was recorded in 98% of the favipiravir patients, and in 80% in the control group (p=0.00007). AEs were observed in 24.04% of the patients of the main group and in 27.45% – the control group [41].

In a number of meta-analyses that summarize the data of clinical studies, the benefits of adding favipiravir to the standard therapy, were confirmed [43, 44]. In the hospitalized patients, Favipiravir, compared with the control group that were receiving only the standard therapy, contributed to a faster elimination of the virus – an average of 5 days (OR=1.60; p=0.02), an earlier temperature decrease – an average of 3 by an average of the 3–4th day (OR=1.99; p <0.01), an improvement in the radiological picture in the lungs (OR=1.33; p <0.01) and an earlier discharge from the hospital (OR=1.19; p <0.01). As for the AEs, the Favipiravir group recorded a higher frequency of hyperuricemia (OR=9.42; p <0.01), increased levels of alanineine-veransferase (OR=1.35; p <0.01), but a lower frequency of nausea (OR=0.42; p <0.01) and vomiting (OR=0.19; p=0.02). The authors arrived at the conclusion that the addition of Favipiravir to the standard therapy is beneficial to the hospitalized COVID-19 patients. At the same time, it has been notified that pregnant women and patients with hyperuricemia in an anamnesis should avoid the use of phavipiral [43].

Favipiravir for *per os* administration has proved to be quite effective and safe for the treatment of a novel coronavirus infection in both mild and moderate courses and has occupied its niche in the outpatient practice. However, in complicated cases, the parenteral therapy has advantages over the oral route of the drug delivery. This therapy can be used in the situations where the patient is in a serious condition or unconscious, has swallowing difficulties or conditions that prevent swallowing. It may also be important in patients with gastrointestinal COVID-19 symptoms, in patients with antibiotic-associated diarrhea (uncontrolled use of antibiotics combinations on an outpatient basis), the exacerbation of chronic gastrointestinal diseases and pseudomembranous colitis, and other situations where the p. o. administration is difficult). The intravenous route of the drug administration is used for a quick and pronounced result, since it immediately enters the bloodstream, its quickly provides maximum bioavailability and the pharmacokinetics are generally more predictable – there is no interaction with food and digestive enzymes [42]. In view of this, in 2021 in the RF was developed and registered a new dosage form of favipiravir for the parenteral administration – Areplivir® (RU LP-007598 dated 18 May 2022), was registered. In the clinical centers of Moscow, Smolensk, Yaroslavl, St. Petersburg, Saransk and Ryazan, an open randomized multicenter comparative study of favipiravir for the parenteral administration (n=209) was conducted in the hospitalized patients aged 18–80 years with moderate form of the coronavirus infection. Based on the results of the study, the data were obtained confirming a high efficacy and safety of the parenteral form of favipiravir for the treatment of COVID-19. In the main group, by the 10th day of therapy, an improvement in the clinical status by 2 or more points on the World Health Organization (WHO) scale was observed in 56.86% of patients, which corresponds to mild symptoms or the complete absence of signs of the disease, and in the control group (the patients receiving the standard therapy) – in 28.04% (p <0.0001). In the group of favipiravir patients, the clinical status improved faster (median=5 days) than in the control group (7 days). On days 5 and 14 of the treatment (visits 2 and 4), a more pronounced improvement in the clinical status was recorded in the main group, in contrast to the patients in the comparison group [42].

A faster and more enhanced favipiravir action for the parenteral use is aimed at increasing the effectiveness of therapy and preventing the development of an extremely severe COVID-19 course, getting to the resuscitation and intensive care unit and death [42, 45].

3.2. Remdesivir

One of the first drugs in the group of RNA-dependent RNA polymerase inhibitors was remdesivir, originally developed for the treatment of the infection caused by the Ebola virus. It is a prodrug that inhibits the reproduction of a wide range of viruses, including filo-, paramyxo-, pneumo- and ortho-coronaviruses (SARS-

CoV and a Middle East respiratory syndrome coronavirus [MERSCoV]) [46–48]. This drug is administered parenterally, which makes it difficult to be used on an outpatient basis[2]. Remdesivir in high doses inhibits the enzyme RNA-dependent RNA polymerase of the virus, causing a delayed termination of the RNA chain without affecting the activity of human polymerases[3] [49, 50].

The National Institute of Allergy and Infectious Diseases (NIAID) in the United States has initiated a placebo-controlled, double-blind, randomized Phase III trial to evaluate the efficacy and safety of remdesivir versus placebo (NCT04280705). This study included 1062 hospitalized patients with COVID-19 and signs of a lower respiratory tract infection (541 patients in the remdesivir group, 521 patients in the placebo group). In the patients treated with remdesivir, the median recovery time was 10 days (95% CI=9-11) compared with 15 days (95% CI=13-18) in the placebo group (OR=1.29; 95% CI = 1.12–1.49; p <0.001). Serious AEs were reported in 131 of 532 patients treated with remdesivir (24.6%) and in 163 of 516 patients treated with placebo (31.6%). The authors concluded that remdesivir is superior to placebo in terms of its effect on the duration of the disease and the severity of clinical symptoms [46].

In patients with moderate COVID-19 who received a 10-day course of remdesivir, there was no statistically significant difference in the clinical status compared to the standard therapy by day 11 of treatment. The patients treated with a 5-day remdesivir course, had a statistically significant difference in clinical status compared to the standard therapy (OR=1.65; 95% CI =1.09–2.48; p=0.02), but this difference, according to the researchers, had no clinical significance [50]. In some other randomized trials, it was not possible to obtain any convincing evidence of the remdesivir effectiveness, either.

Despite the mixed trial results, the FDA has approved remdesivir for the use in hospitalized adult patients with severe COVID-19. Subsequently, the range of indications was expanded and remdesivir was also recommended for the treatment of COVID-19 children aged ≥28 days and weighing ≥3 kg[4]. The data from a number of other clinical studies have also been published in support of the final approval [51–56]. In the double-blind, placebo-controlled study (n=562) of unvaccinated outpatients aged ≥12 years (with one or more risk factors for severe COVID-19), the risk of hospitalization was 87%

lower in the remdesivir group (n=279) compared with placebo (n=283) (95% CI=0.03-0.59) [51]. In the study by Goldman D.L. et al., in 77 children with severe COVID-19, the remdesivir therapy was characterized by a favorable safety profile with a high clinical recovery rate [52].

To date, many additional randomized controlled trials and meta-analyses have been obtained, though their conclusions are still conflicting. Among all these works, the most authoritative is the independent WHO Solidarity study, which, according to the results of the interim analysis, did not reveal a significant effect of remdesivir (as well as other antiviral drugs) on mortality rates in hospitalized COVID-19 patients [54]. For this reason, the WHO did not initially recommend the use of remdesivir in these patients. However, the continuation of the study found out that remdesivir had no effect on the survival of ventilated COVID-19 patients, while it slightly reduced the risk of death (up to 14.6% compared to 16.3% in the control group) or the crossover to the artificial lung ventilation (ALV) (14.1% versus 15.7% in the control group) of the hospitalized patients [54]. Based on these data, the WHO has revised its conclusions regarding the use of remdesivir, and now remdesivir is recommended for the treatment of mild to moderate COVID-19, where there is a high risk of hospitalization[5]. Singh S. et al. summarized the data from 4 studies involving 7,324 patients. No reduction in mortality was observed with remdesivir compared with controls (OR=0.92; 95% CI=0.79–1.07; p=0.30). The authors concluded that, given the lack of a significant effect on mortality and a high cost of the drug, its use in COVID-19 is not appropriate, especially in low-income countries [54].

3.3. Molnupiravir

Molnupiravir has become another innovative drug that has not been previously used in clinical practice and received an accelerated approval during the COVID-19 pandemic. It is a prodrug, an analog of N-hydroxycytidine, which is phosphorylated to form N-hydroxycytidine triphosphate and is integrated into viral RNA with the help of RNA polymerase, leading to the accumulation of mutations in the virus genome and, as a result, inhibiting a replication [57]. Molnupiravir is active against RNA-containing viruses, including SARS-CoV-2, which has been shown in experiments *in vitro* and *in vivo* [58]. The results of phase I/II/III clinical trials confirmed the efficacy and safety of molnupiravir in COVID-19 [59, 60].

During conducting a phase I clinical study on healthy volunteers (n=130), the data on a good tolerability of the

---

[2] Cohen P, Gebo K. COVID-19: Outpatient evaluation and management of acute illness in adults. UpToDate. Literature review current through: Jun 2022.

[3] Coronavirus (COVID-19) update: FDA approves first COVID-19 treatment for young children. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-approves-first-covid-19-treatment-young-children.

[4] Ibid.

---

[5] Remdesivir for COVID-19. Available from: https://apps.who.int/iris/bitstream/handle/10665 /359753/WHO-2019-nCoV-Therapeutics-Remdesivir-Poster-A-2022.1-eng.pdf

drug were obtained. 35.4% and 43.8% (control group) of patients experienced mild side effects with a single dose, 42.9% and 50.0% (control group) – with multiple increasing doses, respectively [59]. By PCR, in a phase IIa clinical trial (n=202), SARS-CoV-2 virus clearance was shorter in the study group compared with placebo (median = 14 days for molnupiravir and 27 days for placebo; p=0,01)[6].

The Phase III, double-blind, randomized, placebo-controlled MOVe-OUT trial included 1 433 non-hospitalized adult patients with mild to moderate COVID-19 (the most common SARS-CoV-2 variants were delta (58.1%), mu (20.5%), gamma (10.7%) and the presence of at least one risk factor for a severe novel coronavirus infection (716 participants received molnupiravir, 717 – placebo). Patients from 15 Russian centers also participated in the MOVe-OUT study. The risk of hospitalization or death was lower in the molnupiravir group (6.8%) compared with placebo (9.7%) (95% CI=5.9–0.1%). The frequency of the AEs registration (including viral pneumonia) in the group of patients receiving molnupiravir was comparable to that in the placebo group (30.4% and 33.0%, respectively). The most common side effects were: diarrhea (1, 7% and 2.1%), nausea (1.4% and 0.7%) and dizziness (1.0% and 0.7%) [60].

Due to the increase in the incidence of COVID-19 and the need to introduce effective drugs for its treatment into clinical practice, the Russian Federation has also developed and registered the drug molnupiravir (Esperavir®) in the oral dosage form capsules (LP-007856 dated 18 May 2022)[7]. According to the results of the clinical study involving 240 outpatients with mild to moderate COVID-19 from 12 Russian centers, the use of molnupiravir for 5 days at the dose of 800 mg 2 times a day led to a 4-fold reduction in the risk of worsening the disease course to the 2nd study week compared with the standard therapy (p=0.0149). It should be notified that about 70% of the patients who participated in the study had concomitant diseases (mainly obesity of degree 2 and above, as well as arterial hypertension).

An important indicator for predicting a COVID-19 course is the virus elimination rate. In 71.67% of patients treated with molnupiravir, SARS-CoV-2 RNA in a swab from the nasopharynx and / or oropharynx was not detected already 6–7 days after the therapy start. In 19% of patients in the molnupiravir group, a complete clinical recovery had been achieved by days 6-7. In the standard therapy group, only 6% of patients (p=0.0039) had been cured by this point.

The treatment of COVID-19 with molnupiravir also led to a significant decrease compared to the standard therapy in the frequency and severity of the disease symptoms, such as cough, changes in osphresis and taste sensitivity over the latest 24 hours after 6–7 days from the therapy start. The data obtained indicate significant advantages of molnupiravir compared to the standard therapy in terms of the dynamics of the COVID-19 symptoms disappearance, the viral load reduction, the improvement in the condition of patients and their clinical status. Therapy with molnupiravir was well tolerated, most of the AEs were of a mild severity, there were no cases of therapy discontinuation or changes in the dose of the study drug due to the development of AEs [61].

Molnupiravir is contraindicated during pregnancy and lactation, and is also prohibited in patients under 18 years [57].

3.4. Nirmatrelvir/ritonavir

The data on the antiviral efficacy of the nirmatrelvir and ritonavir combination in the treatment of COVID-19 are being accumulated. The combination with a commercial product name Paxlovid, was developed by Pfizer and approved by the FDA for an emergency use in mild to moderate COVID-19 in adults and children over 12 years of age at high risk of developing a severe disease. This drug is included in the WHO recommendations for the treatment of COVID-19 [62, 63]. Nirmatrelvir is an inhibitor of the 3-chymotrypsin-like enzyme of SARS-CoV-2 cysteine protease (M[pro]), which is involved in the viral replication. It has a high antiviral activity against different types of SARS-CoV-2, including alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2) and omicron (B.1.1.529) variants [64]. Ritonavir, an inhibitor of cytochrome P450 3A4, acts as a pharmacokinetic booster, slowing down the nirmatrelvir metabolism of [62, 63]. In December 2021, the combination medicine nirmatrelvir/ritonavir was first approved in the UK for the treatment of COVID-19 in adults who did not require supplemental oxygen and are at the increased risk of progression to severe COVID-19. In January 2022, this drug was approved for the same indications in the European Union, then in the United States, as well as in several other countries.

To date, two randomized trials have shown that the use of nirmatrelvir/ritonavir in outpatients with mild to moderate COVID-19 for 5 days leads to a reduction in hospitalization and mortality [62, 64]. The double-blind, randomized, placebo-controlled EPIC-HR Phase

[6] US Food and Drug Administration. Fact sheet for healthcare providers: emergency authorization for Paxlovid. 2022. Available from: https://www.fda.gov/media/155050/download. Accessed 30 April 2022.
[7] Russian State Register of Medicines. Instructions for molnupiravir (Esperavir®). Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=62a879e9-2c06-4028-8a58-5bac4e01d9ef

2/3 trial evaluated the efficacy of nirmatrelvir/ritonavir in 1,120 outpatient unvaccinated patients at a high risk of a severe novel coronavirus infection compared with 1,126 placebo-treated patients. The use of nirmatrelvir/ritonavir resulted in an 88.9% (95% CI=75%, 8 of 1039 [0.8%]) reduction in the risk of severe COVID-19 (hospitalizations and all-cause mortality) vs. 66 of 1046 [6.3%] in the placebo group). There were no deaths in the nirmatrelvir/ritonavir group (0/1039), while 12 deaths (12/1046) were described in the placebo group (12/1046) by day 28 of the observation. Herewith, the incidence of AEs was comparable in both groups (22.6% and 23.9% in the study and control groups, respectively) [64].

The second study (n=180 351 patients) was conducted in January-February 2022 in Israel, when the omicron strain predominated; 2.6% of participants received nirmatrelvir/ritonavir, resulting in a reduced risk of a severe COVID-19 mortality (OR 0.54 (95% CI=0.39–0.75). This was comparable to an adequate vaccine status (OR=0.20; 95% CI=0.17–0.22). The combined antiviral drug appeared to be more effective in elderly and immunocompromised patients, as well as patients with concomitant neurological and cardiovascular diseases (p <0.05 for all), regardless of vaccination status [62].

Currently, there are insufficient clinical data on the use of the nirmatrelvir/ritonavir combination in children under 12 years of age (<40 kg). Gangfeng Y. et al. conducted a cohort study on a small sample of patients (n=5 – the main group, n=30 – the comparison group) aged 6-14 years with comorbidities and found out that this combination may be one of the options for treating COVID-19 in children with comorbidities. Despite the drug is recommended for use in children by the EU from 12 years and older, the efficacy and safety of the nirmatrelvir/ritonavir combination requires a further study in pediatric practice [63].

In a recent review by Saravolatz L.D. et al., the authors analyzed the available data from FDA clinical trials of oral antivirals, concluded that the nirmatrelvir/ritonavir combination showed a greater reduction in the risk of hospitalization and death than molnupiravir compared with placebo [65]. They also notified that this combination had a better safety profile (it does not have a proven teratogenic effect). The WHO considers this drug "today's best therapeutic agent for the treatment of COVID-19"[8].

In the Russian Federation, a unique technology was developed; that made it possible to combine both active ingredients (nirmatrelvir and ritonavir) into one fixed dosage form (Skyvira® LP-008056 from 20 Apr 2022)[9], which lead to the reduction of the number of tablets used, by 6 times compared to the American analogue. This provides a reduction in polypharmacy and increases the adherence and safety of therapy in general.

According to the results of the Russian open two-stage multicenter study, the considered fixed combination has a high efficacy and a favorable safety profile when used in COVID-19 patients (including the patients with comorbid pathology). The proportion of patients receiving Skyvira® who had achieved a complete recovery by the 6th day of observation was twice higher than in the comparison group. In the main group, there were no cases of COVID-19 transition to a severer course, in contrast to the patients who had received the standard therapy (8 patients were hospitalized) (p=0.0035, i.e. p <0.0275) [66].

CONCLUSION

Thus, to varying degrees, etiotropic drugs are currently available for the treatment of COVID-19 patients. Synthetic antivirals, in particular favipiravir, molnupiravir, remdesivir, and nirmatrelvir/ritonavir, have the largest evidence base for efficacy and safety. In the latest version, in addition to the above, the 16th one of the Russian interim recommendations for the prevention, diagnosis and treatment of a novel coronavirus infection (dated 18 Aug 2022), the following immunotropic drugs are marked: anticovid plasma, monoclonal antibodies and intranasal interferon alfa, umifenovir and the original domestic development – a MIR 19 preparation (synthetic small interfering ribonucleic acid, siRNA)[10]. It should be notified that both the search for new effective and safe etiotropic drugs for the COVID-19 treatment as well as the collection and analysis of post-registration data on the drugs already used in clinical practice, are being continued.

---

[8] WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator, 22 April 2022 Statement, Geneva. Available from: https://www.who.int/news/item/22-04-2022-who-recommends-highly-successful-covid-19-therapy-and-calls-for-wide-geographical-distribution-and-transparency-from-originator.

[9] Russian State Register of Medicines. Instructions for Skyvira®. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e51916eb-403a-40a7-adef-0e0421269063

[10] Interim guidelines "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)" Version 16 (18.08.2022). Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/193/original/%D0%92%D0%9C%D0%A0_COVID-19_V16.pdf

Table 1 – Preparations for etiotropic COVID-19 therapy

Drug groups	INN	Mechanism of action	Brief information on efficacy and safety	References
Immunological preparations	Anticovid Plasma	Antiviral (virus-neutralizing action), antibody-dependent cellular cytotoxicity, complement activation and phagocytosis	Efficacy in patients with severe COVID-19 is 76-90%. Safety: serious adverse events were observed in <1% of patients in the first 4 hours after infusion.	11–21
	Intravenous immunoglobulin	Inhibitor of pro-inflammatory complement cytokine cascade activation, dendritic cell differentiation and activation, and neutrophil activation	Efficacy in patients with ARDS due to COVID-19: no improvement in clinical outcomes (on day 28); association with a slight increase in the incidence of thromboembolic complications was found out.	22–24
	Interferons	Block virus replication via stimulation of anti-viral immunity	Hospitalized patients with COVID-19 and respiratory failure had 3.8 times lower levels of interferon-α compared with control group, while improvement of patients' condition was accompanied by an increase in the level of blood interferon-α	25, 26
	Double stranded RNA sodium salt	Inducer of IFN-α (lymphocytic) and IFN-β (fibroblast)	Stimulates formation of endogenous IFN I (IFN-α, IFN-β) and IFN II (IFN-γ) types, which are the most important cytokines of immune response, induce differentiation of myeloid cells, stimulate phagocytosis of neutrophils and macrophages, activate natural killers, enhance T-helper a Th1-type response thus trigger an innate and adaptive immune response.	29
Drugs that block the entry of the virus into the cell	Umifenovir	Blocks virus penetration into "host cells" by inhibiting fusion of the virus cell membrane lipid envelope	Efficacy in patients with COVID-19: higher incidence of negative PCR results on day 14 of illness (OR=1.27; 95% CI=1.04–1.55) compared with control group; no association with reduced risk of COVID-19 progression, clinical improvement, and reduced length of hospital stay	30–32
Drugs that interfere with viral replication	Favipiravir	Inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase complex by binding to its catalytic domain and preventing incorporation of nucleotides for viral RNA replication, leading to increased mutation rates and possible "lethal mutagenesis"	Efficacy of favipiravir in hospitalized COVID-19 patients according to meta-analysis: faster elimination of virus in favipiravir group – on average, on day 5 (OR=1.60; p=0.02), earlier decrease in temperature – on average on days 3–4 (OR=1.99; p <0.01), improvement of X-ray picture in the lungs (OR=1.33; p <0.01) and earlier discharge from hospital (OR=1.19; p <0.01). Efficacy of Areplivir® for parenteral administration in hospitalized patients with moderate and severe COVID-19: improvement in clinical status by 2 or more points on WHO scale by visit 3, was observed in 56.86% of patients, and in control group (patients receiving standard therapy) – in 28.04% (p <0.0001).	34–45
	Remdesivir	SARS-CoV-2 RNA-dependent RNA polymerase enzyme inhibitor	Meta-analysis of 4 studies involving 7 324 patients hospitalized with COVID-19: use of remdesivir compared with control group did not lead to a decrease in mortality (OR=0.92; 95% CI=0.79–1.07; p=0.30)	46–56
	Molnupiravir	Prodrug, N-hydroxycytidine analogue, which is phosphorylated to form N-hydroxycytidine triphosphate and integrated into viral RNA with the help of RNA polymerase, leading to accumulation of mutations in virus genome and "lethal mutagenesis"	MOVe-OUT study (n=1,433): lower risk of hospitalization or death in molnupiravir group (6.8%) compared with placebo (9.7%) (95% CI=5.9–0.1%). Efficacy of molnupiravir in outpatients with COVID-19 (n=240): 4-fold reduction in the risk of worsenig the disease course by week 2 of the study compared with standard therapy (p=0, 0149); in 71.67% of patients treated with molnupiravir, SARS-CoV-2 RNA in a swab from the nasopharynx and/or oropharynx was not determined on already days 6–7 from the start of therapy; there were no cases of therapy discontinuation or changes in the study drug dose due to AEs development.	57–61
	Nirmatrelvir/ ritonavir	SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor	EPIC-HR study in COVID-19 outpatients (n=1120): 88.9% (95% CI=75%, 8 out of 1039) reduction in the risk of developing severe COVID-19 (hospitalizations and all-cause mortality) (95% CI=75%, 8 out of 1039 [0.8%]) vs. 66 of 1046 [6.3%] in placebo group). Efficacy of nirmatrelvir/ritonavir in COVID-19 outpatients: proportion of patients who achieved complete recovery by day 6 of observation was twice as many than in the comparison group; in the main group, there were no cases of transition of COVID-19 to a severer course, in contrast to patients receiving standard therapy (8 patients were hospitalized) (p=0.0035, i.e. p <0.0275).	62–66

REFERENCES

1. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW. Extrapulmonary manifestations of COVID-19. Nat Med. 2020 Jul;26(7):1017–32. DOI: 10.1038/s41591-020-0968-3

2. Saeed S, Tadic M, Larsen TH, Grassi G, Mancia G. Coronavirus disease 2019 and cardiovascular complications: focused clinical review. J Hypertens. 2021 Jul 1;39(7):1282-1292. DOI: 10.1097/HJH.0000000000002819

3. Magleby R, Westblade LF, Trzebucki A, Simon MS, Rajan M, Park J, Goyal P, Safford MM, Satlin MJ. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019. Clin Infect Dis. 2021 Dec 6;73(11):e4197–e4205. DOI: 10.1093/cid/ciaa851

4. Granovskaya MV, Zaslavskaya KYa, Balykova LA, Pushkar DYu. COVID-19 – a set of symptoms or a systemic pathology? Clinical lecture. Part 2. Areplivir (favipiravir) in the treatment of patients with coronavirus infection: background of use and first resultsInfectious Diseases: News, Opinions, Training (Supplement). 2020;9(3):10–7. DOI: 10.33029/2305-3496-2020-9-3S-10-17. Russian

5. Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020 Oct 29;383(18):1757–66. DOI: 10.1056/NEJMcp2009249

6. Okita Y, Morita T, Kumanogoh A. Duration of SARS-CoV-2 RNA positivity from various specimens and clinical characteristics in patients with COVID-19: a systematic review and meta-analysis. Inflamm Regen. 2022 Jun 1;42(1):16. DOI: 10.1186/s41232-022-00205-x

7. Zhirnov OP. Molecular Targets in the Chemotherapy of Coronavirus Infection. Biochemistry (Mosc). 2020 May;85(5):523–30. DOI: 10.1134/S0006297920050016

8. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel- Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497–511. DOI: 10.1056/NEJMoa2023184

9. Pathak DSK, Salunke DAA, Thivari DP, Pandey A, Nandy DK, Harish VK, Ratna D, Pandey DS, Chawla DJ, Mujawar DJ, Dhanwate DA, Menon DV. No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials". Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1673–80. DOI: 10.1016/j.dsx.2020.08.033

10. Patel TK, Patel PB, Barvaliya M, Saurabh MK, Bhalla HL, Khosla PP. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. J Infect Public Health. 2021 Jun;14(6):740–8. DOI: 10.1016/j.jiph.2021.03.015

11. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1;130(4):1545–8. DOI: 10.1172/JCI138003

12. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44–6. DOI: 10.1007/s10096-004-1271-9

13. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787–99. DOI: 10.1056/NEJMoa2001282

14. Roback JD, Guarner J. Convalescent Plasma to Treat

COVID-19: Possibilities and Challenges. JAMA. 2020 Apr 28;323(16):1561-1562. DOI: 10.1001/jama.2020.4940

15. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Apr 28;323(16):1582–9. DOI: 10.1001/jama.2020.4783

16. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X, Zou Y, Zhang S. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest. 2020 Jul;158(1):e9–e13. DOI: 10.1016/j.chest.2020.03.039

17. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, Eubank T, Bernard DW, Eagar TN, Long SW, Subedi S, Olsen RJ, Leveque C, Schwartz MR, Dey M, Chavez-East C, Rogers J, Shehabeldin A, Joseph D, Williams G, Thomas K, Masud F, Talley C, Dlouhy KG, Lopez BV, Hampton C, Lavinder J, Gollihar JD, Maranhao AC, Ippolito GC, Saavedra MO, Cantu CC, Yerramilli P, Pruitt L, Musser JM. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. Am J Pathol. 2020 Aug;190(8):1680–90. DOI: 10.1016/j.ajpath.2020.05.014

18. Tedder RS, Semple MG. Appropriate selection of convalescent plasma donors for COVID-19. Lancet Infect Dis. 2021 Feb;21(2):168–9. DOI: 10.1016/S1473-3099(20)30470-9

19. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P, Bassily-Marcus A, Bander J, Sanky C, Dupper A, Zheng A, Nguyen FT, Amanat F, Stadlbauer D, Altman DR, Chen BK, Krammer F, Mendu DR, Firpo-Betancourt A, Levin MA, Bagiella E, Casadevall A, Cordon-Cardo C, Jhang JS, Arinsburg SA, Reich DL, Aberg JA, Bouvier NM. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020 Nov;26(11):1708–13. DOI: 10.1038/s41591-020-1088-9

20. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, Zhou Y, Du L, Li F. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J Virol. 2020 Feb 14;94(5):e02015–19. DOI: 10.1128/JVI.02015-19

21. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, Carter RE, Klompas AM, Wiggins CC, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Johnson PW, Lesser ER, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Hodge DO, Kunze KL, Buras MR, Vogt MN, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Van Buskirk CM, Winters JL, Stubbs JR, Paneth NS, Verdun NC, Marks P, Casadevall A. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020 Sep 1;130(9):4791–7. DOI: 10.1172/JCI140200

22. Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017 Dec 30;29(11):491–8. DOI: 10.1093/intimm/dxx039

23. Masso Silva JA, Sakoulas G, Nizet V, Crotty ALE, Meier A. Effect of intravenous immunoglobulin on neutrophil antimicrobial and inflammatory functions-implications in neutrophil-mediated immunopathology // American Journal of Respiratory and Critical Care Medicine.– 2021. – Vol. 203, No. 9. DOI: 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1309

24. Mazeraud A, Jamme M, Mancusi RL, Latroche C, Megarbane B, Siami S, Zarka J, Moneger G, Santoli F, Argaud L, Chillet P, Muller G, Bruel C, Asfar P, Beloncle F, Reignier J, Vinsonneau C, Schimpf C, Amour J, Goulenok C, Lemaitre C, Rohaut B, Mateu P, De Rudnicki S, Mourvillier B, Declercq PL, Schwebel C, Stoclin A, Garnier M, Madeux B, Gaudry S, Bailly K, Lamer C, Aegerter P, Rieu C, Sylla K, Lucas B, Sharshar T. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022 Feb;10(2):158–66. DOI: 10.1016/S2213-2600(21)00440-9

25. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020 May 28;181(5):1036–45.e9. DOI: 10.1016/j.cell.2020.04.026

26. Contoli M, Papi A, Tomassetti L, Rizzo P, Vieceli Dalla Sega F, Fortini F, Torsani F, Morandi L, Ronzoni L, Zucchetti O, Pavasini R, Fogagnolo A, Volta CA, Bartlett NW, Johnston SL, Spadaro S, Campo G. Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients. Front Immunol. 2021 Mar 9;12:648004. DOI: 10.3389/fimmu.2021.648004

27. Bastard P, Orlova E, Sozaeva L, Lévy R, James A, Schmitt MM, Ochoa S, Kareva M, Rodina Y, Gervais A, Le Voyer T, Rosain J, Philippot Q, Neehus AL, Shaw E, Migaud M, Bizien L, Ekwall O, Berg S, Beccuti G, Ghizzoni L, Thiriez G, Pavot A, Goujard C, Frémond ML, Carter E, Rothenbuhler A, Linglart A, Mignot B, Comte A, Cheikh N, Hermine O, Breivik L, Husebye ES, Humbert S, Rohrlich P, Coaquette A, Vuoto F, Faure K, Mahlaoui N, Kotnik P, Battelino T, Trebušak Podkrajšek K, Kisand K, Ferré EMN, DiMaggio T, Rosen LB, Burbelo PD, McIntyre M, Kann NY, Shcherbina A, Pavlova M, Kolodkina A, Holland SM, Zhang SY, Crow YJ, Notarangelo LD, Su HC, Abel L, Anderson MS, Jouanguy E, Neven B, Puel A, Casanova JL, Lionakis MS. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021 Jul 5;218(7):e20210554. DOI: 10.1084/jem.20210554

28. Pereda R, González D, Rivero HB, Rivero JC, Pérez A, López LDR, Mezquia N, Venegas R, Betancourt JR, Domínguez RE. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience. J Interferon Cytokine Res. 2020 Sep;40(9):438–42. DOI: 10.1089/jir.2020.0124

29. Radaeva OA, Taganov AV, Rogozhina EA. Prospects for the use of interferon inducers based on double-stranded RNA for the treatment of viral and bacterial infections. RMJ. Medical review. 2022;6(11):643–9. DOI: 10.32364/2587-6821-2022-6-11-643-649. Russian

30. Blaising J, Polyak SJ, Pécheur EI. Arbidol as a broad-

spectrum antiviral: an update. Antiviral Res. 2014 Jul;107:84-94. DOI: 10.1016/j.antiviral.2014.04.006

31. Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, Yang X, Shi Z, Deng F, Hu Z, Zhong W, Wang M. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020 May 2;6:28. DOI: 10.1038/s41421-020-0169-8

32. Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2021 Jan;93(1):481–90. DOI: 10.1002/jmv.26256

33. Jockusch S, Tao C, Li X, Anderson TK, Chien M, Kumar S, Russo JJ, Kirchdoerfer RN, Ju J. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral Res. 2020 Aug;180:104857. DOI: 10.1016/j.antiviral.2020.104857

34. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002 Apr;46(4):977–81. DOI: 10.1128/AAC.46.4.977-981.2002

35. Jochmans D, van Nieuwkoop S, Smits SL, Neyts J, Fouchier RA, van den Hoogen BG. Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4620–9. DOI: 10.1128/AAC.00709-16

36. Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A. Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. J Infect Dis. 2016 Apr 15;213(8):1253–61. DOI: 10.1093/infdis/jiv586

37. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, Gordeev IG, Ilin AP, Karapetian RN, Kravchenko DV, Lomakin NV, Merkulova EA, Papazova NA, Pavlikova EP, Savchuk NP, Simakina EN, Sitdekov TA, Smolyarchuk EA, Tikhomolova EG, Yakubova EV, Ivachtchenko AV. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2021 Aug 2;73(3):531–4. DOI: 10.1093/cid/ciaa1176

38. Hashemian SM, Farhadi T, Velayati AA. A review on favipiravir: the properties, function, and usefulness to treat COVID-19. Expert Rev Anti Infect Ther. 2021 Aug;19(8):1029–37. DOI: 10.1080/14787210.2021.1866545

39. Alamer A, Alrashed AA, Alfaifi M, Alosaimi B, AlHassar F, Almutairi M, Howaidi J, Almutairi W, Mohzari Y, Sulaiman T, Al-Jedai A, Alajami HN, Alkharji F, Alsaeed A, Alali AH, Baredhwan AA, Abraham I, Almulhim AS. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Curr Med Res Opin. 2021 Jul;37(7):1085–97. DOI: 10.1080/03007995.2021.1920900

40. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, Luo Y, Ju L, Zhang J, Wang X. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Front Pharmacol. 2021 Sep 2;12:683296. DOI: 10.3389/fphar.2021.683296

41. Balykova LA, Granovskaya MV, Zaslavskaya KYa, Simakina EN, Agaf'ina AS, Ivanova AYu, Kolontarev KB, Pushkar DYu. New possibilities for targeted antiviral therapy for COVID-19. Results of a multicenter clinical study of the efficacy and safety of using the drug Areplivir. Infectious Diseases: News, Opinions, Training. 2020;9(3):16–29. DOI: 10.33029/2305-3496-2020-9-3-16-29. Russian

42. Balykova LA, Zaslavskaya KY, Pavelkina VF, Pyataev NA, Selezneva NM, Kirichenko NV, Ivanova AYu, Rodoman GV, Kolontarev KB, Skrupsky KS, Simakina EN, Mubarakshina OA, Taganov AV, Pushkar DYu. Effectiveness and safety of favipiravir infusion in patients hospitalized with COVID-19. Pharmacy & Pharmacology. 2022;10(1):113–26. DOI: 10.19163/2307-9266-2022-10-1-113-126

43. Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021 May 26;11(1):11022. DOI: 10.1038/s41598-021-90551-6. Erratum in: Sci Rep. 2022 Feb 1;12(1):1996.

44. Hung DT, Ghula S, Aziz JMA, Makram AM, Tawfik GM, Abozaid AA, Pancharatnam RA, Ibrahim AM, Shabouk MB, Turnage M, Nakhare S, Karmally Z, Kouz B, Le TN, Alhijazeen S, Phuong NQ, Ads AM, Abdelaal AH, Nam NH, Iiyama T, Kita K, Hirayama K, Huy NT. The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies. Int J Infect Dis. 2022 Jul;120:217–27. DOI: 10.1016/j.ijid.2022.04.035

45. Expert board resolution: possibilities of ethiotropic therapy for respiratory infections caused by RNA viruses. Therapy. 2021;7(5). Available from: https://therapy-journal.ru/ru/archive/article/40450.

46. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020 Nov 5;383(19):1813–26. DOI: 10.1056/NEJMoa2007764

47. Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, van Doremalen N, Leighton I, Yinda CK, Pérez-Pérez L, Okumura A, Lovaglio J, Hanley PW, Saturday G, Bosio CM, Anzick S, Barbian K, Cihlar T, Martens C, Scott DP, Munster VJ, de Wit E. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020 Sep;585(7824):273–6. DOI: 10.1038/s41586-020-2423-5

48. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269–71. DOI: 10.1038/s41422-020-0282-0

49. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396):eaal3653. DOI: 10.1126/scitranslmed.aal3653

50. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 Sep 15;324(11):1048–57. DOI: 10.1001/jama.2020.16349

51. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16;395(10236):1569-1578. DOI: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29. Erratum in: Lancet. 2020 May 30;395(10238):1694.

52. Goldman DL, Aldrich ML, Hagmann SHF, Bamford A, Camacho-Gonzalez A, Lapadula G, Lee P, Bonfanti P, Carter CC, Zhao Y, Telep L, Pikora C, Naik S, Marshall N, Katsarolis I, Das M, DeZure A, Desai P, Cao H, Chokkalingam AP, Osinusi A, Brainard DM, Méndez-Echevarría A. Compassionate Use of Remdesivir in Children With Severe COVID-19. Pediatrics. 2021 May;147(5):e2020047803. DOI: 10.1542/peds.2020-047803

53. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA; GS-US-540-9012 (PINETREE) Investigators. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022 Jan 27;386(4):305–15. DOI: 10.1056/NEJMoa2116846

54. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022 May 21;399(10339):1941–53. DOI: 10.1016/S0140-6736(22)00519-0

55. Singh S, Khera D, Chugh A, Khera PS, Chugh VK. Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. BMJ Open. 2021 Jun 24;11(6):e048416. DOI: 10.1136/bmjopen-2020-048416

56. Wahl A, Gralinski LE, Johnson CE, Yao W, Kovarova M, Dinnon KH 3rd, Liu H, Madden VJ, Krzystek HM, De C, White KK, Gully K, Schäfer A, Zaman T, Leist SR, Grant PO, Bluemling GR, Kolykhalov AA, Natchus MG, Askin FB, Painter G, Browne EP, Jones CD, Pickles RJ, Baric RS, Garcia JV. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021 Mar;591(7850):451–7. DOI: 10.1038/s41586-021-03312-w

57. Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ, Szewczyk LJ, Painter GR. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob Agents Chemother. 2021 Mar 1;65(5):e02428-20. DOI: 10.1128/AAC.02428-20

58. Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, André E, Leyssen P, Neyts J, Jochmans D. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022 Feb;198:105252. DOI: 10.1016/j.antiviral.2022.105252

59. Fischer WA 2nd, Eron JJ Jr, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Coombs RW, James Loftis A, Alabanza P, Lipansky F, Painter WP. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022 Jan 19;14(628):eabl7430. DOI: 10.1126/scitranslmed.abl7430

60. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterton JR, Johnson MG, De Anda C; MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022 Feb 10;386(6):509–20. DOI: 10.1056/NEJMoa2116044

61. Pshenichnaya NYu, Omarova KhG, Balykova LA, Pushkar DYu, Zaslavskaya KYa, Zemskov DN, Taganov AV, Bely PA. Efficacy and safety of molnupiravir in adult outpatients with COVID-19. Infect. Dis. 2022;(4). Russian

62. Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein LH, Saliba W. Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients. Clin Infect Dis. 2022 Jun 2:ciac443. DOI: 10.1093/cid/ciac443

63. Yan G, Zhou J, Zhu H, Chen Y, Lu Y, Zhang T, Yu H, Wang L, Xu H, Wang Z, Zhou W. The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6-14 years: a cohort study. Ann Transl Med. 2022 Jun;10(11):619. DOI: 10.21037/atm-22-2791

64. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022 Apr 14;386(15):1397–408. DOI: 10.1056/NEJMoa2118542

65. Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs. Clin Infect Dis. 2022 Mar 4:ciac180. DOI: 10.1093/cid/ciac180

66. Balykova LA, Selezneva NM, Gorshenina EI, Shepeleva OI, Kirichenko NV, Simakina EN, Kolontarev KB, Pushkar DYu, Zemskov DN, Zaslavskaya KY, Noskov SM, Taganov AV, Bely PA. Modern directed antiviral COVID-19 therapy: results of multicenter clinical effectiveness and safety study of fixed nirmatrelvir+ritonavir combination. Pharmacy & Pharmacology. 2022; 10(4):371–86. DOI:10.19163/2307-9266-2022-10-4-371-386

AUTHORS

Dmitry N. Zemskov – Assistant of the Department of Biological and Pharmaceutical Chemistry with a Course of Organization and Management of Pharmacy, National Research Ogarev Mordovia State University. ORCID ID: 0000-0002-0181-4327. E-mail: dizem1978@gmail.com

Larisa A. Balykova – Doctor of Sciences (Medicine), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Pediatrics, Director of National Research Ogarev Mordovia State University. ORCID ID: 0000-0002-2290-0013. E-mail: larisabalykova@yandex.ru

Olga A. Radaeva – Doctor of Sciences (Medicine), Associate Professor, Head of the Department of Immunology, Microbiology and Virology with a Course of Clinical Immunology and Allergology, National Research Ogarev Mordovia State University. ORCID ID: 0000-0003-1383-2474. E-mail: radaevamed@mail.ru

Kira Ya. Zaslavskaya – Assistant of the Department of Biological and Pharmaceutical Chemistry with a course of Organization and Management of Pharmacy, National Research Ogarev Mordovia State

University. ORCID ID: 0000-0002-7348-9412. E-mail: kiryonok@yandex.ru

Petr A. Bely – Candidate of Sciences (Medicine), Senior Laboratory Assistant, Department of Propaedeutics of Internal Diseases and Gastroenterology, Evdokimov Moscow State Medical and Dental University. ORCID ID: 0000-0001-5998-4874. E-mail: pbely@ncpharm.ru

Elena V. Semenova – Candidate of Sciences (Medicine), Associate Professor, Department of Pharmacology, National Research Ogarev Mordovia State University. ORCID ID: 0000-0001-6905-0063. E-mail: yelenadan@mail.ru

Marina V. Shirmankina – Clinical Intern of the Department of Pediatrics, National Research Ogarev Mordovia State University. ORCID ID: 0000-0002-9049-5662. E-mail: shirmankina99@mail.ru

Ksenia N. Koryanova – Candidate of Sciences (Pharmacy), Associate Professor of the Department of Pharmacology with a Course of Clinical Pharmacology, Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University. ORCID ID: 0000-0003-1571-9301. E-mail: kskor-16@mail.ru

CONSUMPTION DETAILS OF SYSTEMICALLY ACTING ANTIVIRAL AND ANTIMICROBIAL PREPARATIONS IN PERIOD OF NOVEL CORONAVIRUS INFECTION SPREAD IN RETAIL SECTOR OF SAMARA REGION PHARMACEUTICAL MARKET

I.K. Petrukhina, P.A. Lebedev, I.I. Sirotko, T.K. Ryazanova, E.P. Gladunova, A.A. Garanin

Samara State Medical University,
89, Chapaevskaya Str., Samara, Russia 443099

E-mail: i.k.petrukhina@samsmu.ru

An analysis of the medicinal preparation consumption structure in the period of the COVID-19 pandemic in the pharmacy network reflects the existing outpatient practice and makes it possible to draw generalized conclusions about its compliance with the pharmacotherapy standards.

The aim. Comparative analysis of population consumption of antimicrobial and antiviral medicines sold in the retail pharmacies of the Samara region in 2015–2021.

Materials and methods. The study was conducted in the retail sector of the Samara region pharmaceutical market. The material of the study was the information on the list of items and dispensing volumes of antibacterial and individual antiviral drugs during the novel coronavirus infection spread (in 2020) in the network of the Samara region pharmacies. The data are compared with the indicators of the drug sales in 2015–2019. Methods of retrospective, comparative, graphical, methodological, content analyzes and statistical methods of analyses were used.

Results. The authors have established a significant distortion in the consumption of systemic antimicrobial preparations in the Samara region pharmacy segment in the period of 2015–2019 with the predominance of the ATC (Anatomical Therapeutic Chemical Classification System) J01D group, primarily cephalosporins (38%), mainly by the parenteral administration route. The share of macrolides (J01F) consumption in volume terms was 14.9%, of fluoroquinolones (J01M) – 11.3%, beta-lactam antibiotics with beta-lactamase inhibitors – 10.7%, beta-lactam antibiotics penicillins (J01C) – 8.1%. Compared to 2019, in 2020, under the conditions of the COVID-19 pandemic, the total consumption of AMPs increased by 2.1 times. In the "Other beta-lactam antibiotics" group with a predominant proportion of cephalosporins, there was an increase by 3.2 times, in the "Macrolides and lincosamides" group – by 3.5 times, in "Quinolone derivatives" – by 2.6 times. The noted facts should be assessed as the phenomenon that can have a direct impact on the growth of an antibiotic resistance on a population scale. Among antivirals, the largest consumption increase was noted for oseltamivir and rimantadine. In absolute terms, the volume of antiviral preparations consumption in 2020 increased by 2.4 times, which was accompanied by an increase in the cost of one package by 55.8%.

Conclusion. In the period of spreading a novel coronavirus infection, a significant increase in the consumption of antimicrobial and antiviral preparations (up to 20 times for certain pharmacotherapeutic groups and names) was notified, which may negatively affect the growth of the antibiotic resistance in the population.

Keywords: systemic antimicrobial preparations; antiviral drugs; pharmacy segment; consumption; COVID-19 pandemic

Abbreviations: AMPs – antimicrobial preparations; MP – medicinal preparations; DDD – Defined Daily Dose; INN – international non-proprietary name; ATC – Anatomical Therapeutic Chemical Classification System; ARVI – acute respiratory viral infection; RNA – ribonucleic acid.

ОСОБЕННОСТИ ПОТРЕБЛЕНИЯ ПРОТИВОВИРУСНЫХ И АНТИМИКРОБНЫХ ПРЕПАРАТОВ СИСТЕМНОГО ДЕЙСТВИЯ В ПЕРИОД РАСПРОСТРАНЕНИЯ НОВОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИИ В РОЗНИЧНОМ СЕКТОРЕ ФАРМАЦЕВТИЧЕСКОГО РЫНКА САМАРСКОЙ ОБЛАСТИ

И.К. Петрухина, П.А. Лебедев, И.И. Сиротко, Т.К. Рязанова, Е.П. Гладунова, А.А. Гаранин

Федеральное государственное бюджетное образовательное учреждение высшего образования
«Самарский государственный медицинский университет»
Министерства здравоохранения Российской Федерации,
443099, Россия, г. Самара, ул. Чапаевская, д. 89

E-mail: i.k.petrukhina@samsmu.ru

Анализ структуры потребления лекарственных препаратов в период пандемии COVID-19 в аптечной сети отражает существующую амбулаторную практику и позволяет сделать обобщенные выводы о соответствии ее стандартам фармакотерапии.

Цель. Сравнительный анализ популяционного потребления антимикробных и противовирусных лекарственных препаратов, реализованных в розничном секторе фармацевтического рынка Самарской области в 2015–2021 гг.

Материалы и методы. Исследование проведено в розничном секторе фармацевтического рынка Самарской области. В качестве материала исследования использовали сведения о номенклатуре и объемах отпуска антибактериальных и отдельных противовирусных лекарственных препаратов в период распространения новой коронавирусной инфекции (в 2020 г.) в сети аптек Самарской области. Данные сопоставлены с показателями реализации лекарственных препаратов в 2015–2019 гг. Использованы методы ретроспективного, сравнительного, графического, методологического, контент-анализ и статистические методы анализа.

Результаты. Авторами установлена значительная деформация потребления антимикробных препаратов системного действия в аптечном сегменте Самарской области в период 2015–2019 гг. с преобладанием группы ATX J01D с доминированием цефалоспоринов (38%) преимущественно парентерального пути введения. Доля потребления в натуральном выражении макролидов (J01F) составила 14,9%, фторхинолонов (J01M) — 11,3%, бета-лактамных антибиотиков с ингибиторами бета-лактамаз — 10,7%, бета-лактамных антибиотиков-пенициллинов (J01C) — 8,1%. В сравнении с 2019 г., в 2020 г. в условиях пандемии COVID-19 общее потребление АМП увеличилось в 2,1 раз. В группе «Другие бета-лактамные антибиотики» с преимущественной долей цефалоспоринов произошло увеличение в 3,2 раза, «Макролиды и линкозамиды» — в 3,5 раз, «Производные хинолона» — в 2,6 раза. Отмеченные факты следует оценивать как фактор, который может оказать непосредственное влияние на рост антибиотикорезистентности в популяционном масштабе. Среди противовирусных препаратов наибольший рост потребления отмечен для осельтамивира и римантадина. В абсолютном выражении объем потребления противовирусных лекарственных препаратов в 2020 г. увеличился в 2,4 раза, что сопровождалось увеличением стоимости одной упаковки на 55,8%.

Заключение. В период распространения новой коронавирусной инфекции отмечен значительный рост потребления антимикробных и противовирусных лекарственных препаратов (по отдельным фармакотерапевтическим группам и наименованиям – до 20 раз), что может негативным образом отразиться на росте антибиотикорезистентности у населения.

Ключевые слова: антимикробные препараты системного действия; противовирусные препараты; аптечный сегмент; потребление; пандемия COVID-19

Список сокращений: АМП – антимикробные препараты; ЛП – лекарственные препараты; DDD – суточная поддерживающая доза; МНН – международное непатентованное наименование; АТХ – анатомо-терапевтическо-химическая классификация; ОРВИ – острая респираторная вирусная инфекция; РНК – рибонуклеиновая кислота.

INTRODUCTION

A new coronavirus infection has become an unprecedented challenge for the health care system of the Russian Federation (RF), the pharmaceutical industry, and the regional drug supply system [1–3]. The greatest difficulty is the search for the effective methods of etiotropic treatment. In the absence of new medicinal preparations (MPs) that effectively suppress the SARS-Cov-2 replication, screening of the known antiviral agents seems relevant. Obtaining reliable data on the clinical benefit of drugs has proved to be very problematic in the current situation and has led to the fact that the preference of physicians and patients has become a criterion for benefit [4–8].

The consumption structure of antimicrobial and antiviral preparations by the population through the pharmacy network, reflecting the outpatient practice in the period preceding the pandemic, as well as the

dynamics of the MPs consumption during the pandemic, seems important in terms of compliance with the directions of modern recommendations[1]. Herewith, the scope of use of antimicrobial and antiviral preparations in the outpatient practice of the Russian Federation regions is not reliably known; such data are rare in the press. At the same time, the problem of the antibiotic resistance may become particularly acute in the near future in case of an irrational increase in the AMPs use [9–15]. The AMPs prescribtion and use should always be justified, since the irrational use of this pharmacotherapeutic group MPs can lead to a noticeable increase in the antibiotic resistance on a population-based study [1, 12, 16]. The dynamics of the antimicrobial and antiviral preparations consumption makes it possible to indirectly assess the optimality of pharmacotherapy for the novel coronavirus infection, as well as to establish compliance with current guidelines. The results of such an analysis can be used to improve the medicinal preparations efficiency and safety at the population level [17–26].

In this regard, marketing research is becoming highly relevant, making it possible to identify trends in the population consumption of antimicrobial and antiviral preparations in the retail sector of the pharmaceutical market.

THE AIM. Comparative analysis of population consumption of antimicrobial and antiviral medicines sold in the retail pharmacies of the Samara region in 2015–2021.

MATERIALS AND METHODS

The study was conducted on the retail sector example of the Samara region pharmaceutical market. According to a number of demographics, medical, social, economic and infrastructural indicators, this region is among the most developed ones of the Volga Federal District and the Russian Federation. The regional pharmaceutical market is highly concentrated with a high degree of competition.

The material of the study was information on the list of items and volumes of antimicrobial and antiviral preparations sale during the spread of the coronavirus infection (in 2020–2021) in the pharmacy network of the Samara region. The analyzed pharmacy network includes 30 pharmacies located in different municipalities of the Samara region. These network pharmacies have a wide range of medicines and other pharmacy products (about 30 thousand items).

The following analytical methods were used: methods of the retrospective analysis (changes in

---

[1] Interim guidelines "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19). Version 3 (03.03.2020). Available from: http://edu.rosminzdrav.ru/fileadmin/user_upload/specialists/COVID-19/Vremennye_MR_COVID-19_03.03.2020__versija_3__6-6_ver1.pdf. Russian

the indicators of the retail sale of medicines to the population during 2015–2021), a comparative analysis (the one of individual groups and intragroup indicators), a graphical analysis (presentation pharmaceutical sales time series), a methodological analysis (the identification of common characteristics for the objects, the analysis relationships between the phenomena), content analysis (the analysis of the text arrays content about the medicinal preparations implementation in the analyzed period) and statistical methods of the analysis. A statistical processing was performed using IBM SPSS Advanced Statistics 24.0 No. 5725-A54 (IBM, USA).

The representativeness assessment of the sample in the conducted studies was carried out by assessing the number of the medicinal preparations purchases of the groups under consideration in the analyzed retail network of the Samara region pharmaceutical market. For this purpose, the following formula was used:

$$m = 2\sqrt{n,}$$

where: m is the resulting sample size; n is the size of the general totality.

In the conducted studies, the general totality is understood as the Samara region population (n in 2021 was 3 154 200 people). Therefore, to ensure the representativeness of the sample size, it should be 3 552 purchases of antibacterial medicinal preparations in 2020. In the studied pharmacy chain, in 2015-2021, about 50 thousand purchases were made annually, which confirms the representativeness of the data obtained, i.e. the correspondence of the characteristics of the sample to the characteristics of the general population.

As for the medicinal preparations, the cost of one defined daily dose (DDD) was calculated by dividing the total cost of the medicinal preparations packages with one INN by the total number of DDDs.

RESULTS

Consumption of systemic antimicrobials

For the period of 2015–2021, in the studied retail segment sector of the Samara region pharmaceutical market, about 18 million packages of MPs and other pharmacy products were sold, 2.57% of which were accounted for AMPs. In the total volume of the dispensed packages, the average share of AMPs for the period of 2015–2021 was 3.38%. For comparison, in the Russian pharmaceutical market, the share of AMPs sales by volume was about 11.69%. Herewith, 43.7% of purchases were made at the expense of the population's personal funds. In general, in 2015–2021, the range of AMPs averaged (± standard deviation, SD) 54±3 international non-proprietary names (INN), which corresponds to 138±3 trade names.

A noticeable increase in the consumption of antibacterial medicinal preparations in the retail sector of the Samara region pharmaceutical market was notified in 2020 (compared to 2019, the sales in packages increased by 2.12 times), which exceeds the average annual fluctuations in realized demand for this group of MPs in 2015-2019. The dynamics study of the realized demand for individual systemic AMPs subgroups (in accordance with subgroups in the anatomical-chemical-therapeutic [ATC-]classification) revealed a significant increase in the number of dispensed packages in 2020 for the following subgroups: J01D "Other beta-lactam antibacterials", J01F "Macrolides, lincosamides and streptogramins", J01M "Quinolone antibacterials" (Table 1, Fig. 1). In the authors' opinion, this circumstance is due to the influence of the novel coronavirus infection spread and, in some cases, the rush demand for drugs from certain pharmacotherapeutic groups.

Herewith, at the end of 2021, the level of the consumer demand returned to the values of 2015–2019. Possible reasons for this trend may be as follows: the formation of AMPs stocks in home medicine cabinets by the end of 2020; the implementation of programs providing the COVID-19 patients with the MPs prescribed for them at the expense of the federal budget; a change in the algorithm for treating outpatients (in 2021, at the outpatient stage of medical care, AMPs were excluded from pharmacotherapy regimens).

In 2020, against the background of a significant increase in demand for drugs of ATC subgroups J01D "Other beta-lactam antibacterials", J01F "Macrolides, lincosamides and streptogramins", J01M "Quinolone antibacterials", a decrease in the share of the AMPs packages total sales for the drugs of J01A subgroups "Tetracyclines" was notified. Besides, there were J01C "Beta-lactam antibacterials, penicillins", J01G "Aminoglycoside antibacterials", J01X "Other AMPs", and "Beta-lactam antibacterials with beta-lactamase inhibitors". As Fig. 2 shows, in 2021, there was a return to the existing picture of demand for AMPs in 2015–2019, with the exception of aminoglycosides, the number of sold packages decreased in 2019–2021 by an average of 35% annually (Fig. 2).

In 2015–2021, the maximum share of the total volume of the realized demand was accounted for the ATCs subgroup J01D "Other beta-lactam antibiotics" (Fig. 3). The average value of the share (± SD) of the volume of the realized demand in real terms for this ATCs subgroup was 38.5±5.6%.

In 2020, against the background of the beginning of a novel coronavirus infection pandemic, an increase in the proportion of the medicines of this ATCs subgroup to 47.6% was notified. In 2021, the value of the share of J01D MPs in the total volume of the realized demand returned to the previous average annual values (39.0%)

(Table 1, Fig. 1). Over the past two years, an extraordinary demand for these drugs was notified in October, although in 2021 it was less pronounced compared to 2020 (Fig. 4).

In 2020, as in the previous period (2015–2019), in the "Other beta-lactam antibacterials" group, ceftriaxone preparations had the largest volumes of consumption in volume terms (median 72.2%), ranging from 63.5 % in 2020 to 76.8% in 2017 of the total realized demand for drugs from this ATC subgroup. At the same time, in 2020, in the overall structure of the dispensed drugs packs of the ATC J01D subgroup, there was a sharp increase in the share and number of the dispensed packs for the drugs of cefazolin, cefditoren and meropenem, which returned to their previous values in 2021. The greatest demand in the outpatient practice is for parenteral preparations from the group of cephalosporins "Other β-lactam antibacterials", including ceftriaxone, as well as cefazolin (8.3–12.9%) and cefotaxime (7.7–5.4%). In accordance with the current recommendations, amoxicillin and its combination with clavulanic acid (β-lactam antibiotics and β-lactam penicillins with β-lactamase inhibitors) should be the basic treatment for the vast majority of bacterial infections in the outpatient practice. However, the frequency of amoxicillin sales from 2015 to 2021 decreased from 14.1% to 6.1% (Table 1). In combination with β-lactamase inhibitors, where the main share of MPs is accounted for amoxicillin (96.9–81.6%), the frequency of this antibacterial sales does not exceed 10% in total in 2020 (Table 1).

According to the literature data, in outpatient practice, the first-line MPs of choice is amoxicillin, administered orally for pneumonia, exacerbation of chronic obstructive pulmonary disease, acute rhinosinusitis, bronchitis, acute tonsillitis, and uncomplicated skin and soft tissue infection [8, 15, 17]. At the same time, a high consumer demand for β-lactam antibiotics was notified in the retail sector of the Samara Region pharmaceutical market.

In 2015–2021, a significant share in the structure of consumption volume in physical terms was also occupied by medicines of J01F ATC subgroups "Macrolides, lincosamides and streptogramins" (15.0%) and J01M "Quinolone antibacterials" (11.4%) (Table 1, Fig. 1). In 2020, for the group "Macrolides, lincosamides and streptogramins", an increase in the share was notified (in the total structure of the dispensed packages – up to 19.9%). In 2021, this share decreased compared to 2020, but continued to be high compared to the average annual data for the period of 2015–2019 (14.4%). When analyzing the demand by months, it was found out that in 2020 and 2021, the demand for these AMPs, as in the case of the ATC subgroup J01D "Other beta-lactam antibacterials", peaked in October (Fig. 5).

Figure 1 – Dynamics of realized demand for some groups of antibacterial medicinal preparations, pandemic sales of which increased

Figure 2 – Dynamics of realized demand for some groups of antibacterials, sales of which decreased or did not change during pandemic

Figure 3 – Median shares of realized demand volume for antibacterial MPs in 2015–2021

**Figure 4 – Dynamics of demand for ATC subgroup medicinal preparations –
J01D "Other beta-lactam antibacterials" in 2015–2021 (by months)**

**Figure 5 – Dynamics of demand for ATC subgroup medicinal preparations – J01F
"Macrolides, lincosamides and streptogramins" in 2015–2021 (by months)**

**Figure 6 – Median volume shares of realized demand for antiviral medicinal preparations
in 2015–2020**

Figure 7 – Incidence of acute respiratory viral infections, influenza, COVID-19, community-acquired pneumonia in 2019 (according to Samara region Rospotrebnadzor), volumes of realized antiviral MPs and AMPs packages

Figure 8 – The incidence of acute respiratory viral infections, influenza, COVID-19, community-acquired pneumonia in 2020 (according to Samara region Rospotrebnadzor), volumes of realized of antiviral MPs and AMPs packages

Figure 9 – Dynamics of oseltamivir demand in 2015–2021

Figure 10 – Dynamics of rimantadine demand in 2015–2020

Figure 11 – Dynamics of imidazolylethanamide pentadioic acid demand in 2015–2020

Figure 12 – Dynamics of thyrolon demand in 2015–2020

Figure 13 – Dynamics of umifenovir demand in 2015–2020

**Table 1 – Consumption structure of antibacterials in retail sector
of Samara region pharmaceutical market**

| ATC-subgroups and medicines (INN)	Share of realized demand volume (in packages), %*							Median (minimum-maximum) in 2015–2021
	Year							
	2015	2016	2017	2018	2019	2020	2021	
J01A Tetracyclines	**2.6**	**3.0**	**2.7**	**2.5**	**2.6**	**1.2**	**2.0**	**2.6 (1.2–3.0)**
Doxycycline	85.5	88.7	85.6	84.3	86.5	80.2	87.7	87.6 (80.2–88.7)
Tetracycline	14.5	11.1	12.8	15.3	13.3	19.1	9.9	13.3 (9.9–19.10)
J01C Beta-lactam penicillins	**14.1**	**10.3**	**8.7**	**7.6**	**7.2**	**3.6**	**6.1**	**7.6 (3.6–14.1)**
Amoxicillin	58.6	81.3	85.4	93.3	91.3	95.5	100.0	91.3 (58.6–100.0)
J01D Other beta-lactam antibacterials	**34.0**	**33.5**	**41.0**	**41.4**	**35.0**	**47.6**	**39.0**	**39.0 (33.5–47.6)**
Ceftriaxone	71.8	65.8	76.8	74.0	72.5	63.5	75.7	72.6 (63.5–76.8)
Cefazolin	8.5	8.3	5.1	4.0	3.5	12.8	4.5	5.1 (3.5–12.8)
Cefotaxime	5.5	7.8	3.1	5.4	5.1	6.3	2.5	5.4 (2.5–7.8)
Cefixime	4.6	5.4	5.9	6.8	8.1	3.9	8.3	5.9 (3.9–8.3)
Cefditoren	0.0	0.4	0.3	1.0	1.8	8.1	2.1	1.0 (0.00–8.1)
Beta-lactam antibacterials with beta-lactamase inhibitors	**9.5**	**10.8**	**10.5**	**10.9**	**11.9**	**7.6**	**11.7**	**10.8 (7.6–11.9)**
Amoxicillin + clavulanic acid	88.2	94.6	95.4	96.9	91.9	81.6	93.3	93.3 (81.6–96.9)
J01E Sulfonamides and trimethoprim	**2.1**	**2.0**	**1.9**	**2.2**	**2.3**	**1.2**	**1.5**	**2.0 (1.2–2.3)**
Co-trimoxazole	85.8	85.7	81.8	85.9	89.6	91.2	98.8	98.9 (81.8–98.8)
Sulfadimethoxine	12.8	12.9	10.6	12.8	9.8	8.4	1.1	10.6 (1.1–12.9)
J01F Macrolides, lincosamides and streptogramins	**14.8**	**15.0**	**13.3**	**13.4**	**15.5**	**19.9**	**18.1**	**15.0 (13.3–19.9)**
Azithromycin	48.2	46.1	44.6	50.4	49.4	79.7	68.7	49.4 (44.6–79.7)
Clarithromycin	23.9	25.3	28.6	27.3	30.2	12.4	20.0	25.3 (12.4–30.2)
Josamycin	8.4	10.4	10.1	7.8	8.2	3.4	5.5	8.2 (3.4–10.4)
Lincomycin	9.0	8.1	8.0	7.4	7.5	2.7	4.2	7.5 (2.7–9.0)
J01G Aminoglycosides	**1.6**	**2.5**	**1.4**	**2.2**	**2.3**	**0.8**	**0.1**	**1.6 (0.1–2.5)**
Gentamicin	19.0	14.1	18.1	13.0	11.1	29.2	72.4	18.1 (11.1–72.4)
Amikacin	51.5	37.9	65.8	86.8	88.5	70.8	27.6	65.8 (27.6–88.5)
J01M Quinolone antibacterials	**10.9**	**11.8**	**10.9**	**10.5**	**11.6**	**11.7**	**11.4**	**11.4 (10.5–11.8)**
Ciprofloxacin	37.1	37.4	37.3	36.1	35.6	21.8	30.4	36.1 (21.8–37.4)
Levofloxacin	25.9	31.1	33.7	37.1	38.1	59.8	49.6	37.1 (25.9–59.8)
Norfloxacin	18.3	17.6	15.4	15.2	15.6	7.8	13.0	15.4 (7.8–18.3)
J01X Other antibacterials	**6.1**	**6.2**	**5.4**	**5.3**	**7.4**	**4.4**	**6.7**	**6.1 (4.4–7.4)**
Metronidazole	96.0	92.8	93.6	91.8	94.8	91.7	92.9	92.9 (91.7–96.0)
Antibiotic combinations	**4.3**	**4.9**	**4.2**	**4.1**	**4.3**	**2.0**	**3.4**	**4.2 (2.0–4.9)**
Benzathine benzylpenicillin + Benzylpenicillin procaine	37.6	35.3	23.9	33.3	21.1	16.3	18.5	23.9 (16.3–37.6)
Benzathine benzylpenicillin + Benzylpenicillin procaine + Benzylpenicillin sodium	18.7	11.7	16.7	13.7	13.3	18.0	13.6	13.7 (11.7–18.7)
Ciprofloxacin + tinidazole	39.8	44.2	51.6	48.2	57.9	63.5	66.5	51.6 (39.8–66.5)

Note: * – indicators of realized demand in packages were used for the analysis. For pharmacotherapeutic groups, the shares of the total volume of realized demand are indicated, for INN it is the share of the volume of realized demand for a particular pharmacotherapeutic group; the table shows INNs with the largest volumes of realized demand within each pharmacotherapeutic group.

Table 2 – Consumption structure of antiviral medicinal preparations prescribed for treatment of respiratory viral infections in retail sector of Samara region pharmaceutical market

Antiviral medicinal preparations (INN)	Share in realized demand structure, %						
	2015	2016	2017	2018	2019	2020	2021
Zanamivir	0.10	0.40	0.20	0.34	0.23	0.19	0.06
Pentandioic acid imidazolylethanamide	24.97	22.20	22.64	25.63	16.80	15.85	11.96
Inosine acedoben dimepranol	3.49	2.58	2.95	4.63	4.82	2.09	3.23
Oseltamivir	0.71	1.60	2.11	3.23	3.25	17.26	8.04
Rimantadine	24.74	25.55	24.69	23.35	20.35	13.34	12.81
Tiloron	10.26	14.10	14.34	14.60	20.56	17.71	17.00
Umifenovir	25.61	26.97	25.70	19.97	17.13	26.79	40.13
Favipiravir*	–	–	–	–	–	0.44	1.18
Paracetamol + Rimantadine + Ascorbic Acid + Loratadine + Rutoside + Calcium Gluconate	10.11	6.61	7.36	8.23	0.17	6.22	5.52

Note: for the analysis, indicators of realized demand in packages were used; * – Favipiravir preparations were registered in Russia in 2020.

Table 3 – Average cost of treatment for one maintenance daily dose of antiviral MPs in 2019–2020

INN	Median (minimum-maximum) cost of 1 DDD, rub. (2019)	Median (minimum-maximum) cost of 1 DDD, rub. (2020)	Median (minimum-maximum) cost of 1 DDD, rub. (2021)	Median (minimum-maximum) cost of 1 DDD in treatment with original drugs, rub. (as exemplified by 2021)
Zanamivir	234.09 (234.09–234.09)	276.33 (256.33–300.10)	280.32 (280.32–280.32)	280.32 (280.32–280.32)
Pentandioic acid imidazolylethanamide	82.21 (77.34–87.08)	103.38 (85.86–120.70)	102.09 (73.33–122.79)	102.09 (73.33–122.79)
Inosine Acedoben Dimepranol	192.43 (93.19–417.22)	209.75 (115.25–374.58)	216.98 (145.00–312.09)	247.40 (187.88–245.72)
Oseltamivir	174.88 (133.92–291.74)	202.99 (167.22–288.68)	210.53 (126.46–248.71)	245.38 (242.05–248.71)
rimantadine	11.64 (6.87–255.80)	20.65 (11.32–261.82)	16.92 (7.72–157.55)	–
Tiloron	102.09 (41.66–143.53)	102.26 (51.99–151.42)	92.27 (46.29–134.74)	133.43 (132.12–134.74)
Umifenovir	169.06 (97.77–291.56)	188.25 (99.85–335.25)	238.62 (119.60–384.22)	253.10 (246.88–384.22)
Favipiravir	–	2 073.68 (1 795.27–2 073.68)	1 255.79 (1 001.78–2 382.38)	–

In 2020–2021, in the group "Macrolides, lincosamides and streptogramins", there was an increase in the share of azithromycin-containing medicines in the total number of the dispensed packages of this ATC subgroup, which amounted to 79.7% and 68.7%, respectively (compared to the average value of 47.8±2.4% in 2015–2019). The demand for other medicines within this ATC subgroup remained at the same level or slightly decreased. According to the document of the World Health Organization (WHO) and domestic recommendations, macrolides should be considered as second-line drugs in the treatment of respiratory infections [16].

The group of fluoroquinolones is considered as reserve AMPs and is not recommended for the treatment of acute uncomplicated infections in the outpatient practice. In this study, their share of the total number of the dispensed packages remained approximately at the same level and averaged 11.4±0.5%. The drugs of

the ATC subgroup "Quinolone antibacterials" were more often applied for. They were the medicines containing the active ingredients ciprofloxacin, levofloxacin or norfloxacin (medians for the period of 2015–2021 – 36.1%, 37.1% and 15.4% of the volume of this group realized demand, respectively). At the same time, in 2020–2021, there was an increase in demand for "respiratory" drugs of this group: levofloxacin and moxifloxacin.

In 2020, for the ATC subgroups "Other beta-lactam antibacterials", the number of the dispensed packages increased by 3.2 times, for "Macrolides, lincosamides and streptogramins" – by 3.5 times, for "Quinolone antibacterials" – by 2.6 times in 2020 (compared to the average values of the dispensed MPs packages of these subgroups in 2015–2019). A similar increase was notified for individual INNs: ceftriaxone – by 2.9 times, cefazolin – by 7.5 times, by cefotaxime – by 3.3 times, cefditoren –

by 33 times, meropenem – by 90 times, azithromycin – by 5.8 times, levofloxacin – by 4.7 times, moxifloxacin – by 7.0 times. Interest in cefditoren is obviously due to the fact that it was included in the domestic clinical guidelines for the treatment of community-acquired pneumonia in 2018. The number of dispensed packages of the remaining drugs was approximately at the level of the previous period, respectively, their share in the total consumption structure in 2020 slightly decreased.

For most of the groups and individual items of the MPs under consideration, there was an increase in the cost of 1 DDD in 2020 compared to 2019. The cost of one package increased by 15%, the median cost of 1 DDD increased by 20%. In 2021, the corresponding values compared to 2020, were 3.5% and 5.0%, respectively.

Antiviral medicinal preparations

The range of antiviral medicinal preparations approved for use in the treatment of acute respiratory viral infections was represented by 8 out of 9 INNs registered in the Russian Federation (except baloxavir carboxyl, registered in September 2020), which corresponded to 35 trade names. At the end of 2021, the share of antiviral medicinal preparations in the total structure of the dispensed packages amounted to 0.92% (for comparison, in 2018 and 2020 – 0.93% and 1.02%, respectively). In absolute terms (in terms of the package quantity), in 2020, the volume of consumption of medicinal preparations increased by 2.38 times, which exceeds the average annual fluctuations in the consumer demand in the period preceding the start of the novel coronavirus infection spread (an average increase by 1.15 times).

Among antiviral medicines, the largest consumption volume in physical terms was accounted for the MPs of imidazolylethanamide pentadioic acid (median 22.2% of the realized demand volume, the range of 15.9% – 25.6%), umifenovir (25.7%, 16.7% – 40.1%) and rimantadine (23.4%, 12.8% – 25.6%) (Table 2, Fig. 6). In 2020–2021, the consumption of rimantadine naturally decreased to 13.3 and 12.8%, respectively, since the indications for its use do not refer to ARVI, SARS-Cov-2 infections, while the incidence of influenza in 2020, compared to 2019, decreased by 25%.

In the period of the new coronavirus infection spread (2020), a significant increase in the share of oseltamivir was notified in the overall consumption structure (up to 17.26% compared to 0.71% in 2015, 1.60% in 2016, 2, 11% – in 2017, 3.23% – in 2018 and 3.25% – in 2019), and the number of the dispensed packages (by 23.5 times compared to the average value in 2015–2019). Oseltamivir, a neuraminidase inhibitor approved for the treatment of influenza, has no documented *in vitro*

activity against SARS-CoV-2. It seems that understanding of oseltamivir ineffectiveness in the SARS-CoV-2 infection and diagnostics advance led to a decrease in the share of the total oseltamivir demand to 8.0% in 2021.

In addition, in 2020, a number of the dispensed imidazolylethanamide pentanedioic acid, tilorone and umifenovir packages increased by 2.2, 3.9 and 3.8 times, respectively, compared with the average values in 2015–2019). Inosine acedoben dimepranol has been registered in more than 70 countries as an antiviral and immunomodulatory MP that has received a good evidence base since 1971. It has been shown to inhibit the replication of herpes simplex virus, cytomegalovirus and Epstein-Barr virus, human papillomavirus, human immunodeficiency virus, influenza viruses and SARS [22, 24]. Nevertheless, the positive qualities of the medicines did not affect its consumption frequency, which remains one of the lowest in the considered segment of the pharmacy market (Table 2).

Umifenovir has a high sales rating in this study (Table 2, Fig. 6), since it is officially recommended by the Ministry of Health of the Russian Federation to be used in patients with mild COVID-19, as well as in patients with signs of SARS and unconfirmed SARS-Cov-2 [25, 27]. In 2021, umifenovir MPs were accounted for 40.1% of total antiviral MPs sales.

Among the antiviral medicinal preparations used to treat acute respiratory viral infections, the highest cost per 1 DDD was for medicines containing favipiravir, a substance active against the novel coronavirus infection (according to the results of 2021, the median was 1,255.79 rubles, in the range from 1,001.78 to 2,382.38 rub.).

Taking into account the fact that in 2019 the MPs containing favipiravir was not introduced in the retail sector, the increase in the cost of 1 DDD of antiviral MPs in 2020, compared to 2019, occurred by 43.1% (at the same time, the average cost of one package increased by 55.8%). Excluding these medicines, the average cost of 1 DDD increased by 9.4% (the average price of one package increased by 13.7%). In 2021, there were no significant changes in the price level compared to 2020, with the exception of umifenovir MPs, for which the cost of 1 DDD increased by 26.8% (Table 3). In all the cases, the cost of treatment with original MPs exceeded the cost of treatment with generic MPs (if available on the pharmaceutical market).

Fig. 7 and 8 show the incidence of acute respiratory viral infections, influenza, community-acquired pneumonia in 2019 and 2020, as well as COVID-19[2] in 2020. In addition to the well-known dynamics of

---

[2] [Information materials of the Office of Rospotrebnadzor of the Samara Region on the epidemiological situation of the incidence of SARS and influenza in the Samara Region for the period 2019 and 2020]. Available from: https://www.63.rospotrebnadzor.ru

a decrease in the incidence in the summer period, an increase in the incidence of the acute respiratory viral infections by 24% in 2020 and a decrease in the incidence of influenza by 25% compared to 2019 should be notified. The sales volumes of antiviral MPs presented in these graphs in volume terms show clearly defined seasonal fluctuations with maximum values in the autumn-winter-spring period, which corresponds to the period of the highest incidence of SARS. As expected, the smallest volumes of antiviral MPs sales during 2015–2020 were recorded in July and August. It should be notified that the volume of AMPs sales is significantly higher than that of antiviral MPs, and this trend is most pronounced in 2020.

Fig. 9–13 show a monthly dynamics of antiviral MPs realization in 2015–2021. Despite different ranges of the MPs, their consumption dynamics is exactly the same. The dynamics of demand for typical anti-influenza MPs, oseltamivir and rimantadine, is absolutely consistent with other antiviral drugs and does not correlate with the incidence of influenza among the Samara region population. In 2020–2021, in all cases, an extraordinary demand for antiviral drugs was observed in the autumn period, however, in 2021 it was lower compared to 2020.

Thus, a significant increase in demand for antibacterial and antiviral MPs was recorded in the autumn period of 2020 against the backdrop of an increase in the incidence of the novel coronavirus infection.

CONCLUSION

There was a 2.12-fold increase in the AMPs consumption in 2020 compared to the average values of the dispensed MD packages of these subgroups in 2015–2019. For the ATC subgroups "Other β-lactam antibacterials", "Macrolides, lincosamides and streptogramins", "Quinolone antibacterials" in 2020, this indicator increased by 3.2, 3.5 and 2.6 times, respectively, which has adverse consequences for the bacterial resistance.

In 2020, the dynamics of the SARS, COVID-19 and community-acquired pneumonia incidence have largely a similar pattern, which is probably more due to the difficulty of recognizing these respiratory infection forms, mainly based on the results of the PCR method for detecting SARS-Cov-2 RNA. The AMPs and antiviral MPs consumption is closely related to the incidence of acute respiratory viral infections and has clear maxima in the spring and autumn-winter periods. At the same time, the AMPs consumption is higher than that of antiviral MPs. In 2020, the cumulative influenza incidence was 25% lower than in 2019, which can be explained by the curing effect of sanitary measures during the COVID-19 pandemic.

In absolute terms, in 2020, the volume of antiviral MPs consumption increased by 2.38 times, which was accompanied by an increase in the average cost of one package by 55.8%. In the initial period of the novel coronavirus infection spread (2020), a significant increase in the share of oseltamivir was notified in the overall consumption structure (up to 17.26% compared to 0.71%, 1.60%, 2.11%, 3.23% and 3.25% in 2015–2019, respectively), and the number of the dispensed packages (by 23.5 times compared to the average value in 2015–2019). In 2021, the share of umifenovir MPs in the total volume of the realized demand increased (up to 40.1%).

In the authors' opinion, the results of the study confirm the need to strengthen control over the implementation of AMPs. Other measures may include timely informing outpatient medical specialists about the new editions appearance of methodological recommendations of the Russian Ministry of Health for the treatment of a novel coronavirus infection. By no means unimportant is the educational work with the population about the inadmissibility of following false algorithms for COVID-19 therapy. They periodically appear in the public domain on the Internet, social networks and instant messengers, and contain information about the need to take two, and sometimes three AMPs at the same time, even with mild course of the novel coronavirus infection.

AUTHORS' CONTRIBUTION
IKP, PAL – concept and design of the study, editing, approval of the article final version;
IIS, EPG – collection and processing of material, statistical data processing;
TKR – collection and processing of material, writing a text, compiling a references;
AAG – writing a text, compiling a references.

REFERENCES

1. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JR, Daneman N. Bacterial co-infection and secondary infection in patients with COVID19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622–9. DOI: 10.1016/j.cmi.2020.07.016

2. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020 Aug;81(2):266–75. DOI: 10.1016/j.jinf.2020.05.046

3. Shishkova VN. [The possibilities of modern drugs in the prevention and treatment of SARS and influenza]. RMJ. 2016;6:395–400. Russian

4. Sidorenko SV, Yakovlev SV, Spichak TV, Suvorova MP, Rafalskiy VV, Tatochenko VK, Dronov IA, Zakharova IN, Zaplatnikov AL, Geppe NA, Lobzin YuV, Abeuova BA, Boyadzhyan GG, Bakradze MD, Malakhov AB, Mumladze EB, Myrzabekova GT, Ursova NI. [Strategy and tactics of the rational use of antimicrobial drugs in outpatient practice. Eurasian clinical guidelines. 2016]. Consilium Medicum. Pediatrics (Suppl.). 2016; (4): 10–20. Russian

5. Baranov AA, Bogomilsky MR, Volkov IK, Geppe NA, Kozlov RS, Kozlova LV, Korovina NA, Manerov FK, Mizernitsky YuL, Namazova LS, Nasonova VA, Samsygina GA, Sergeeva TV, Spichak TV, Strachunsky LS, Tatochenko VK, Yakushin SB. [The use of antibiotics in children in outpatient practice: practical recommendations]. Clinical microbiology and antimicrobial chemotherapy. 2007;9(3);200–10. Russian

6. Gulliford MC, Moore MV, Little P, Hay AD, Fox R, Prevost AT, Juszczyk D, Charlton J, Ashworth M. Safety of reduced antibiotic prescribing for self limiting respiratory tract infections in primary care: cohort study using electronic health records. BMJ. 2016 Jul 4;354:i3410. DOI: 10.1136/bmj.i3410

7. Misurski DA, Lipson DA, Changolkar AK. Inappropriate antibiotic prescribing in managed care subjects with influenza. Am J Manag Care. 2011 Sep;17(9):601–8.

8. Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, Saleem Z, Sneddon J, Hoxha I, Islam S, Mwita J, do Nascimento RCRM, Dias Godói IP, Niba LL, Amu AA, Acolatse J, Incoom R, Sefah IA, Opanga S, Kurdi A, Chikowe I, Khuluza F, Kibuule D, Ogunleye OO, Olalekan A, Markovic-Pekovic V, Meyer JC, Alfadl A, Phuong TNT, Kalungia AC, Campbell S, Pisana A, Wale J, Seaton RA. Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. Life (Basel). 2021 Jun 7;11(6):528. DOI: 10.3390/life11060528

9. Tatochenko VK. [Therapy of acute respiratory infections in children]. RMJ. 2004;(21):1200. Russian

10. Strathdee SA, Davies SC, Marcelin JR. Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election. Lancet. 2020;396(10257):1050–3. DOI: 10.1016/S0140-6736(20)32063-8

11. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020 Dec 3;71(9):2459–68. DOI: 10.1093/cid/ciaa530

12. Crane MA, Popovic A, Panaparambil R, Stolbach AI, Romley JA, Ghanem KG. Reporting of Infectious Diseases in the United States During the Coronavirus Disease 2019 (COVID-19) Pandemic. Clin Infect Dis. 2022 Mar 9;74(5):901–4. DOI: 10.1093/cid/ciab529

13. Kozlov RS. [Antimicrobial resistance as a real threat to national security]. RMJ. Medical review. 2014;22(4):321. Russian

14. Volkova US, Slobodenyuk EV. [Antimicrobals for systemic use in the pharmaceutical market of Khabarovsk]. Pacific Medical Journal. 2014;(2):35–7. Russian

15. Yakovlev SV. New Concept of Rational Use of Antibiotics in Outpatient Practice. Antibiotics and Chemotherapy. 2019;64(3-4):48–58. DOI: 10.24411/0235-2990-2019-100017. Russian

16. Yakovlev SY, Zhuravleva MV, Protsenko DN, Beloborodov VB, Briko NI. etc. Antibiotic stewardship program for inpatient care. Clinical guidelines for Moscow hospitals. Consilium Medicum. 2017;19(7.1. Surgery):15–51. Russian

17. Liu JW, Lin SH, Wang LC, Chiu HY, Lee JA. Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2021 Aug 2;4(8):e2119151. DOI: 10.1001/jamanetworkopen.2021.19151. Erratum in: JAMA Netw Open. 2021 Oct 1;4(10):e2133433.

18. Sel'kova EP, Iakovlev VN, Semenenko TA, Filatov NN, Gotvianskaia TP, Danilina GA, Pantiukhova TN, Nikitina GIu, Tur'ianov MKh. Otsenka profilakticheskogo éffekta amiksina v otnoshenii ostrykh respiratornykh virusnykh infektsiĭ [Evaluation of amyxin effect in prophylaxis of acute respiratory viral infections]. Zh. Mikrobiol. Epidemiol. Immunobiol. 2001 May-Jun;(3):42–6.

19. Ekins S, Lane TR, Madrid PB. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond. Pharm Res. 2020 Mar 25;37(4):71. DOI: 10.1007/s11095-020-02799-8. Erratum in: Pharm Res. 2020 Nov 6;37(12):239.

20. Semenenko TA, Selkova EP, Nikitina GY, Gotvyanskaya TP, Yudina TI, Amaryan MP, Nosik NN, Turyanov MH. Immunomodulators in the prevention of acute respiratory viral infections. Russ J Immunol. 2002 Jul;7(2):105–14.

21. Zakirov IG. Opyt primeneniia amiksina pri lechenii i profilaktike nekotorykh virusnykh infektsionnykh zabolevaniĭ [Use of amixin in the therapy and prevention of some viral infections]. Klin Med (Mosk). 2002;80(12):54–6. Russian

22. Leneva IA, Fedyakina IT, Eropkin MUб Gudova NV, Romanovskaya AA, Danilenko DM, Vinogradova SMб Lepeshkin AYu, Shestopalov AM. [To study the antiviral activity of domestic anti-influenza chemotherapy drugs in cell culture and on animal models]. Questions of virology. 2010;3:19–25. Russian

23. Sliva J, Pantzartzi CN, Votava M. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Adv Ther. 2019 Aug;36(8):1878–905. DOI: 10.1007/s12325-019-00995-6

24. Beran J, Šalapová E, Špajdel M; Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis

from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016 Nov 7;16(1):648. DOI: 10.1186/s12879-016-1965-5

25. Leneva IA, Pshenichnaya NY, Bulgakova VA. Umifenovir and coronavirus infections: a review of research results and clinical practice. Terapevticheskii arkhiv. 2020;92(11):91–7. DOI: 10.26442/00403660.2020.11.000713

26. Alavi Darazam I, Shokouhi S, Mardani M, Pourhoseingholi MA, Rabiei MM, Hatami F, Shabani M, Moradi O, Gharehbagh FJ, Irvani SSN, Amirdosara M, Hajiesmaeili M, Rezaei O, Khoshkar A, Lotfollahi L, Gachkar L, Dehbsneh HS, Khalili N, Soleymaninia A, Kusha AH, Shoushtari MT, Torabinavid P. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial. Int Immunopharmacol. 2021 Oct;99:107969. DOI: 10.1016/j.intimp.2021.107969

AUTHORS

Irina K. Petrukhina – Doctor of Sciences (Pharmacy), Associate Professor, Deputy Director of the Institute of Pharmacy, Head of the Department of Pharmacy Management and Economics, Samara State Medical University. ORCID ID: 0000-0001-6207-5575. E-mail: ditrich@samaramail.ru

Pyotr A. Lebedev – Doctor of Sciences (Medicine), Professor, Head of the Department of Therapy at the Institute of Professional Education, Samara State Medical University. ORCID ID: 0000-0003-3501-2354. E-mail: p.a.lebedev@samsmu.ru

Ilya I. Sirotko – Doctor of Sciences (Medicine), Professor of the Department of Therapy at the Institute of Professional Education, Samara State Medical University. ORCID ID: 0000-0002-8884-7016. E-mail: i.i.sirotko@samsmu.ru

Tatyana K. Ryazanova – Candidate of Sciences (Pharmacy), Associate Professor of the Department of Pharmacy Management and Economics, Samara State Medical University. ORCID ID: 0000-0002-4581-8610. E-mail: i.i.sirotko@samsmu.ru

Elena P. Gladunova – Doctor of Sciences (Pharmacy), Associate Professor, Professor of the Department of Pharmacy Management and Economics, Samara State Medical University. ORCID ID: 0000-0001-5198-0393. E-mail: e.p.gladunova@samsmu.ru

Andrey A. Garanin – Candidate of Sciences (Medicine), Assistant of the Department of Propaedeutic Therapy, Samara State Medical University. ORCID ID: 0000-0001-6665-1533. E-mail: a.a.garanin@samsmu.ru

CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19

E.V. Tavlueva[1], E.V. Zernova[1], M.P. Kutepova[1], N.E. Kostina[2], V.S. Lesina[2], D.R. Mould[4], K. Ito[4],
A.V. Zinchenko[3], A.N. Dolgorukova[3], M.V. Nikolskaya[3], M.C. Lemak[3], O.V. Filon[3], M.Yu. Samsonov[3]

[1] Inozemtsev Municipal Clinical Hospital,
1, Fortunatovskaya St., Moscow, Russia, 105187

[2] Voronezh Regional Clinical Hospital No. 1,
151, Moskovsky Ave., Voronezh, Russia, 394066

[3] Joint Stock Company "R-Pharm",
Bld. 1, 19, Berzarin St., Moscow, Russia, 123154

[4] Projections Research, Inc,
535, Springview Lane, Phoenixville, PA, USA, 19460

E-mail: mv.nikolskaya@rpharm.ru

The aim of the article is to study pharmacokinetic characteristics of intravenous olokizumab in patients with moderate COVID-19 to relieve a hyperinflammation syndrome.

Materials and methods. The pharmacokinetic study was conducted as a part of a phase III clinical study (RESET, NCT05187793) on the efficacy and safety of a new olokizumab regimen (intravenous, at the doses of 128 mg or 256 mg) in COVID-19 patients. Plasma concentrations of olokizumab were determined by the enzyme immunoassay. The population analysis was performed using a previously developed pharmacokinetic model based on a linear two compartment.

Results. The pharmacokinetic analysis included the data from 8 moderate COVID-19 patients who had been administrated with olokizumab intravenously at the dose of 128 mg. According to the analysis results in this population, there was an increase in the drug clearance, compared with the data obtained in healthy volunteers and the patients with rheumatoid arthritis: 0.435, 0.178 and 0.147 l/day, respectively. The parameters analysis within the framework of a population pharmacokinetic model showed that the main factors for the increased olokizumab clearance are a high body mass index. In addition, the presence of COVID-19 itself is an independent factor in increasing the drug clearance.

Conclusion. After the intravenous olokizumab administration, an increase in the drug clearance is observed in moderate COVID-19 patients against the background of the disease course. The main contribution to the increased clearance is made by the characteristics of the population of COVID-19 patients associated with the risk of a severe disease and inflammation. When administered intravenously at the dose of 128 mg, a therapeutically significant olokizumab level was maintained throughout the acute disease phase for 28 days.

Keywords: COVID-19, olokizumab; clearance; pharmacokinetic model

Abbreviations: IL(s) – interleukins; PAIT – proactive anti-inflammatory therapy; Ig(s) – immunoglobulins; PK – pharmacokinetics; RA – rheumatoid arthritis; RESET – hyperinflammation; CRP – C-reactive protein; CT – computer tomography; RR – respiratory rate; ALT – alanine aminotransferase; AST – aspartate aminotransferase; ULN – upper limit of normal; BMI – body mass index; ELISA – enzyme-linked immunosorbent assay; $T_{1/2}$ – half-life; AUC_{0-t} – area under the concentration-time pharmacokinetic curve from zero to the last blood draw; Kel – elimination constant; $AUC_{0-\infty}$ – area under the concentration-time curve from time zero to infinity; CL – clearance; T_{max} – time to reach the maximum concentration of olokizumab in blood plasma; C_{max} – maximum concentration of olokizumab in blood plasma; MRT – Mean Resident Time.

ОСОБЕННОСТИ ФАРМАКОКИНЕТИКИ ОЛОКИЗУМАБА У ПАЦИЕНТОВ С НОВОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИЕЙ COVID-19

Е.В. Тавлуева[1], Е.В. Зернова[1], М.П. Кутепова[1], Н.Э. Костина[2], В.С. Лесина[2], Д.Р. Моулд[4], К. Ито[4], А.В. Зинченко[3], А.Н. Долгорукова[3], М.В. Никольская[3], М.С. Лемак[3], О.В. Филон[3], М.Ю. Самсонов[3]

[1] Государственное бюджетное учреждение здравоохранения города Москвы
«Городская клиническая больница им. Ф.И. Иноземцева Департамента здравоохранения города Москвы»,
105187, Россия, г. Москва, ул. Фортунатовская, д. 1

[2] Бюджетное учреждение здравоохранения Воронежской области
«Воронежская областная клиническая больница № 1»,
394066, Россия, г. Воронеж, пр-т Московский, д. 151

[3] Акционерное общество «Р-Фарм»,
123154, Россия, г. Москва, ул. Берзарина, д. 19, кор. 1

[4] Projections Research, Inc.,
19460, США, Пенсильвания, Фениксвилл, Springview Lane, 535

E-mail: mv.nikolskaya@rpharm.ru

Цель. Изучение особенностей фармакокинетики олокизумаба при внутривенном введении у пациентов с COVID-19 среднетяжелого течения для купирования синдрома гипервоспаления.

Материалы и методы. Изучение фармакокинетики проводилось в рамках клинического исследования III фазы (исследование RESET, NCT05187793) эффективности и безопасности нового режима применения олокизумаба (внутривенно, в дозах 128 мг или 256 мг) у пациентов с COVID-19. Определение концентрации олокизумаба в плазме крови проводили методом иммуноферментного анализа. Популяционный анализ выполнен с помощью ранее разработанной фармакокинетической модели на основе линейной двухкамерной модели.

Результаты. В анализ фармакокинетики были включены данные 8 пациентов с COVID-19 среднетяжелого течения, получавшие олокизумаб в дозе 128 мг внутривенно. Согласно результатам анализа в данной популяции наблюдалось увеличение клиренса препарата, по сравнению с данными, полученными у здоровых добровольцев и пациентов с ревматоидным артритом: 0,435, 0,178 и 0,147 л/сут, соответственно. Анализ параметров в рамках популяционной фармакокинетической модели показал, что основными факторами повышенного клиренса олокизумаба являются высокий индекс массы тела. Кроме того, независимым фактором повышения клиренса препарата является само наличие COVID-19.

Заключение. У пациентов со среднетяжелым течением COVID-19 после внутривенного введения олокизумаба наблюдается увеличение клиренса препарата на фоне течения заболевания. Основной вклад в повышенный клиренс вносят особенности популяции пациентов с COVID-19, связанные с риском тяжелого течения заболевания и выраженным воспалением. При внутривенном введении в дозе 128 мг терапевтически значимый уровень олокизумаба сохранялся в течение всей острой фазы заболевания на протяжении 28 дней.

Ключевые слова: COVID-19; олокизумаб; клиренс; фармакокинетическая модель

Список сокращений: ИЛ — интерлейкины; УПТ — упреждающая противовоспалительная терапия; Ig — иммуноглобулины; ФК — фармакокинетика; РА — ревматоидный артрит; RESET — гипервоспаление; СРБ — С-реактивный белок; КТ — компьютерная томография; ЧДД — частота дыхательных движений; АЛТ — аланинаминотрасфераза; АСТ — аспартатаминотрансфераза; ВГН — верхняя граница нормы; ИМТ — индекс массы тела; ИФА — иммуноферментный анализ; $T_{1/2}$ — период полувыведения; AUC_{0-t} — площадь под фармакокинетической кривой «концентрация-время» от нуля до последнего отбора крови; K_{el} — константа элиминации; $AUC_{0-\infty}$ — площадь под фармакокинетической кривой «концентрация-время», начиная с нулевого значения времени, экстраполированная до бесконечности; CL — клиренс; T_{max} — время достижения максимальной концентрации олокизумаба в плазме крови; C_{max} — максимальная концентрация олокизумаба в плазме крови; MRT — среднее резидентное время.

INTRODUCTION

In December 2019, a large outbreak of a disease caused by a novel coronavirus (SARS-CoV-2) affecting the lower respiratory tract, occurred in Wuhan, China [1].

Most patients suffer from a mild form of the disease (like an acute respiratory viral infection), but the infection can turn into an acute respiratory distress syndrome. In this case, there is a rapid replication of the virus, a rapid release of pro-inflammatory cytokines against the background of the inflammatory infiltrates formation in the lung parenchyma and pulmonary vascular endothelium, damage to the alveoli, vascular microthrombosis, etc. There is a pattern of systemic hyperinflammation with increased levels of interleukins (ILs) cytokines such as IL-1β, IL-1Ra, IL-6 and the IL-2

receptor. The progressive development of systemic pathological inflammation results in a pronounced increase in the severity of the disease and the development of multiorgan damage [2–4].

According to the Interim Guidelines (IGs) of the Russian Ministry of Health "Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)"[1], the use of proactive anti-inflammatory therapy (PAIT) in combination with active anticoagulant therapy is currently the standard of care. Monoclonal antibodies – blockers of the IL-6, IL-6, IL-1 receptors, can be used among others as PAIT.

Olokizumab (Artlegia®) is a humanized monoclonal antibody of the immunoglobulin (Ig) G4/kappa isotype that can specifically bind to the IL-6 molecule. The drug has a unique action mechanism, since it directly binds IL-6 and thus blocks the pathological cascade of inflammatory reactions. In this, it differs from tocilizumab, sarilumab, and levilimab, which are antagonists of the IL-6 receptor [5–7]. Due to the high affinity for IL-6 and the mode of action (inhibition of the interaction between IL-6 and the glycoprotein gp130), the pharmacodynamic effects of olokizumab are realized at lower doses [8, 9].

Olokizumab was originally developed as a drug for the treatment of rheumatoid arthritis (RA) and has successfully passed a full-fledged clinical development program that included phase II studies [10] in 380 patients, and phase III studies in 2443 patients (CREDO 1[2] , CREDO 2[3], CREDO 3[4] and CREDO 4[5]), as well as post-marketing studies [11]. According to the studies, the recommended olokizumab dose in RA is 64 mg once every 2 or 4 weeks when administered subcutaneously. In case of pathogenetic therapy of a cytokine release syndrome in a new coronavirus infection (COVID-19) – 64 mg subcutaneously once.

Subsequently, the effect of olokizumab was studied in COVID-19 patients. The use of olokizumab as a

part of the complex therapy for COVID-19 revealed a number of pharmacokinetic characteristics of the drug in this population, compared with healthy volunteers and RA patients. In general, the patient population in which olokizumab was prescribed as proactive anti-inflammatory therapy (PAIT) is characterized by a number of trends in both demographic data and laboratory parameters. In particular, a body mass index, or rather overweight, which, in turn, is a risk factor for severe COVID-19, has a known effect on the pharmacokinetics of drugs. In COVID-19, a typical pattern of deviations in the biochemical analysis of blood is observed: an increase in the levels of inflammatory markers, a change in the levels of protein fractions, reflecting the course and severity of the inflammatory process, which also affects the drugs pharmacokinetics.

THE AIM of the article is to study pharmacokinetic characteristics of intravenous olokizumab in patients with moderate COVID-19 to relieve hyperinflammation syndrome.

MATERIALS AND METHODS

Study design

Currently, according to the Interim guidelines (version 16 dated 18 Aug 2022), the intravenous administration of olokizumab is included in the recommended standards of COVID-19 therapy. The pharmacokinetics of the drug when administered intravenously in COVID-19 patients, was evaluated as a part of a multicenter, open, randomized phase III research, the aim of which was to study the efficacy and safety of a new olokizumab regimen (at the doses of 128 and 256 mg, respectively, administered intravenously) in COVID-19 patients with signs of hyperinflammation (RESET). The randomization of patients in the study was central and it was performed using an electronic system. The patients were randomized into 2 groups at the ratio of 1:1 – the olokizumab group (group 1) and the comparison group (group 2). In order to evenly distribute patients into the treatment groups, the stratification was carried out according to the following criteria:

• according to the need for the oxygen support at screening (yes / no),

• the presence of a concomitant disease that is a risk factor for severe COVID-19 (no risk factors or there is one or more risk factors).

Thus, as a result of the stratification, the patients in groups will be equivalent in terms of the presence of respiratory failure and risk factors for severe COVID-19.

Selection criteria for the study

The RESET study was conducted with the approval

---

[1] Interim Guidelines of the Russian Ministry of Health "Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19), version 16, 18.08.2022. Available from: https://static-0.minzdrav.gov.ru

[2] Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (CREDO 1). Available from: https://grlsbase.ru/clinicaltrails/clintrail/2763

[3] Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (CREDO 2). Available from: https://clinicaltrials.gov/ct2/show/NCT02760407

[4] Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (CREDO 3). Available from: https://clinicaltrials.gov/ct2/show/NCT02760433

[5] Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis (CREDO 4). Available from: https://clinicaltrials.gov/ct2/show/NCT03120949

of the Ethics Council of the Department for Regulation of the Circulation of Medicines (Ministry of Health of the Russian Federation, Protocol No. 273 dated 20 Apr 2021); the local ethics committees of Voronezh Regional Clinical Hospital No. 1 (Protocol No. 117 dated 22 Jul 2021) and Inozemtsev City Clinical Hospital (Protocol No. 11 dated 28 May 2021). The results of the pharmacokinetic study in the subgroup of COVID-19 patients, compared with the data from the previous studies in healthy volunteers and RA patients, are presented in this paper. The study included hospitalized patients with a confirmed moderate-to-severe coronavirus infection and signs of hyperinflammation, aged over 18 years.

The main inclusion criteria were: moderate COVID-19, pneumonia on computer tomography (CT) and the body temperature > 38°C, in combination with 1 or more features, including the saturation level (SpO$_2$) < 95%, respiratory rate (RR) > 22, dyspnea on exertion, C-reactive protein (CRP) >10 mg/l; the presence of one of the risk factors (diabetes mellitus, severe cardiovascular pathology, chronic renal failure, oncological pathology, obesity, or age ≥65 years); the presence of the hyperinflammation signs (a body temperature ≥38°C for 2 days or more, in combination with 1 or more signs: a CRP level >3×upper limit of normal (ULN), the leukocyte count – 2.0–3.5 × 10^9/l, the absolute number of lymphocytes – 1.0–1.5×10^9/l).

The main exclusion criteria were: a severe or extremely severe COVID-19 course, the presence of severe laboratory abnormalities (hemoglobin <80 g/l, an absolute neutrophil count <0.5×109/l, a leukocyte count <2.0×109/l, a number of platelets <50 x 109/L, alanine aminotransferase (ALT) ≥ 3.0 × ULN and/or aspartate aminotransferase (AST) ≥ 3.0 × ULN), the creatinine clearance < 30 ml/min, confirmed sepsis by pathogens other than COVID- 19, a high probability of a disease progression to death within the next 24 hours.

Selection criteria for the pharmacokinetics subgroup

The pharmacokinetics (PK) study subgroup included patients with a body mass index (BMI) in the range of 18.5–35.0 kg/m^2 who had signed an additional voluntary informed consent form for the inclusion in the PK study. A total of 9 patients were included in the PK subgroup. These patients were administrated with Artlegia® (INN: olokizumab), a solution for the subcutaneous administration, 160 mg/mg, as an intravenous 60-minute infusion, at the dose of 128 mg (8 patients were administrated with the drug once at the dose of 128 mg), 1 patient was not included into statistical analysis (total dose 256 mg). 1 patient was administrated with the drug twice with a total dose of 256 mg).

In addition to olokizumab, the patients received baricitinib (4 mg/day, for 7 days) and low-doses of glucocorticosteroids (dexamethasone at the doses of 4–20 mg/day IV or IM, or methylprednisolone at the dose of 1 mg/kg intravenously every 12 hours), as well as etiotropic therapy for COVID-19 (favipiravir or remdesivir), symptomatic and anticoagulant therapy drugs.

In the patients included in the PK assessment subgroup, blood biosamples were taken to study olokizumab concentrations as follows: before the start of the infusion, then after 2, 4, 8, 24, 48 and 72 hours; then every day, starting from 4 to 10 days; at the end on days 14 and 28 after the first administration of the drug (i.e. from the moment the infusion began). After the selection, plasma biosamples were frozen and stored at the temperature not exceeding –65°C.

For the analysis of biosamples, a bioanalytical method based on enzyme immunoassay (ELISA) was developed. The method is based on the interaction of olokizumab with IL-6 associated with goat antibodies to human IL-6 immobilized on the surface of the plate. The method was validated in the concentration range of 2.5–100 µg/ml.

Statistical analysis

To assess a possible influence of various factors on the olokizumab clearance, the results were combined with a previously created phases 1 and 2 database of olokizumab clinical trials, including the data from the pharmacokinetic samples analysis of 30 healthy volunteers and 30 RA patients, and the ones who had received a single intravenous olokizumab injection at various concentrations [12].

The description of the olokizumab pharmacokinetics was performed using a linear 2 compartment model with the absorption kinetics and the first order elimination. The model parameterization included pharmacokinetic parameters such as clearance (CL), an distribution volume (V), an elimination rate constant (K$_{el}$) and rate constants of exchange between compartments (Q/Vc, Q/Vp) (Fig. 1). Interindividual variability (IIV) parameters were included in the final model for the volume of distribution parameters of the central (Vc) and peripheral compartments (Vp). The influence of the following covariates was assessed: age, sex, body weight, serum albumin, liver enzymes, bilirubin, creatinine clearance. Since study CL04041094 did not collect data on participants' albumin levels, for modeling purposes, missing individual albumin levels were reconstructed using the following formula (ALB = −0.4714×CRP+50.714) based on the literature data [13].

Figure 1 – Diagram of linear two compartment model to describe olokizumab pharmacokinetics

Note: Q/V_c, Q/V_p – speed constants of exchange between cameras; K_{el} – elimination rate constant.

Figure 2 – Goodness of fit plots for the final model

Note: DV – dependent variable; PRED – predicted values; IPRED – individual predicted values; TAD – time after the last dose; CWRES – conditional weighted residuals calculated using the FOCI algorithm.

Figure 3 – Assessments of the normality assumption of interindividual variability
Note: ETA = η; IIV – interindividual variability; CL - clearance; Vc – volume of the central chamber; Vp – volume of the peripheral chamber; Normal QQ Plot – quantile-quantile plot for assessing normality of the distribution.

**Figure 4 – Graphical representation of observed and predicted pharmacokinetic olokizumab profiles
for COVID-19 patients, healthy volunteers, and RA patients**
Note: The area marked in pink is the boundaries of the 95% confidence interval for estimating the median; the areas marked in gray are the
boundaries of the 95% confidence interval for estimating the 5th and 95th percentiles.

Table 1 – Individual pharmacokinetic olokizumab parameters and mean values

PK parameter	Healthy volunteers [15] 1 mg/kg (76 mg) IV, n = 3[1]	RA patients [16] 1 mg/kg (75 mg) IV, n = 7	COVID-19 patients (RESET study) 128 mg, IV, n=8
C_{max} (µg/ml)			
Mean (±SD)	21.4 (±0.842)	22.28 (±3.9)	40.20 (±18.06)
Geometric mean (CV%)	–	21.98 (17.53)	35.69 (44.93)
T_{max} (h)			
Median	4.00	2.00	6.00
L.Qu., U.Qu.	2.03–4.00	2.0 – 14.0	2,0–18,0
Geometric mean (CV%)	–	4.49 (123.26)	7.44 (159,72)
AUC_{0-t} (h×mcg/ml)			
Mean (±SD)	9 427 (±524)	7 001.58 (±1,259.89)	7 802,19 (±4005,29)
Geometric mean (CV%)	–	6 911.9 (17.99)	6 855.77 (51.34)
$AUC_{0-\infty}$ (h×mcg/ml)			
Mean (±SD)	10 435 (±1,266)	13 979.67 (±3,267.86)	13 117.51 (±9,777.32)
Geometric mean (CV%)	–	13 633.52 (23.38%)	10 600.21 (74.54)
$T_{1/2}$ (days)			
Mean (±SD)	27.9 (±12)	30.66 (±14.2)	13.8 (±10.86)
Geometric mean (CV%)	–	28.13 (46.31)	10.35 (78.65)
CL, l/day			
Mean (±SD)	0.177 (±0.020)	0.145 (±0.03)	0.349 (±0.214)
Geometric mean (CV%)	–	0.143 (20.372)	0.289 (61.275)
Vd, l			
Mean (±SD)	7.08 (±3.04)	6.29 (±2.97)	5.26 (±4.56)
Geometric mean (CV%)	–	5.79 (47.23)	4.33 (86.81)

Notes: SD – standard deviation; CV% – coefficient of variation; L.Qu. – lower quartile (25%); U.Qu. – upper quartile (75%); IV – intravenously;
max. – maximum; min. – minimum; n is the number of patients; CL – clearance; Vd – volume of distribution; 1 – the comparison table includes
only the data of volunteers administered with olokizumab at the dose of 1 mg/kg intravenously. A total of 87 volunteers participated in the phase
1 studies, 67 – in the European population (RA0001), 20 – in the Asian (Japanese) population (RA0074).

Table 2 – Mean pharmacokinetic olokizumab parameters in general population of RA and COVID-19 patients

Parameter		Final model		RSD (%)
		Value	η-shrinkage	
CL (l/day)	θ1	0.154	–	6.8
Vc (l)	θ2	4.1	–	5.6
Q (l/day)	θ3	0.348	–	16.3
Vp (l)	θ4	1.67	–	12.2
Residual error – frequent sampling	θ7	0.167	5.9	–
IIV CL (CV%)	η1	34.2	2.2	–
IIV Vc (CV%)	η2	27.3	2.6	–
IIV Vp (CV%)	η3	56.7	16.0	–
Correlation of random effects				
IIV CL – IIV Vc	CORR$_{1,2}$	0.651	–	–
IIV CL – IIV Vp	CORR$_{1,3}$	0.110	–	–
IIV Vc – IIV Vp	CORR$_{2,3}$	0.512	–	–

Note: RSD – relative standard deviation; CL – total clearance; Vc, Vp – volume of distribution of the central, peripheral, respectively; Q/Vc, Q/Vp – speed constants of exchange between cameras; IIV(CV%) – interindividual variability (coefficient of variation %); θ is a parameter with a fixed value; η is the variability parameter given by a value with a normal distribution; CORR – correlation between random effects.

Table 3 – Effects of individual patients' characteristics

Covariates		Final model	
		Value	RSD (%)
Impact of body weight on CL and Q	θ8	0.654	57.3
Impact of body weight on Vc andVp	θ14	0.498	60.0
Impact of COVID-19 disease on CL	θ16	0.965	23.4

Note: θ – parameter with a fixed value; RSD – relative standard deviation; CL – total clearance; Q – intercompartmental clearance; Vc, Vp – volume of distribution of the central, peripheral, respectively.

Diagnostic plots were used to assess model assumptions and goodness-of-fit; satisfactory η-shrinkage values were obtained, and Visual Predictive Check was performed. The stability of the model, the asymmetry and kurtosis of the η distribution were also evaluated [13, 14].

Population pharmacokinetic olokizumab parameters were evaluated using the First Order Condition Estimation (FOCE) algorithm in NONMEM 7.4 software. The construction of diagnostic plots, the exploratory analysis, and post-processing of the NONMEM output data were performed using R version 3.5.3 software. The analysis was performed in accordance with FDA[6] and EMEA[7] guidelines for population pharmacokinetics.

RESULTS

The mean age of the patients was 56.4 (±10.0) years [45 to 74 years], the majority were males (87.5%), the average body weight of the patients was 87.0 (±15.1) kg,

and BMI – 26.8 (±3.4). All patients were Caucasian. In five patients, biosamples were taken at all planned points, in 2 patients the sampling was completed at the point of 366 hours and in 1 – at the point of 240 hours (a withdrawal due to death).

Standard non-compartmental PK parameters from individual studies are presented in Table 1, compared with the results of the previous studies in healthy volunteers and RA patients. After the administration, the drug was distributed fairly fast. In the studied population, C_{max} was reached quite fast and was about 36 µg/ml, the median T_{max} was 6 hours. Further on, the concentration decreased during the entire subsequent observation period. Despite a faster decrease in the concentration compared with the intravenous (IV) olokizumab administration at the dose of 1 mg/kg (mean 75 mg) in RA patients [10], 7 days after the administration, in 7 out of 8 patients, the plasma concentration of olokizumab exceeded 10 mcg/ml; after 14 days, in 5 out of 7 patients, the concentration was above 5 mcg/ml. In this case, the mean $T_{1/2}$ was about 13.8 days, which was significantly lower than when administered intravenously to healthy volunteers (27.9 days) and RA patients (30.66 days).

Analysis of individual characteristics influence on olokizumab clearance

A graphical analysis of the goodness-of-fit criteria and a visual assessment of the compliance with the model predictions demonstrated the satisfactory ability of the selected population pharmacokinetic model to describe plasma concentrations of olokizumab (Fig. 2–4).

The average pharmacokinetic olokizumab parameters in the general population of RA and COVID-19 patients, determined on the basis of the developed population pharmacokinetic model, generally corresponded to the previously obtained individual pharmacokinetic parameters in the RA population (clearance 0.153 l/day vs. 0.147 l/day)[8].

The covariates analysis showed that a body weight has the greatest effect on the drug elimination rate (Table 3). After adjusting for albumin and body weight, a COVID-19 disease was found to be an independent significant factor in increasing olokizumab clearance by 96.5% (θ16).

DISCUSSION

The peak intravenous concentration in COVID-19 patients was about 36 µg/mL; it was consistent with the previous data in healthy volunteers and RA patients however, in only two patients T_{max} exceeded 8 hours. Thus, in general, the time to peak concentration was comparable in all studied populations, the observed differences may be associated with differences in the speed and techniques of intravenous infusion of the drug in different studies. Although the rate of elimination and the volume of olokizumab distribution did not significantly differ between healthy volunteers and RA patients, the patients with moderate COVID-19 showed a significantly faster clearance of the drug. The median of $T_{1/2}$ in COVID-19 patients was about 6 days compared to about 30 days in healthy volunteers and RA patients. For a more detailed analysis, a previously developed population pharmacokinetic model based on the results intravenous administration of olokizumab in healthy volunteers and patients with RA program, was adapted to assess the impact of individual patients' characteristics on the drug clearance in COVID-19 patients. It has been shown that a decrease in albumin levels and an increase in body weight are associated with an increase in the rate of olokizumab clearance. Decreased albumin levels are a hallmark of a COVID-19 disease: hypoalbuminemia is observed in 30–50% of

hospitalized patients and can serve as an independent predictor of a severe disease and death [23, 24], while average levels of albumin in healthy volunteers and RA patients do not differ. An increased body weight is a risk factor for severe COVID-19, and therefore such patients are more likely to be hospitalized and are disproportionately represented in the study populations. The median body weight of patients in the COVID-19 patient cohort was higher compared to RA patients and healthy volunteers (92, 78 and 76 kg, respectively). Thus, a faster olokizumab clearance in COVID-19 patients may be partly explained by a higher incidence of hypoalbuminemia and the greater body weight of patients. A COVID-19 disease was also independently associated with increased olokizumab clearance, which may be due to the acceleration of protein metabolism in infectious and inflammatory diseases [25], one of the markers of which can serve as a reduced level of albumin. Hypoalbuminemia is a characteristic feature of a COVID-19 disease: it is observed in 30–50% of hospitalized patients and plays an independent predictor of a severe disease and death [17–22], while mean albumin levels do not differ between healthy volunteers and RA patients.

A similar effect, comparable in magnitude, was previously demonstrated for another inhibitor of the IL-6 signaling pathway, tocilizumab, in patients with severe COVID-19 [21]. In the review by Leung E. et al. (2022), 2 routes for the elimination of monoclonal antibodies are described. The first pathway, providing a linear clearance, is associated with proteolytic catabolism of drugs after the administration. The second pathway involves a specific a ligand-receptor (e.g., IL-6 receptor and tocilizumab) binding to both soluble and membrane-bound targets, followed by an internalization and an intracellular degradation. This process provides a non-linear clearance and depends on the relative expression of the target. Therefore, this mechanism may be influenced by patient-specific factors such as the type and severity of the disease. In this case, the linear part of the tocilizumab clearance, apparently, to some extent depends on a body weight.

In the study by Moes D.J.A.R. et al (2021), in patients with severe COVID-19, the clearance (CL) estimate was 0.725 l/day and it was higher than the estimate in adult RA patients (0.2–0.3 l/day), children with systemic juvenile idiopathic arthritis (0.17 l/day), children and adults with a CAR T-induced cytokine release syndrome (0.5 l/day) [26]. Similar trends are shown by the ratio of the olokizumab clearance in patients with moderate

---

[8] Instructions for drug use Artlegia®. Available from: https://artlegia.com/#close

COVID-19 (0.349 l/day) and RA patients (0.145 l/day). However, it should be taken into account that the study did not show the feasibility of calculating the dose of tocilizumab based on the body weight of patients, the use of fixed doses is preferable. Given these data, a caution should be exercised when interpreting the study results of this population olokizumab pharmacokinetics. Thus, until further pharmacokinetic data are obtained in COVID-19 patients, a revision of the dosing olokizumab regimen seems unreasonable in this population.

CONCLUSION

After the intravenous administration of olokizumab, during the disease course, in patients with moderate COVID-19, an increase in clearance was demonstrated compared with previously studied populations of healthy volunteers and RA patients. The main contribution to the increased olokizumab clearance is made by the characteristics of the COVID-19 patients population associated with the risk of the severe disease (overweight) and the effect of accelerated protein metabolism due to the severe inflammation, characterized by hypoalbuminemia. At the same time, the contribution of the unidentified factors of the increased clearance associated with a COVID-19 disease, and probably due to the interaction of the mechanism of olokizumab action and COVID-19 pathogenesis, was also observed. However, when administered intravenously at the dose of 128 mg, a therapeutically significant olokizumab level was maintained throughout the acute phase (28 days) of the disease.

CONFLICT OF INTERESTS
The clinical trial was organized by the sponsor, the JSC "R-Pharm", the manufacturer and owner of the registration certificate for the drug Artlegia® (olokizumab) dated May 21, 2020. The authors of the article Zinchenko A.V., Dolgorukova A.N., Nikolskaya M.V., Lemak M.S., Filon O.V., Samsonov M.Yu. are employees of the JSC "R-Pharm". The authors of the article Tavlueva E.V., Zernova E.V., Kutepova M.P., Kostina N.E., Lesina V.S. are physicians-researchers of the scientific centers of Voronezh Regional Clinical Hospital No. 1 (Center No. 03) and Inozemtsev City Clinical Hospital, Department of Health of the City of Moscow (Center No. 04) according to the protocol "Multicenter open randomized study of efficacy and safety of a new regimen for the use of the drug Artlegia® (INN: olokizumab) in patients with a coronavirus infection (COVID-19) with signs of hyperinflammation, sponsored by the JSC "R-Pharm".

AUTHORS' CONTRIBUTION
Tavlueva E.V., Zernova E.V., Kutepova M.P., Kostina N.E., Lesina V.S. – implementation of the experimental part of the study; Mould D.R., Ito K. – development of population pharmacokinetic model; Zinchenko A.V. – analytical processing of the obtained results; Dolgorukova A.N. – statistical processing of the study results; Nikolskaya M.V. – text writing and editing; Lemak M.C. – planning and description of the pharmacokinetic model; Filon O.V. – development of research design, text writing and editing; Samsonov M.Yu. – aim setting, research design development.

REFERENCES

1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. DOI: 10.1038/s41586-020-2012-7

2. Zhou J, He W, Liang J, Wang L, Yu X, Bao M, Liu H. Association of Interleukin-6 Levels with Morbidity and Mortality in Patients with Coronavirus Disease 2019 (COVID-19). Jpn J Infect Dis. 2021 Jul 21;74(4):293–8. DOI: 10.7883/yoken.JJID.2020.463

3. Luo K, Chen Y, Yang J, Tao Q, Luo M. Liver Injury and Elevated Levels of Interleukins, Interleukin-2 Receptor, and Interleukin-6 Predict the Severity in Patients With COVID-19. Front Public Health. 2021 Dec 14;9:778340. DOI: 10.3389/fpubh.2021.778340

4. Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, Kronbichler A, Shin JI. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021 Jan 1;11(1):316–29. DOI: 10.7150/thno.49713

5. Yu SY, Koh DH, Choi M, Ryoo S, Huh K, Yeom JS, Yoon YK. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerg Microbes Infect. 2022 Dec;11(1):1154–65. DOI: 10.1080/22221751.2022.2059405

6. Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017 May 24;11:1593–603. DOI: 10.2147/DDDT.S100302

7. Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm. 2008 Aug 1;65(15):1413–8. DOI: 10.2146/ajhp070449

8. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774–82. DOI: 10.4161/mabs.28612

9. Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, Krechikova DG, Maslyanskiy AL, Samsonov M, Stoilov R, Zonova EV, Genovese M. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(Issue 4): 469–79. DOI: 10.1136/annrheumdis-2021-219876

10. Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C, Durez P, Kretsos K. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 Sep;73(9):1607–15. DOI: 10.1136/annrheumdis-2013-204760

11. Mikhaylenko DS, Kuznetsova EB, Musatova VV, Bure IV, Deryagina TA, Alekseeva EA, Tarasov VV, Zamyatnin AA Jr, Nemtsova MV. Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis. J Pers Med. 2022 Apr 15;12(4):641. DOI: 10.3390/jpm12040641

12. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503–12.

13. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17–20. DOI: 10.1038/sj.clpt.6100241

14. Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the Visual Predictive Check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35(2):185–202. DOI: 10.1007/s10928-007-9081-1

15. Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, Jose J, Oliver R. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014 Sep;3(5):388–95. DOI: 10.1002/cpdd.121

16. Fleischmann R, Kivitz AJ, Wagner F, Feinstein JA, Fuhr U, Rech J, Sidhu J, Hill PL, Oliver R, Kretsos K. A Pilot Study Investigating the Tolerability and Pharmacodynamic Effect of Single Intravenous/Subcutaneous Doses of Olokizumab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Rheumatoid Arthritis. Arthritis and Rheumatism. 2012;64(10):576-7.

17. Chowdhury AI, Alam MR, Rabbi MF, Rahman T, Reza S. Does higher body mass index increase COVID-19 severity? A systematic review and meta-analysis. Obesity medicine. 2021;23:100340. DOI: 10.1016/j.obmed.2021.100340

18. Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6:576–88. DOI: 10.1002/psp4.12224

19. Moes DJAR, van Westerloo DJ, Arend SM, Swen JJ, de Vries A, Guchelaar HJ, Joosten SA, de Boer MGJ, van Gelder T, van Paassen J. Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. Clin Pharmacokinet. 2022;61:231–47. DOI: 10.1007/s40262-021-01074-2

20. Huang J, Cheng A, Kumar R, Fang Y, Chen G, Zhu Y, Lin S. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and comorbidity. J Med Virol. 2020;92:2152–8. DOI: 10.1002/jmv.26003

21. Zekri-Nechar K, Zamorano-León JJ, Segura-Fragoso A, Alcaide JR, Reche C, Andrés-Castillo A, Martínez-Martínez CH, Giner M, Jiménez-García R, López-de-Andrés A, Navarro-Cuellar C, García-Fernández MA, López-Farré A. Albumin Binds COVID-19 Spike 1 Subunit and Predicts In-Hospital Survival of Infected Patients—Possible Alteration by Glucose. J Clin Med. 2022;11(3):587. DOI: 10.3390/jcm11030587

22. Turcato G, Zaboli A, Kostic I, Melchioretto B, Ciccariello L, Zaccaria E, Olivato A, Maccagnani A, Pfeifer N, Bonora A. Severity of SARS-CoV-2 infection and albumin levels recorded at the first emergency department evaluation: a multicentre retrospective observational study. Emerg Med J 2022;39:63–9. DOI: 10.1136/emermed-2020-210081

23. Xu Y, Yang H, Wang J, Li X, Xue C, Niu C, Liao P. Serum Albumin Levels are a Predictor of COVID-19 Patient Prognosis: Evidence from a Single Cohort in Chongqing, China. Int J Gen Med. 2021 Jun 24;14:2785–97. DOI: 10.2147/IJGM.S312521

24. Viana-Llamas MC, Arroyo-Espliguero R, Silva-Obregón JA, Uribe-Heredia G, Núñez-Gil I, García-Magallón B, Torán-Martínez CG, Castillo-Sandoval A, Díaz-Caraballo E, Rodríguez-Guinea I, Domínguez-López J. Hypoalbuminemia on admission in COVID-19 infection: An early predictor of mortality and adverse events. A retrospective observational study. Medicina Clínica. 2021;156(Iss. 9):428–36. DOI: 10.1016/j.medcli.2020.12.018

25. Pietri L, Giorgic R, Bégub A, Lojoub M, Koubid M, Cauchoisad R, Grangeotb R, Duboisb N, Kaplanskid G, Valéroab R, Béliardab S. Excess body weight is an independent risk factor for severe forms of COVID-19. Metabolism. 2021;117:154703. DOI: 10.1016/j.metabol.2021.154703

26. Leung E, Crass RL, Jorgensen SCJ, Raybardhan S, Langford BJ, Moore WJ, Rhodes NJ. Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. Clin Pharmacokinet. 2022;61:155–65. DOI: 10.1007/s40262-021-01092-0

AUTHORS

Evgenia V. Tavlueva – Doctor of Sciences (Medicine), Leading Researcher of the Department of Pathogenetic Aspects of Aging; Head of the Regional Vascular Center, Inozemtsev City Clinical Hospital. ORCID ID: 0000-0002-6796-212X. E-mail: tavlev1@mail.ru

Evgenia V. Zernova – Deputy Chief Physician for Therapeutic Care, Inozemtsev City Clinical Hospital. ORCID ID: 0000-0003-4565-6743. E-mail: evgenya.gor@mail.ru

Marina P. Kutepova – general practitioner, Inozemtsev City Clinical Hospital. ORCID ID: 0000-0002-9283-9721. E-mail: kutepovam@mail.ru

Natalya E. Kostina – Head of the Department of Pulmonology, Voronezh Regional Clinical Hospital No. 1. ORCID ID: 0000-0002-5128-5005. E-mail: nata166k@yahoo.con

Victoria S. Lesina – pulmonologist, Voronezh Regional Clinical Hospital No. 1. ORCID ID: 0000-0001-8231-6591. E-mail: vita252007@yandex.ru

Diane R. Mould – PhD, president Projections Research, Inc. ORCID ID: 0000-0002-8908-0136. E-mail: drmould@pri-home.net

Kaori Ito – PhD-MBA, scientific consultant Projections Research, Inc. E-mail: kaori.ito@appliedpmx.com

Arkady V. Zinchenko – Head of Biosimilars Research, JSC "R-Pharm". ORCID ID: 0000-0001-8148-5086. E-mail: a.zinchenko@rpharm.ru

Antonina N. Dolgorukova – biostatistician, JSC "R-Pharm". ORCID ID: 0000-0003-4189-7910. E-mail: an.dolgorukova@gmail.com

Maria V. Nikolskaya – Head of Medical Records Department, JSC "R-Pharm". ORCID ID: 0000-0001-6716-0357. E-mail: mv.nikolskaya@rpharm.ru

Maria S. Lemak – scientific adviser to JSC "R-Pharm". ORCID ID: 0000-0003-4793-7477. E-mail: lemak@rpharm.ru

Olga V. Filon – Director of the Department, JSC "R-Pharm". ORCID ID: 0000-0002-8735-7429. E-mail: ov.filon@rpharm.ru

Mikhail Y. Samsonov – Candidate of Sciences (Medicine), Associate Professor, Medical Director, JSC "R-Pharm". ORCID ID: 0000-0003-2685-1623. E-mail: samsonov@rpharm.ru

HEMOSTIMULATING PROPERTIES OF THE CONJUGATES OF GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR WITH ALENDRONIC ACID

G.G. Shimina, A.V. Bateneva, E.S. Tsyplenkova, S.G. Gamaley, T.I. Esina, E.A. Volosnikova, E.D. Danilenko

Institute of Medical Biotechnology of State Research Center of Virology and Biotechnology "VECTOR",
Federal Service for Surveillance on Consumer Rights Protection and Human Well-being,
9, Khimzavodskaya St., Berdsk, Russia, 633004

E-mail: shimina_gg@vector.nsc.ru

The aim of the work is to evaluate the hemostimulating activity of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) conjugates with alendronic acid (ALN) in the model of cytostatic myelosuppression and the dynamics of rhGM-CSF accumulation as a part of the conjugate in the bone tissue and bone marrow of mice.

Materials and methods. The conjugates obtained by a solid-phase synthesis using 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide or periodate oxidation, were used. A hemostimulating activity was evaluated in a model of a cytostatic myelosuppression induced by the administration of cyclophosphamide to CBA/Calac mice. RhGM-CSF preparations were injected subcutaneously for 4-5 days at the dose of 90 µg/kg. After the injections cycle had been completed, the total leukocyte and segmented neutrophil counts were carried out in the blood samples, and the total karyocyte count was carried out in the bone marrow samples.

The tissue distribution of rhGM-CSF preparations was assessed in outbred CD-1 mice after a single intravenous administration at the effective dose. The content of rhGM-CSF in blood, femoral tissue and bone marrow was determined by enzyme immunoassay.

Results. RhGM-CSF conjugates with ALN have been shown to retain the ability of the original protein to increase the number of leukocytes, segmented blood neutrophils, and bone marrow karyocytes under the action of conjugates. The stimulation of the neutrophil production used to be observed at earlier times than in the case of rhGM-CSF. The increase in the total number of bone marrow cells after the introduction of all three conjugates was more pronounced compared to the original protein (by 34%). The increased hemostimulatory effect of the AEG conjugate was accompanied by a more intense accumulation of rhGM-CSF in the bone tissue and bone marrow of mice. The rhGM-CSF introduced into the conjugate was detected in the bone tissue for 24 h and it circulated in the bloodstream for a longer time compared to the original protein.

Conclusion. The data obtained make it possible to conclude that further work on the development of effective hemostimulating drugs based on rhGM-CSF conjugates with ALN, is promising.

Keywords: recombinant human granulocyte-macrophage colony-stimulating factor; alendronic acid; conjugate; hemostimulating activity; accumulation in bone tissue and bone marrow.

Abbreviations: ALN – alendronic acid; GM-CSF – granulocyte-macrophage colony-stimulating factor; rhGM-CSF – recombinant human granulocyte-macrophage colony-stimulating factor; HAP – hydroxylapatite; EDC – 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide; CP – cyclophosphan; ELISA – electronic intelligence search and analysis; TKC – total karyocyte count.

ГЕМОСТИМУЛИРУЮЩИЕ СВОЙСТВА КОНЪЮГАТОВ ГРАНУЛОЦИТАРНО-МАКРОФАГАЛЬНОГО КОЛОНИЕСТИМУЛИРУЮЩЕГО ФАКТОРА С АЛЕНДРОНОВОЙ КИСЛОТОЙ

Г.Г. Шимина, А.В. Батенева, Е.С. Цыпленкова, С.Г. Гамалей, Т.И. Есина, Е.А. Волосникова, Е.Д. Даниленко

Институт медицинской биотехнологии Федерального бюджетного учреждения науки «Государственный научный центр вирусологии и биотехнологии «Вектор» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека, 633004, Россия, г. Бердск, ул. Химзаводская, д. 9

E-mail: shimina_gg@vector.nsc.ru

Цель. Оценка гемостимулирующей активности конъюгатов рекомбинантного гранулоцитарно-макрофагального колониестимулирующего фактора человека (рчГМ-КСФ) с алендроновой кислотой (АЛН) на модели цитостатической миелосупрессии и динамики накопления рчГМ-КСФ в составе конъюгата в костной ткани и костном мозге мышей.

Материалы и методы. В работе использовали конъюгаты, полученные методом твердофазного синтеза с помощью 1-этил-3-[3-диметиламинопропил]карбодиимида или реакции периодатного окисления. Гемостимулирующую активность оценивали на модели цитостатической миелосупрессии, вызванной введением мышам СBA/Calac циклофосфана. Препараты рчГМ-КСФ вводили подкожно в течение 4–5 дней в дозе 90 мкг/кг. По окончании курса инъекций в образцах крови подсчитывали общее количество лейкоцитов, сегментоядерных нейтрофилов, в образцах костного мозга – общее число кариоцитов. Оценку распределения препаратов рчГМ-КСФ по тканям проводили на аутбредных мышах CD-1 после однократного внутривенного введения в эффективной дозе. Содержание рчГМ-КСФ в крови, ткани бедренной кости и костном мозге определяли иммуноферментным методом.

Результаты. Показано, что конъюгаты рчГМ-КСФ с АЛН сохраняли присущую исходному белку способность повышать число лейкоцитов, сегментоядерных нейтрофилов крови и кариоцитов костного мозга. Стимуляция продукции нейтрофилов под действием конъюгатов наблюдалась в более ранние сроки, чем в случае рчГМ-КСФ. Увеличение общего числа клеток костного мозга после введения всех трех конъюгатов было более выраженным по сравнению с исходным белком (на 34%). Повышенный гемостимулирующий эффект конъюгата AEG сопровождался более интенсивным накоплением рчГМ-КСФ в костной ткани и костном мозге мышей. Введенный в состав конъюгата рчГМ-КСФ обнаруживался в костной ткани в течение 24 ч и более длительно циркулировал в кровеносном русле по сравнению с исходным белком.

Заключение. Полученные данные позволяют сделать вывод о перспективности дальнейших работ по созданию эффективных гемостимулирующих препаратов на основе конъюгатов рчГМ-КСФ с АЛН.

Ключевые слова: рекомбинантный гранулоцитарно-макрофагальный колониестимулирующий фактор человека; алендроновая кислота; конъюгат; гемостимулирующая активность; накопление в костной ткани и костном мозге

Список сокращений: АЛН – алендроновая кислота; ГМ-КСФ – гранулоцитарно-макрофагальный колониестимулирующий фактор; рчГМ-КСФ – рекомбинантный гранулоцитарно-макрофагальный колониестимулирующий фактор человека; ГАП – гидроксилапатит; EDC – 1-этил-3-[3-диметиламинопропил]карбодиимид; ЦФ – циклофосфан; ИФА – иммуноферментный анализ; ОКК – общее количество кариоцитов.

INTRODUCTION

The relevance of the search for new drugs and methods for the treatment of neutropenia of various etiologies, arising, in particular, as a result of chemotherapy and radiotherapy in cancer patients, is extremely high. Chemotherapy-induced disorders of hematopoiesis and, above all, suppression of leukocyte production, in some cases become the main indicators for interrupting the treatment, despite a distinct oncolytic therapy effect [1].

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a natural cytokine protein that regulates the proliferation and differentiation of stem cells with the formation of colonies of neutrophilic, eosinophilic leukocytes, and macrophages [2–4]. The ability of GM-CSF to enhance hematopoiesis served as a basis for the development and introduction of drugs based on it, Leukine and Leucomax (USA), into clinical practice, to reduce the side effects of the antitumor therapy, increase resistance to infections, during bone marrow transplantation. However, despite a high level of GM-CSF preparations safety, their use leads to the development of adverse reactions such as fever, chills, lethargy, myalgia, bone pain, fever, body weight fluctuations,

generalized pruritus, redness and an aerythematous reaction around the site of the subcutaneous injection [5–8]. In this regard, the improvement of GM-CSF preparations in terms of increasing their affinity for the target tissues, reducing the therapeutic dose and, as a result, side treatment effects, is of undoubted interest.

Literature references describe examples of various vector molecules used for the targeted delivery of immunoregulatory ligands, in particular, cytokines [9–11]. As a means of delivering biologically active substances to the bone tissue and bone marrow, bisphosphonates which are characterized by a high affinity for calcium ions and the ability to rapidly accumulate in the bone, are used [12–17]. One of the methods for obtaining the targeted drugs based on bisphosphonates, is their conjugation with medicinal preparations [12, 13].

Taking into account all of the above, conjugates of a human tumor necrosis factor alpha with alendronic acid aminobisphosphonate (ALN), which demonstrated the ability to accumulate in the foci of bone metastasis of the tumor, thereby exhibiting an antitumor activity, was obtained [18, 19]. These data became a basis for the use of ALN as a vector molecule for a delivery of a recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) to bone marrow cells.

A technology for the production of rhGM-CSF in a prokaryotic expression system (recombinant strain E. coli SG20050/p280_2GM) [20], as well as methods for conjugating rhGM-CSF with ALN using different types of cross-linking agents, has been developed at the Institute of Medical Biotechnology of the State Research Center for Virology and Biotechnology "Vector", Federal Service for Surveillance on Consumer Rights Protection and Human Well-being (IMBT FBRI SRC VB "Vector", Rospotrebnadzor) [21]. It has been shown that the resulting conjugates, compared to rhGM-CSF, have an increased affinity for hydroxylapatite, an analog of the mineral bone tissue matrix. The evaluation of the specific conjugates activity *in vitro* confirmed the preservation of the biological activity of rhGM-CSF in the composition [21].

THE AIM of the work is to evaluate the hemostimulatory activity of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) conjugates with alendronic acid (ALN) in the model of cytostatic myelosuppression and the dynamics of rhGM-CSF accumulation as a part of the conjugate in the bone tissue and bone marrow of mice.

MATERIALS AND METHODS

Study drugs

Experimental preparations were conjugates of rhGM-CSF with ALN obtained by the described methods [21]. The key point in the synthesis process was the choice of conditions that would minimize conformational changes in protein molecules in order to preserve their

biological activity. For this, equimolar amounts of the rhGM-CSF protein and ALN were used. 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) was chosen as the crosslinking agent; dextran with a molecular weight of 40,000 Da, activated with periodate, was used as a linker. The conjugation with EDC was carried out in two ways: a direct (rhGM-CSF →EDC → ALN) and reverse (ALN →EDC → rhGM-CSF) sequence of components application to the solid phase (hydroxyapatite sorbent, HAP).

For the direct sequence conjugation, the HAP chromatographic column was equilibrated with 2 mM potassium phosphate buffer, pH 7.0. A rhGM-CSF protein solution was applied to the balanced column, after the sorption of which the EDC solution was also fed to the column. The outlet of the solution from the column was blocked for 2 h to bind the components, then the column was washed with 2 mM potassium phosphate buffer (pH 7.0), and the ALN solution was applied. The column was repeatedly washed with phosphate buffer to remove the unbound components. The resulting conjugate was eluted from the column with 0.2 M potassium phosphate buffer, pH 7.0. The synthesized conjugate was transferred into a *physiological saline solution* by dialysis.

When dextran was used as a linker during the conjugation, it was added to the solution containing sodium periodate to form reactive aldehyde groups in the ratio of 1:40 (mol/mol), mixed, and incubated at 20°C for an hour. The activated dextran was separated by a gel filtration on the Sephadex G-25 column. The solutions of protein and ALN were added to the dextran solution in equimolar ratios: 1 mol of protein and 1 mol of ALN per 1 mol of dextran. The resulting mixture was incubated for 3 h at 20°C. To remove the unreacted components, the gel filtration was performed on the Sephadex G-25 column. The synthesized conjugate was transferred into the physiological saline by dialysis.

Three types of conjugates were obtained:

1 – GEA – rhGM-CSF conjugate with ALN, obtained by a solid-phase synthesis through the carboxyl group of the protein using EDC by the method of a direct (protein→EDC→ALN) sequence of applying components to the sorbent, with a protein concentration of 1.09 mg/ml (Fig. 1, track 1);

2 – AEG – conjugate of rhGM-CSF with ALN, obtained by a solid-phase synthesis through the carboxyl group of the protein using EDC by the reverse (ALN→EDC→protein) sequence of applying components to the sorbent, with a protein concentration of 1.45 mg/ml (Fig. 1, track 2);

3 – DGA – conjugate of rhGM-CSF with ALN, obtained by a synthesis through the protein amino group *via* a dextran molecule as a linker using the Malaprade reaction [22], with a protein concentration of 0.86 mg/ml (Fig. 2, track 1).

Reference drug

The rhGM-CSF protein, obtained at the IMBT FBRI SRC VB "Vector", Rospotrebnadzor according to the described method [23], was used as a reference drug and to obtain conjugates with ALN.

The protein substance was characterized by quality indicators in accordance with the requirements of regulatory documentation[1]. The protein concentration in the used substance was 1.5 mg/ml, the homogeneity of the preparation was 99.2%.

Experimental animals

The study was carried out on 66 healthy male CBA/Calac mice weighing 19–23 g, obtained from the nursery of Goldberg Research Center of Pharmacology and Regenerative Medicine (Tomsk), and 45 female white outbred CD-1 (ICR) mice weighing 22–25 g from the nursery of the Federal Budgetary Institution of the State Research Center "Vector" of Rospotrebnadzor (Koltsovo, the Novosibirsk region). The age of the animals was 2.0–2.5 months. Before the start of study, the animals had gone through a period of the adaptive quarantine. The mice were kept under standard vivarium conditions at the constant temperature and humidity; food and drink were available at any time of the day. The animals' keeping and experimental studies were carried out in accordance with the requirements of the International Convention for the Protection of Vertebrate Animals used for Experimental and Scientific Purposes (Strasbourg, 1986), as well as in compliance with Directive 2010/63/EU of the European Parliament and Council of the European Union dated September 22, 2010, for the protection of the animals used for scientific purposes. The studies were approved by the Bioethical Commission of "Vector" (protocol No. 5 dated 01.10.2020).

Method for assessing hemostimulating activity of conjugates

The hemostimulating activity of the drugs was studied in a model of cytostatic myelosuppression induced by the administration of cyclophosphamide (CP, Sigma-Aldrich, USA) to CBA/Calac mice [24].

The animals were divided into 5 experimental groups (4 experimental and 1 control); there were 12 male mice in each one. All the experimental animals received a single intraperitoneal injection of a CP solution at the maximum tolerated dose (250 mg/kg) in the volume of 0.25 ml per 20 g of body weight.

24 hours after the CP injection, the mice of the experimental groups were injected subcutaneously for

4–5 days with one of the following drugs: 1) rhGM-CSF; 2) GEA conjugate; 3) AEG conjugate; 4) DGA conjugate. The administration dose, previously determined as an effective hemostimulating agent using the rhGM-CSF preparation [25], was 90 μg/kg; the volume of the administration was 0.2 ml per 20 g of the animal body weight. The mice of the control group received subcutaneous saline in the equivalent volume according to the similar scheme. Six intact animals were used as an additional control group (without the administration of rhGM-CSF and CF preparations). All manipulations with the animals were carried out at the same time (in the morning).

One day after the drug administration completion (on the 5th day after the CP administration), the blood samples from the tip of the tail were taken for the analysis from each group in half of the animals, and after the cervical dislocation of the cervical vertebrae, the bone marrow samples were taken. On that day, the second half of the animals received another injection; the biomaterial was taken for the analysis 24 hours after injection.

In the blood samples, the total leukocyte count was determined by a light microscopy (the blood was diluted 20 times with a 3% solution of acetic acid, the calculation was carried out in Gorjaev's chamber), the relative and absolute contents of neutrophils and other morphological forms of leukocytes were also detremined. In the bone marrow samples, the total karyocyte count (TKC) was carried out and the number of cells per femur was calculated. To obtain the bone marrow, the mouse femur was isolated, it was cleaned from the soft tissues of the femur, and the bone marrow canal was thoroughly washed with a 3% acetic acid solution in the volume of 1 ml. The TKC was carried out using Gorjaev's chamber.

Method for studying rhGM-CSF accumulation dynamics

To study the rhGM-CSF accumulation dynamics in bone tissue and bone marrow, CD-1 female mice were divided into 3 groups: a control group (5 individuals) and two experimental groups (20 individuals in each). On the eve of the experiment, at the end of the working day, the mice were transferred to clean cages without food. The animals were given food 2 hours after the drugs administration, there was water without restrictions.

The animals of the first experimental group received an intravenous rhGM-CSF injection; the mice of the second experimental group were injected with the AEG conjugate. The preparations were administered at the dose of 90 μg/kg of body weight, 0.2 ml per 20 g of animal weight. The intact mice served as control animals (the third group).

---

[1] GPM.1.7.1.0007.15 "Medicines obtained by recombinant DNA methods". Russian State Pharmacopeia ed 14. 2018;4: 2575-95. Available from: https://docs.rucml.ru/feml/pharma/v14/vol2/763/

Figure 1 – Electrophoregram of conjugates obtained by direct sequence of applying components, GEA (1) and reverse sequence, AEG (2)

Note: Electrophoresis in 15% polyacrylamide gel under reducing conditions, R-250 Coomassie staining. Tracks: 3 – protein marker 10–250 kDa; 4 – rhGM-CSF protein, 20 µg.

Figure 2 – Electropherogram of conjugate obtained using dextran (1)

Note: Electrophoresis in 15% polyacrylamide gel under reducing conditions, R-250 Coomassie staining. Tracks: 2 – rhGM-CSF protein, 20 µg; 3 – protein marker 10–250 kDa.

Figure 3 – Leukocyte count in peripheral CBA mice blood against the background of CP administration, rhGM-CSF drug and its conjugates with ALN

Note: abscissa shows study time (days); * – statistically significant difference in relation to the control (saline); ** – statistically significant difference in relation to rhGM-CSF at $p \leq 0.05$. Area between dotted lines is confidence interval of indicator in intact mice.

Figure 4 – Count of segmented neutrophils in peripheral CBA mice blood against the background of CP administration, rhGM-CSF drug and its conjugates with ALN

Note: abscissa shows study time (days); * – statistically significant difference in relation to the control (saline); ** – statistically significant difference in relation to rhGM-CSF at p ≤0.05. Area between dotted lines is confidence interval of indicator in intact mice.

Figure 5 – Karyocyte counts in CBA mice bone marrow against the background of CP, rhGM-CSF its conjugates with ALN administration

Note: abscissa shows study time (days); * – statistically significant difference in relation to the control (saline); ** – statistically significant difference in relation to rhGM-CSF at p ≤0.05. Area between dotted lines is confidence interval of indicator in intact mice.

Table 1 – Dynamics of changes in the level of rhGM-CSF in the blood, bone tissue and bone marrow of mice after a single intravenous administration of rhGM-CSF preparations

Drug	Concentration of rhGM-CSF in samples			
	Blood serum, pg/ml			
	3 minutes	1 hour	4 hours	24 hours
rhGM-CSF	151 715±32 571	3 138±214	24.5±2.3	0.174±0.148
AEG conjugate	406 468±54 586**	8 500±2 539**	48.8±9.0**	0.676±0.676
	Femur, pg/g			
Control	184±139			
rhGM-CSF	3 869±458*	322±151	436±52	137±105
AEG conjugate	11 154±1 613*,**	1 108±387	1 706±374*,**	1 652±449
	Bone marrow of femur, pg/femur			
Control	3.52±2.03			
rhGM-CSF	237±36*	9.84±7.47	0±0	1.20±1.20
AEG conjugate	567±127*	20.3±12.8	5.64±5.64	15.7±9.7

Note: experimental data are presented as arithmetic mean and standard error (M±m); * – differences are statistically significant compared to control; ** – differences are statistically significant compared to mice that were injected with rhGM-CSF (p<0.05 for blood; p<0.017 for tissues).

3 minutes later, 1, 4 and 24 hours after the drugs administration, the blood and one femur was taken from 5 animals from each experimental group after euthanasia. On the first day of the experiment, a similar material was taken from the mice in the control group. The serum was obtained from the blood; the bone marrow was extracted from the femur by washing the bone marrow canal with a 0.9% sodium chloride solution in the volume of 1 ml. The bone marrow cells were resuspended with a dispenser until a homogeneous suspension. After the bone marrow removal, the femur was weighed and a 10% homogenate was prepared in 0.1 M potassium phosphate buffer (pH 7.2) using a GlasCol homogenizer (USA). The resulting biomaterial was stored at the temperature not exceeding –20°C. On the day of the analysis, the bone marrow and femur homogenates were thawed, centrifuged (5810R centrifuge, Eppendorf, Germany) at 5000 g and the temperature of 2–8°C for 5 min, and the supernatants were collected.

In the blood serum and supernatants of femur homogenatesthe content of rhGM-CSF was determined by electronic intelligence search and analysis (ELISA) using reagent kits for the determination of human GM-CSF in serum, blood plasma, supernatants of cell cultures and organ homogenates "Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) ELISA Kit", "CUSABIO", China. The range of the standard sample determined concentrations included in the kit, was 15.6–1000 pg/ml, the sensitivity was less than 3.9 pg/ml.

Statistical processing of obtained results

The results obtained were processed using the "Statgraphics, Version 5.0" software package ("Statistical Graphics Corp.", USA). Due to the small sample sizes, non-parametric tests were used to assess the significance of intergroup differences – the two-sample Mann-Whitney U-test and the Kruskal-Wallis H-test of multiple comparisons with a critical level of statistical significance (p) equal to 0.05. When statistically significant differences were found in the H-test, post-hoc comparisons were performed using the U-test, while the adjusted critical significance level (p) for three pairwise comparisons was taken equal to 0.0170 [26, 27]. The experimental data are presented as the arithmetic mean and standard error (M±m). The figures are constructed using Microsoft Excel.

RESULTS AND DISCUSSION

The study showed that a single CP administration to the mice at the dose of 250 mg/kg led to the regular development of myelosuppression. The total karyocyte count of the bone marrow in the control group mice on the 5th day after the CP administration decreased by 1.5 times, the blood total leukocyte count- by 5.5 times, the count of segmented neutrophils – by 13.9 times.

The change in the counts of leukocytes, segmented neutrophils, and bone marrow cells in the mice after the drug administration was evaluated in comparison with the indicators of the control group (physiological saline), the values of which were taken as 100%. The administration of both rhGM-CSF and its conjugates with ALN to the animals resulted in a faster statistically significant (p ≤0.05) increase in the blood leukocyte count compared to the control values (Fig. 3). On the 5th day after the CP administration, the blood leukocyte count in the mice treated with rhGM-CSF preparations exceeded the control value by 46–100%, on the 6th day – by 56–94%. Significant differences in the level of the leukopoiesis stimulation in the groups that had been injected with different types of conjugates or rhGM-CSF, were not observed.

On the 5th day after the CP administration, in the mice groups that had been injected with GEA and

DGA conjugates, a statistically significant increase in the number of segmented neutrophils compared with the control ones, was notified by 414 and 200%, respectively, p≤0.05). On the 6th day, with the conjugates administration, the increased values of the indicator were registered in all the two groups (by 77 and 169%). A significant stimulating effect of the initial rhGM-CSF was observed only on the 6th day, the count of the segmented neutrophils in the blood during this period increased by 218% compared with the index of the animals treated with saline (Fig. 4).

The data presented in Fig. 5, shows that 5 days later, the rhGM-CSF administration led to a statistically significant increase in the total karyocytes count, by 43% after the CP administration compared with the control values. Similar, but more pronounced, changes were notified in the groups of mice that had been injected with the conjugates. At the same time, the DGA effect (an increase of 100% compared to the control) was maximal. Six days after the cytostatic administration, the karyocytes count in the bone marrow of the mice that had been injected with conjugates, was 58–63% higher than the control level, and 30–34% higher than the level recorded after the rhGM-CSF administration.

Thus, the conjugation of rhGM-CSF with ALN did not lead to a decrease in the hemostimulatory protein activity. No significant differences were found in the level of the leukostimulating activity of the studied preparations. The GEA and DGA conjugates accelerated the recovery of the murine blood neutrophil count. The AEG and DGA conjugates had a more pronounced stimulating effect on the production of bone marrow cells compared to GM-CSF, which was manifested in a more intense and earlier increase in the total bone marrow cellularity after the exposure to the cytostatic.

The enhancement of the stimulating rhGM-CSF effect in the conjugate on the production of karyocytes can obviously be associated with an increased affinity of the protein to the bone tissue cells.

To confirm the targeted rhGM-CSF delivery in the composition of the ALN conjugate to the bone tissue, a comparative study of the drug accumulation in the bone tissue and bone marrow after the intravenous rhGM-CSF and its AEG conjugate administration, was carried out.

The dynamics in protein concentration changes in the blood, the bone tissue and bone marrow of mice after a single intravenous rhGM-CSF and its conjugate administration at the effective hemostimulating dose (90 µg/kg), is presented in Table 1.

The obtained data indicate that the highest rhGM-CSF blood values in the mice were registered 3 min after the drug administration and amounted to 19.2% of the administered dose in the mice treated with AEG conjugate, and to 7.2% in the mice after the rhGM-CSF administration. (Table 1). The protein was retained in the blood serum of mice of the both experimental groups for 4 hours of the observation.

1 hour after the drugs administration, the values of the indicator decreased by 48 times compared to the "3 min" point, and in the subsequent periods, their further decrease to the background level was notified. The rhGM-CSF concentration in the blood of mice that had been administered with the conjugate, exceeded the corresponding indicator after the rhGM-CSF administration by 2.7 times after 3 minutes and 1 hour, and twice after 4 hours after the administration (the differences are statistically significant, p ≤0, 05). 24 hours after the injection, rhGM-CSF was detected in small amounts in the blood of two out of five animals after the rhGM-CSF administration, and in one out of five mice that had been administered with the AEG conjugate. In the blood serum of the control animals, the values of the indicator did not differ from the zero in any of the observation periods.

The highest rhGM-CSF level in the mice femoral bone homogenates was detected 3 min after the drug administration. At the same time, the protein content in the bone tissue of the mice treated with the conjugate at this point was 60 times higher than that of the animals administered with rhGM-CSF. In the subsequent periods, the protein concentration in all the mice femurs that had been administered with rhGM-CSF, decreased to the control level (1 hour after the administration, Table 1). In the bone tissue samples of the mice that had been administered with AEG conjugate, the concentration of rhGM-CSF 1 hour after the injection was 6 times higher than the control level (the differences are not statistically significant, p ≤0.017), in the subsequent periods (4 and 24 hours) – by 9 times (the statistial differences were observed at the 4-hour point). 24 hours after injection, only two out of five mice that had been administrated with rhGM-CSF, had an increased rhGM-CSF content in the bone tissue (541 and 146 pg/g of the tissue), while a higher level of rhGM-CSF than in the control CSF (from 1408 to 2460 pg/g) after the administration of the AEG conjugate was observed in four out of five animals.

The maximum rhGM-CSF concentration in the bone marrow of the mice from the both experimental groups, as well as in the blood and femoral bone homogenates, was recorded at the first point, 3 minutes after the administration (Table 1). The values of the indicator in the mice that had been administered with the AEG conjugate, were 161 times higher than the control values, and 2.4 times higher than the indicator of the mice that had been administered with rhGM-CSF. In the subsequent periods, the protein content in both experimental groups decreased. However, it should be notified that 4 and 24 hours after the rhGM-CSF administration of all five mice, the protein in the bone marrow was not detected, while in the group that had been administered with the AEG conjugate, the trace amounts of rhGM-CSF were registered in 2 mice (from 28.2 to 42.2 pg/femur).

Thus, the introduction of alendronic acid into the

composition of rhGM-CSF contributed to an increase in the accumulation and distribution of rhGM-CSF in the bone tissue and bone marrow of the mice, which is consistent with the available literature data on the accumulation of alendronic acid preparations in the bone tissue, their strong binding and retention by the bone matrix [28-34]. The concentration of the conjugated protein in the blood in the first hours after the administration was higher than that of the free rhGM-CSF, which may be due to an increase in the protein resistance to proteolytic enzymes as a result of modification and, as a result, the appearance of its ability to circulate in the bloodstream for a longer time.

CONCLUSION

It has been established that rhGM-CSF conjugates with ALN have a hemostimulating activity comparable to the activity of the original protein. In the composition of conjugates, the effect of rhGM-CSF on the bone marrow cells was more pronounced and prolonged, which is apparently due to the longer presence of the protein in the conjugate in the blood and its increased accumulation in the bone tissue and bone marrow. The data obtained make it possible for us to conclude that further work on the development of hemostimulating drugs based on rhGM-CSF conjugates with alendronic acid, is promising.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHORS' CONTRIBUTION

GGSh – conducting experimental studies, statistical data processing, diagramming, writing the article text;
AVB – literature search, experimental research, statistical data processing, writing the article text;
EST – conducting experimental studies; SGG – conducting a literature search, forming the purpose and objectives of the study, developing the design of the study, finalizing the article text;
TIE – obtaining drugs for research; EAV – obtaining drugs for research; EDD – approval of the pilot study plan, editing and revision of the article text content, approval of the final article text version.

REFERENCES

1. Dygai AM, Zhdanov VV, Miroshnichenko LA, Zyuz'kov GN, Udut EV, Simanina EV, Stavrova LA, Khrichkova TY, Agafonov VI. Comparison of Specifi c Activity of Granulocytopoiesis Stimulators after Treatment with Cytostatics with Different Mechanisms of Action. Bull Exp Biol Med. 2013;55:631–5. DOI: 10.1007/s10517-013-2212-3

2. Hamilton JA, Anderson GP. GM-CSF Biology. Growth Factors. 2004 Dec;22(4):225–31. DOI: 10.1080/08977190412331279881

3. Bhattacharya P, Budnick I, Singh M, Thiruppathi M, Alharshawi K, Elshabrawy H, Holterman MJ, Prabhakar BS. Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. J Interferon Cytokine Res. 2015 Aug;35(8):585–99. DOI: 10.1089/jir.2014.0149

4. van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood. 2012 Apr 12;119(15):3383–93. DOI: 10.1182/blood-2011-11-370130

5. Hübel K, Dale DC, Liles WC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis. 2002 May 15;185(10):1490–501. DOI: 10.1086/340221

6. Steward WP, Scarffe JH, Austin R, Bonnem E, Thatcher N, Morgenstern G, Crowther D. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. Br J Cancer. 1989 Jan;59(1):142–5. DOI: 10.1038/bjc.1989.28

7. Morita M, Lamkhioued B, Soussi Gounni A, Aldebert D, Delaporte E, Capron A, Capron M. Induction by interferons of human eosinophil apoptosis and regulation by interleukin-3, granulocyte/macrophage-colony stimulating factor and interleukin-5. Eur Cytokine Netw. 1996 Dec;7(4):725–32.

8. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med. 1992 Jul 2;327(1):28–35. DOI: 10.1056/NEJM199207023270106

9. Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv. 2012;2012:915375. DOI: 10.1155/2012/915375

10. Mu CF, Shen J, Liang J, Zheng HS, Xiong Y, Wei YH, Li F. Targeted drug delivery for tumor therapy inside the bone marrow. Biomaterials. 2018 Feb;155:191–202. DOI: 10.1016/j.biomaterials.2017.11.029

11. Kamada H, Tsutsumi Y, Yamamoto Y, Kihira T, Kaneda Y, Mu Y, Kodaira H, Tsunoda SI, Nakagawa S, Mayumi T. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice. Cancer Res. 2000 Nov 15;60(22):6416–20.

12. Danilenko ED, Belkina AO. The use of bisphosphonates as a means of drug delivery. Russian Journal of Biopharmaceuticals. 2014;6(6):44-53. Russian

13. Farrell KB, Karpeisky A, Thamm DH, Zinnen S. Bisphosphonate conjugation for bone specific drug targeting. Bone Rep. 2018 Jul 3;9:47-60. DOI: 10.1016/j.bonr.2018.06.007

14. Sedghizadeh PP, Sun S, Junka AF, Richard E, Sadrerafi K, Mahabady S, Bakhshalian N, Tjokro N, Bartoszewicz M, Oleksy M, Szymczyk P, Lundy MW, Neighbors JD, Russell RG, McKenna CE, Ebetino FH. Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms. J Med Chem. 2017 Mar 23;60(6):2326–43. DOI: 10.1021/acs.jmedchem.6b01615

15. Kamble S, Varamini P, Müllner M, Pelras T, Rohanizadeh R. Bisphosphonate-functionalized micelles for targeted delivery of curcumin to metastatic bone cancer. Pharm Dev Technol. 2020 Nov;25(9):1118–26. DOI: 10.1080/10837450.2020.1798458

16. Yamashita S, Katsumi H, Sakane T, Yamamoto A. Bone-targeting dendrimer for the delivery of methotrexate and treatment of bone metastasis. J Drug Target. 2018 Nov;26(9):818–28. DOI:10.1080/1061186X.2018.1434659

17. Xie Z, Liu G, Tang P, Sun X, Chen S, Qin A, Zhu P, Zhang J, Fan S. Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo. Drug Deliv. 2018 Nov;25(1):187–97. DOI: 10.1080/10717544.2017.1422295

18. Volosnikova EA, Demin IF, Levagina GM, Lebedev LR, Zakabunin AI, Danilenko ED. The Synthesis of Conjugates of TNF-Alpha and Alendronic Acid. Russian Journal of Bioorganic Chemistry. 2016;42(6):704–11. DOI: 10.7868/S0132342316060154

19. Zakabunin AI, Danilenko ED, Volosnikova EA, Levagina GM, Demin IF. Antitumor agent. Russian Federation Patent No. 2609871 C. 2017 Feb 06. Russian

20. Gileva IP, Esina TI, Volosnikova EA, Gogina YaS, Lebedev LR, Danilenko ED. Recombinant plasmid DNA p280_2GM coding polypeptide with properties of granulocyte-macrophage colony-stimulating factor of human, strain Escherichia coli SG 20050/p280_2GM — producer of polypeptide with properties of granulocyte-macrophage colony-stimulating factor of human and method of obtaining of said polypeptide. Russian Federation Patent No. 2708556. 20198 Dec 09. Russian

21. Esina TI, Volosnikova EA, Lebedev LR, Kochneva GV, Grazhdantseva. A. A. Study on the Methods for Synthesis of GM-CSF Conjugates with Alendronic Acid. Russian Journal of Bioorganic Chemistry. 2020;46(3):1–8. DOI: 10.31857/S0132342320030112. Russian

22. Mamaeva SA, Kruppa IS, Dyatlov VA, Rustamov IR, Gumnikova VI. Influence of periodate oxidation on fractional inhomogeniety and molecular weight of polysacharides. Uspekhi v himii i himicheskoj tekhnologii=Success in Chemistry and Chemical Technology. 2014;28(3): 45–8. Russian

23. Esina TI, Lebedev LR, Volosnikova EA, Gileva IP, Gogina YaS, Tereshchenko TA, Kochneva GV, Grazhdantseva AA, Danilenko ED. Method for obtaining recombinant human granulocyte-macrophage colony-stimulating factor. Biotechnology in Russia. 2019;35(3): 68–73. DOI: 10.21519/0234-2758-2019-35-3-68-73

24. Goldberg ED, Dygai AM, Zyuzkov GN, Zhdanov VV, Simanina EV, Guryantseva LA, Khrichkova TYu, Udut EV, Stavrova LA, Sotnikova NV. Method of granulocytopenia-stimulating effect evaluation for pharmacological substances. Russian Federation Patent No. 2332667. 2008 Aug 27. Russian

25. Shimina GG, Bateneva AV, Gamaley SG, Esina TI, Tereshchenko TG, Danilenko ED. Study on Hemostimulating Properties of Granulocyte-Macrophage Colony Stimulating Factor. BIOpreparations. Prevention, Diagnosis, Treatment. 2020;20(4):268–76. DOI: 10.30895/2221-996X-2020-20-4-268-276. Russian

26. Grzhibovsky AM. Analysis of quantitative data for two independent groups. Human Ecology. 2008;(2):54-61. Russian

27. Grzhibovsky AM. Analysis of three or more independent groups of quantitative data. Human Ecology. 2008;(3):50-8. Russian

28. Nguyen TD, Pitchaimani A, Aryal S. Engineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma. Sci Rep. 2016 Nov 8;6:36707. DOI: 10.1038/srep36707

29. Pan H, Sima M, Kopecková P, Wu K, Gao S, Liu J, Wang D, Miller SC, Kopecek J. Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol Pharm. 2008 Jul-Aug;5(4):548–58. DOI: 10.1021/mp800003u

30. Miller K, Eldar-Boock A, Polyak D, Segal E, Benayoun L, Shaked Y, Satchi-Fainaro R. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharm. 2011 Aug 1;8(4):1052-62. DOI: 10.1021/mp200083n

31. Chen H, Li G, Chi H, Wang D, Tu C, Pan L, Zhu L, Qiu F, Guo F, Zhu X. Alendronate-conjugated amphiphilic hyperbranched polymer based on Boltorn H40 and poly(ethylene glycol) for bone-targeted drug delivery. Bioconjug Chem. 2012 Sep 19;23(9):1915–24. DOI: 10.1021/bc3003088'

32. Akyol UK, Sipal S, Demirci E, Gungormus M. The influence of low-level laser therapy with alendronate irrigation on healing of bone defects in rats. Lasers Med Sci. 2015 Apr;30(3):1141–6. DOI: 10.1007/s10103-015-1720-y

33. Lin JH, Duggan DE, Chen IW, Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos. 1991 Sep-Oct;19(5):926–32.

34. Lin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos. 1992 Jul–Aug;20(4):473–8.

AUTHORS

Galina G. Shimina – Researcher of the Department of Biological Research, Institute of Medical Biotechnology of State Research Center of Virology and Biotechnology "VECTOR", Rospotrebnadzor. ORCID ID: 0000-0002-1078-7033. E-mail: shimina_gg@vector.nsc.ru

Alena V. Bateneva – Researcher of the Department of Biological Research, Institute of Medical Biotechnology of State Research Center of Virology and Biotechnology "VECTOR", Rospotrebnadzor. ORCID ID: 0000-0002-3761-7798. E-mail: bateneva_av@vector.nsc.ru

Elena S. Tsyplenkova – Junior Researcher, Department of Biological Research, Institute of Medical Biotechnology of State Research Center of Virology and Biotechnology "VECTOR", Rospotrebnadzor. ORCID ID: 0000-0002-1277-6258. E-mail: tsyplenkova_es@vector.nsc.ru

Svetlana G. Gamaley – Head of the Department of Biological Research Institute of Medical Biotechnology of State Research Center of Virology and Biotechnology "VECTOR", Rospotrebnadzor. ORCID ID: 0000-0002-7441-333X. E-mail: gamaley_sg@vector.nsc.ru

Tatyana I. Esina – Junior Researcher at the Department of Technology Development and Pilot Production of Biological Products, Institute of Medical Biotechnology of State Research Center of Virology and Biotechnology "VECTOR", Rospotrebnadzor. ORCID ID: 0000-0001-9006-8313. E-mail: esina_ti@vector.nsc.ru

Ekaterina A. Volosnikova – Candidate of Sciences (Biology), Head of the Laboratory for Obtaining and Analyzing Biosubstances of the Department for Technology Development and Pilot Production of Biological Products, Institute of Medical Biotechnology of State Research Center of Virology and Biotechnology "VECTOR", Rospotrebnadzor. ORCID ID: 0000-0001-5028-5647. E-mail: volosnikova_ea@vector.nsc.ru

Elena D. Danilenko – Candidate of Sciences (Biology), Director of the Institute of Medical Biotechnology of State Research Center of Virology and Biotechnology "VECTOR", Rospotrebnadzor. ORCID ID: 0000-0001-5026-1602. E-mail: danilenko_ed@vector.nsc.ru

B6.A-DYSF^PRMD/GENEJ MICE AS A GENETIC MODEL OF DYSFERLINOPATHY

M.V. Korokin[1], E.V. Kuzubova[1], A.I. Radchenko[1], R.V. Deev[3,6], I.A. Yakovlev[2], Deikin A.V.[1], N.S. Zhunusov[1], A.M. Krayushkina[1], V.M. Pokrovsky[1], O.A. Puchenkova[1], K.D. Chaprov[1,4], N.V. Ekimova[1], S.N. Bardakov[5], O.N. Chernova[3], A.M. Emelin[1,3], I.S. Limaev[3]

[1] Belgorod State National Research University,
85, Pobedy Str., Belgorod, Russia, 308015
[2] LLC "Genotarget",
48/7, Nobel Str., Skolkovo Innovation Center, Moscow, Russia, 121205
[3] North-Western State Medical University named after I.I. Mechnikov,
41, Kirochnaya Str., St. Petersburg, Russia, 191015
[4] Institute of Physiologically Active Compounds at Federal Research Center
of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences (IPAC RAS),
1, Severny Driveway, Chernogolovka, Russia, 142432
[5] S. M. Kirov Military Medical Academy,
6, Academician Lebedev Str., St. Petersburg, Russia, 194044
[6] PJSC "Human Stem Cells Institute",
Bld. A, 10, 60-Letiya Oktyabrya Ave., Moscow, Russia, 117292

E-mail: mkorokin@mail.ru

The aim of the work was behavioral and pathomorphological phenotyping of the mice knockout for the DYSF gene, which plays an important role in the development and progression of dysferlinopathy.

Materials and methods. A B6.A-Dysf^prmd/GeneJ (Bla/J) mice subline was used in the work. During the study, a muscle activity was determined basing on the following tests: "Inverted grid", "Grip strength", "Wire Hanging", "Weight-loaded swimming", Vertical Pole". Histological and immunofluorescent examinations of skeletal muscles *(m. gastrocnemius, m. tibialis)* were performed. The presence and distribution of the dysferlin protein was assessed, and general histological changes in the skeletal muscle characteristics of mice at the age of 12 and 24 weeks, were described. A morphometric analysis with the determination of the following parameters was performed: the proportion of necrotic muscle fibers; the proportion of fibers with centrally located nuclei; the mean muscle fiber diameter.

Results. The "Grip strength" test and the "Weight-loaded swimming" test revealed a decrease in the strength of the forelimbs and endurance in the studied mice of the Bla/J subline compared to the control line. The safety of physical performance was checked using the "Wire Hanging" test and the "Vertical Pole" test, which showed a statistically significant difference between the studied mice and control. The coordination of movements and muscle strength of the limbs examined in the "Inverted Grid" test did not change in these age marks. Decreased grip strength of the forelimbs, decreased physical endurance with age, reflects the progression of the underlying muscular disease. Histological methods in the skeletal muscles revealed signs of a myopathic damage pattern: necrotic muscle fibers, moderate lympho-macrophage infiltration, an increase in the proportion of fibers with centrally located nuclei, and an increase in the average fiber diameter compared to the control. The dysferlin protein was not found out in the muscle tissues.

Conclusion. Taking into account the results of the tests performed, it was shown that the absence of Dysf^-/- gene expression in Bla/J subline mice led to muscular dystrophy with the onset of the development of phenotypic disease manifestations at the age of 12 weeks and their peak at 24 weeks. Histopathological phenotypic manifestations of the disease are generally

nonspecific and corresponded to the data of intravital pathoanatomical examination in diferlinopathy patients. The mice of the studied subline Bla/J are a representative model of dysferlinopathy and can be used to evaluate new therapeutic agents for the treatment of this disease.

Keywords: dysferlinopathy; DYSF gene; Myoshi's myopathy; muscular dystrophy; phenotyping; knockout; genotyping; animals; mouse model; B6.A-Dysf[prmd]/GeneJ

Abbreviations: Bla/J – B6.A-Dysf[prmd]/GeneJ; CK – creatine kinase; DNA – deoxyribonucleic acid; PCR – polymerase chain reaction; bp – base pairs; WT – wild-type mice; EDTA – ethylenediaminetetraacetic acid; Gas M – *M. gastrocnemius medialis*; Gas L – *M. gastrocnemius lateralis*; tib – *M. tibialis.*

МЫШИ B6.A-DYSF[PRMD]/GENEJ КАК ГЕНЕТИЧЕСКАЯ МОДЕЛЬ ДИСФЕРЛИНОПАТИИ

М.В. Корокин[1], Е.В. Кузубова[1], А.И. Радченко[1], Р.В. Деев[3,6], И.А. Яковлев[2], А.В. Дейкин[1], Н.С. Жунусов[1], А.М. Краюшкина[1], В.М. Покровский[1], О.А. Пученкова[1], К.Д. Чапров[1,4], Н.В. Екимова[1], С.Н. Бардаков[5], О.Н. Чернова[3], А.М. Емелин[1,3], И.С. Лимаев[3]

[1] Федеральное государственное автономное образовательное учреждение высшего образования «Белгородский государственный национальный исследовательский университет»,
308015, Россия, г. Белгород, ул. Победы, д. 85

[2] Общество с ограниченной ответственностью «Генотаргет»,
121205, Россия, г. Москва, Инновационный центр «Сколково», ул. Нобеля, д. 7, пом. 48

[3] Федеральное государственное бюджетное образовательное учреждение высшего образования «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Министерства здравоохранения Российской Федерации
191015, Россия, г. Санкт-Петербург, ул. Кирочная, д. 41

[4] Институт физиологически активных веществ федерального государственного бюджетного учреждения науки федерального исследовательского центра проблем химической физики и медицинской химии Российской академии наук (ИФАВ РАН),
142432, Россия, г. Черноголовка, Северный проезд, д. 1

[5] Федеральное государственное бюджетного военное образовательное учреждение высшего образования «Военно-медицинская академия имени С.М. Кирова» Министерства обороны Российской Федерации,
194044, Россия, г. Санкт-Петербург, ул. Академика Лебедева, д. 6

[6] Публичное акционерное общество «Институт стволовых клеток человека»,
117292, Россия, г. Москва, пр-т 60-Летия Октября, д. 10а

E-mail: mkorokin@mail.ru

Цель. Поведенческое и патоморфологическое фенотипирование мышей, нокаутных по гену Dysf, играющему важнейшую роль в развитии и прогрессировании дисферлинопатии.

Материалы и методы. В работе использована сублиния мышей B6.A-Dysf[prmd]/GeneJ (Bla/J). В ходе исследования определяли мышечную активность при помощи следующих тестов: «Перевернутая сетка», «Сила хватки», «Удержание на проволоке», «Вынужденное плавание с грузом», «Удержание животного на скользком вертикальном стержне». Выполнено гистологическое и иммунофлюоресцентное исследование скелетной мускулатуры (*m. gastrocnemius*, *m. tibialis*). Оценено наличие и распределение белка дисферлина, описаны общие гистологические изменения скелетной мышцы, характерные для мышей в возрасте 12 и 24 недель. Также выполнен морфометрический анализ с определением следующих параметров: доля некротизированных мышечных волокон; доля волокон с центрально расположенными ядрами; средний диаметр мышечного волокна.

Результаты. Тест «Сила хватки» и «Принудительное плавание с грузом» выявили снижение силы передних конечностей и выносливости у исследуемых мышей сублинии Bla/J по сравнению с контрольной линией. Сохранность физической работоспособности проверена при помощи тестов «Проволочный тест» и «Удержание животного на скользком вертикальном стержне», которые показали статистически значимое различие между исследуемыми мышами и контролем. Координация движений и мышечная сила конечностей, исследованных в тесте «Перевёрнутая сетка», в данных возрастных метках не изменена. Уменьшение силы хватки передних конечностей, снижение физической выносливости с возрастом отражает прогрессирование основного мышечного заболевания. Гистологическими методами в скелетной мускулатуре выявлены признаки миопатического паттерна повреждения: некротизированные

мышечные волокна, умеренная лимфо-макрофагальная инфильтрация, увеличение по сравнению с контролем доли волокон с центрально расположенными ядрами, среднего диаметра волокна. Белок дисферлин в тканях мышц не обнаружен.

Заключение. С учетом результатов проведенных тестов показано, что отсутствие экспрессии гена Dysf$^{-/-}$ у мышей сублинии Bla/J приводило к мышечной дистрофии с началом развития фенотипических проявлений болезни в 12 недель жизни и их пиком к 24 неделе. Патогистологические фенотипические проявления болезни в целом неспецифичны и соответствовали данным прижизненного патологоанатомического исследования у пациентов с диферлинопатией. Мыши исследуемой сублинии Bla/J являются репрезентативной моделью дисферлинопатии и могут быть использованы для оценки новых терапевтических средств для лечения данного заболевания.

Ключевые слова: дисферлинопатия; ген Dysf; миопатия Миоши; мышечная дистрофия; фенотипирование; нокаут; генотипирование; трансгенные животные; мышиная модель; B6.A-Dysf^{prmd}/GeneJ

Список сокращений: Bla/J — B6.A-Dysf^{prmd}/GeneJ; КК — креатинкиназа; ДНК — дезоксирибонуклеиновая кислота; ПЦР — полимеразная цепная реакция; п.о. — пар оснований, WT — мыши дикого типа; ЭДТА — этилендиаминтетраууксусная кислота; Gas M — *M. gastrocnemius medialis*; Gas L — *M. gastrocnemius lateralis*; tib — *M. tibialis*.

INTRODUCTION

Dysferlinopathy is phenotypically heterogeneous progressive muscular dystrophy caused by mutations in the DYSF (2p13) gene, which encodes the transmembrane protein dysferlin (230 kDa) involved in the sarcolemma repair. [1]. Dysferlinopathy includes a presymptomatic stage of an asymptomatic increase in the level of creatine kinase (CK) in the blood, and a manifest stage, characterized by a progressive lesion of the proximal and/or distal muscles of the extremities [2]. There are five main phenotypes of dysferlinopathy: Miyoshi's distal myopathy (OMIM # 254130), limb-girdle muscular dystrophy R2 (LGMD R2, OMIM # 253601); distal myopathy of the anterior bed of the leg (distal, with the origin in the anterior tibial muscle (DMAT, OMIM # 606768); a proximal-distal form (transitional form) and a congenital phenotype [3]. Dysferlin consists of seven C2 domains and is a transmembrane protein of skeletal muscles, also expressed by cardiomyocytes and monocytes [4]. The main role of dysferlin is Ca^{2+} dependent repair of the sites of the sarcolemma damage [5]. Dysferlinopathy is manifested in the range from late adolescence to early adulthood, followed by a steady increase in disease manifestations [6].

The disease manifestation occurs in late adolescence – early adulthood, followed by a steady progression of muscle weakness and an outpatient status loss at 35–45 years [7].

A proper conduct of a clinical trial requires understanding of disease progression patterns and response to various outcome measures over time [8]. The complexity of choosing indicators for clinical studies of dysferlinopathy is determined by the variability of the manifestation age, a phenotype, a severity of the muscular dystrophic process, a variable progression rate, and modifying factors that have not been fully identified [9]. It has been previously shown that the assessment

of a motor function in dysferlinopathy is a reliable method of objectification, however, the variability in the rate of progression of the disease makes it difficult to demonstrate a response in small cohorts [10, 11]. It has been established that, despite the absence of dysferlin protein expression in skeletal muscles, there is a variation in the age of manifestation, clinical manifestations, and a disease severity. Similarly, dysferlinopathy can progress at different rates, even in the presence of the same mutation [12, 13]. A number of factors that modify a phenotype and a dysferlinopathy progression rate have been described: a physical activity degree and duration and a type of mutation (homozygosity for nonsense mutations), in the absence of stable clinical and genetic correlations [14, 15].

THE AIM of the work was behavioral and pathomorphological phenotyping of the mice knockout for the DYSF gene, which plays an important role in the development and progression of dysferlinopathy.

MATERIALS AND METHODS

Laboratory animals

The subline of mice B6.A-Dysf^{prmd}/GeneJ (Bla/J), obtained from the testing center "Vivarno-experimental complex LLC "Mitoengineering Research Institute of Moscow State University", was used in the work. The animal cohorts were obtained by crossing A/J mice (#:000646), in which a spontaneous insertion in intron 4 was accidentally detected, with C57BL/6J wild-type mice. Maintenance and reproduction of the colony was carried out by crossing mutant animals with each other from the same litter.

Experimental and control (Bla/J, n=20; C57BL/6J, n=10 and n=13) animals were kept in a pathogen-free vivarium of Belgorod State National Research University under conditions of artificially regulated

daylight hours (12 hours of darkness and 12 hours of daylight) at the temperatures from +22 to +26°C, and had a free access to food and water. The work was guided by ethical principles for the treatment of laboratory animals in accordance with the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes (ETS No 170). All painful manipulations with the animals were carried out in accordance with regulatory standards: Directive 2010/63/EU of the European Parliament and of the Council of the European Union dated September 22, 2010 on the protection of the animals used for scientific purposes. Experimental studies were approved by the Bioethical Commission of Belgorod State National Research University (protocol No. 15/10 dated 2021 Oct 29). Vivisection was carried out in accordance with the ethical principles for the treatment of laboratory animals as set out in the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes (CETS No. 123).

Behavioral tests were carried out mainly in the morning hours with fixed "home" lighting (to minimize the stress factor). Representative groups of the experimental animals were formed (homozygous knockouts – Bla/J, n=20). The groups were tested at two age points – 12 and 24 weeks – and the control animals without a genome modification (WT, n=10 and 13, respectively).

Inverted Grid Test

The inverted grid is a 45×45 cm wire grid with a mesh size of 12×12 mm and a wire diameter of 1 mm, surrounded by a 4 cm partition preventing a mouse from attempting to climb over to the other side. The test is used to assess the coordination of movements and muscle strength of both pairs of limbs. The mice were placed in the center of a wire grid, which was inverted and placed 50 cm above a soft surface. The fall time of the animal was recorded or the animal was removed from the grid if the time reached 180 sec. The test was evaluated in points: the more time the animal managed to hold on the higher its score was [16–18].

Grip strength test

The setup was a stainless-steel grid connected to a sensor to measure the grip strength (in grams) of a mouse's forelimbs. The animal was allowed to grasp a horizontal grid with its front paws, and then the mouse was pulled back by the tail until its grip was weakened,

while the hind legs of the mouse should not touch the grid. The force measurement sensor stored the peak value of the thrust force. The test was used to study the function of the neuromuscular system. For the analysis, the mean values from 5 successful measurements of the forelimbs strength were used [19, 20].

Wire Hanging test

The test was based on the instinct of mice to avoid falling. The mouse was placed on a horizontally stretched wire with the capture of all four limbs (the diameter of 3 mm, the height above the surface of 60 cm). The ability to stay on the wire was measured by evaluating the time the mouse had been held until the moment of falling, using a stopwatch timer. The best result of two attempts was taken as the final value, the pause between which was 20 min [21, 22].

Weight-loaded swimming test

A physical performance of the animals in this test was assessed by the swimming duration with a load, which was 5% of the body weight (the weight of the load had been found out experimentally), attached to the root of the animal's tail with a rubber bandage. The weight of the animals was determined with an accuracy of 0.1 g; the load was selected with an accuracy of 0.01 g. The duration of testing (swimming) was recorded using a stopwatch timer with an accuracy of 1 sec. The end of the experiment was considered the moment of the animal's fatigue, the sign of which was the animal's inability to rise to the water surface within 5 seconds or a refusal to swim (submersion to the bottom for more than 5 sec). A sign of the animal's fatigue was a violation of the motor-coordination function (rotation around its axis and falling on its side in the water column).

Swimming was carried out in organic glass vessels with an inner diameter of 30 cm and a height of 60 cm. The height of the water column was 30 cm, and the water temperature was 23±1°C [23, 24].

Vertical Pole test

In the studies on laboratory animals for screening and assessing the safety of physical performance, this technique was mainly used. The setup consists of a tripod with a diameter of 7 mm and a height of 60 cm, with a plastic fence installed on the top. For the experiment, the animal was placed at the same distance from the top of the tripod strictly upside down, at least 1 m above the floor. The time of the animal's fall from the tripod using a

stopwatch, was recorded. The preservation of a physical performance was judged by comparison with the control group [25].

Genotyping of transgenic animals

For the analysis, genomic DNA was obtained by ear biopsy (about 30 mg of tissue). The biopsy material was placed in a lysing solution containing 100 mM of sodium chloride, 50 mM Tris-HCl (pH 8.0), 2 mM ethylenediaminetetraacetic acid (EDTA), and 2 mg/ml of proteinase K. The material was incubated at 55°C for 12–16 h, after that the reaction mixture was heated at 85°C for 40 min. The lysate was centrifuged using a Thermo SL16R laboratory centrifuge (Thermo Scientific, USA) for 1 min at 10,000 g, and 1 µl of the supernatant was used as a template in the PCR reaction.

Primer sequences from the JAX protocol (Protocol 26095) were used. They simultaneously amplified the retrotranspason area (if present) and the animal genomic DNA area. A mixture of 3 primers was used in the reaction:

1) reverse primer DYSF-R (5': CTT CAC TGG GAA GTA TGT CG), homologous to the sense strand sequence of intron 4 of the DYSF gene, is common;

2) forward primer DYSF-F (5': TTC CTC TCT TGT CGG TCT AG), homologous to the sequence of the antisense strand of intron 4 of the DYSF gene, is common;

3) specific forward primer ETn-oR (5': GCC TTG ATC AGA GTA ACT GTC), homologous to the sequence of long terminal repeats (3'LTR) in the retrotransposon inserted into intron 4.

The reaction mixture contained 1x Taq Turbo buffer (Evrogen, Russia), 0.2 mM of each dNTP (Evrogen, Russia), 0.5 µM of each forward primer and 1 µM of common reverse primer, 2 units of HS Taq DNA polymerase (Evrogen, Russia). The amplification program consisted of the following steps:

1. Activation of HS Taq DNA polymerase at 95°C for 3 min;

2. Denaturation – at 95°C for 20 sec;

3. Annealing – at 60°C for 20 sec;

4. Elongation – at 72°C for 20 sec;

5. Cyclic repetition of steps 2–4 – 30 times;

6. Final elongation – at 72°C for 2 min.

Amplification products were separated by electrophoresis in 3% agarose gel in 1x TAE buffer (40 mM Tris-HCl, 20 mM acetic acid, 1 mM EDTA, 0.5 µg/ml ethidium bromide) at 90 V for 60 min.

Figure 1 – Scheme of primers position for amplification of genomic area (wild type) and 3'LTR area of retrotransposon (mutant)
Note: WT – wild type; DYSF-F – common forward primer; DYSF-R – common reverse primer; ETn-OR – forward primer homologous to 3'LTR area of retrotransposon; 5'LTR, 5' – long terminal repeats; 3'LTR – 3' – long terminal repeats.

Figure 2 – Detection of retrotransposon presence in Bla/J mice by PCR
Note: product size WT (wild type) is 204 bps; product size Bla/J 237 – bps; NTC – negative control without template.

Figure 3 – Physiological parameters of Bla/J mice
Note: the analysis of forelimbs grip strength in the "Grip strength test" (A and B), endurance in the "Weight-loaded swimming test" (C and D), physical performance in the "Wire Hanging test" (E and F) and the "Vertical Pole test" (G and H), coordination of movements and limbs muscle strength in the "Inverted Grid test" (K and L). Experimental Bla/J and control mice without a genome modification (WT) were tested at the age of 12 (A, C, E, G, K) and 24 weeks (B, D, F, H, L). Medians and a standard error of the mean are presented, the number of animals is indicated at the bottom of the corresponding column. Samples were tested for normality, and statistical significance was assessed using the Mann-Whitney U-test (**$p < 0.01$; ***$p < 0.0004$, ****$p < 0.0001$).

Figure 4 – Immunofluorescent reaction with antibodies to dysferlin
Note: A – C57Bl mouse; B –line Bla/J mouse. Red color – detectable dysferlin of sarcoplasmic localization, blue color – nuclei. Finishing dyeing: DAPI. Magnification ×200

Figure 5 – Striated skeletal muscle tissue of studied animals
Note: A – control, C57Bl; B–D – Bla / J. 1 – endomysial and perimysial edema; 2 – fibers with centrally located nuclei;
3 – lympho-macrophage infiltration around necrotic muscle fibers; 4 – necrotic muscle fibers, incl. macrophage invasion;
5 – rounded muscle fibers. Colour: eosin. Magnification: A–C ×200, D ×400

Figure 6 – Morphometric parameters of striated skeletal muscle tissue of Bla/J mice at 12 and 24 weeks of age
Note: A – proportion of necrotic muscle fibers; B – Average cross-sectional area of muscle fibers; C – proportion of central nuclear muscle fibers (CNMFs); D – proportion of connective tissue in skeletal muscle (*p < 0.05)

Pathological examination

The material included tissue fragments of *M. gastrocnemius medialis* (Gas M), *M. gastrocnemius lateralis* (Gas L), and *M. tibialis* (tib) skeletal muscles obtained from Bla/J mice and wild-type mice (WT) with a functional DYSF gene. The cryopreserved material was transferred to the chamber of a Thermo Fisher Scientific HM525 NX cryostat (USA), where it was oriented on a freezing platform in a mounting gel NEG-50 (Richard-Allan Scientific, TS, USA). The sections obtained were 3–7 microns thick. The slides with cryosections were fixed in 10% neutral buffered formalin (Biovitrum, Russia) for 10 min. Next, they were washed 3 times for 5 min in a Tris-HCL buffer solution pH 7.4 (Nevareaktiv,

Russia); Background Block solution (Cell Marque, USA) was applied, the cryosections were transferred to a humid chamber, where they were incubated for 1 h. The protein block was removed by swiping, then primary recombinant rabbit monoclonal antibodies were applied to dysferlin (clone: JAI-1-49-3; ab124684; Abcam, UK) diluted 1:200 with Diamond: Antibody Diluent (Cell Marque, 938B-05, USA), in which cryosections were kept for 2 h at room temperature in a humid chamber. Over time, the sections were washed three times in a Tris-HCL buffer solution, after which a 1-hour incubation was performed at room temperature in a humid chamber with secondary goat anti-rabbit IgG H&L antibodies (Alexa Fluor 555, abcam, ab150078, UK) diluted in the

ratio of 1:500 with Diamond:Antibody Diluent. After an hour, the sections were washed 4 times in a Tris-HCL buffer solution and incubated in a DAPI working solution (Thermo FS, D1306, USA) for 10 min. The conclusion was carried out in the mounting medium of glycerogel according to Kaiser.

For the paraffin sections manufacturing, after fixation, the tissue material was subjected to standard histological wiring, paraffin embedding, and microtoming. After deparaffinization, the sections were stained with hematoxylin and eosin according to the standard method. Photodocumentation was carried out using a computer video system (IBM PC + Leica DM 1000 microscope, Germany) and the ImageScope-M software package (Russia).

Based on the previous studies [26, 27], the estimated parameters for morphometry were chosen: the cross-sectional area of the muscle fiber, as well as the number of fibers with an internalized nucleus and the number of necrosis in relation to the total number of fibers in the field of view.

Statistical processing

Statistical processing was performed using GraphPad Prism Software 8.0 (GraphPad Software Inc, USA). Depending on the feature distribution type and equality of variances, the significance of the results obtained was assessed using a parametric (ANOVA) or nonparametric (Kruskal-Wallis test) one-way analysis of variance, and unpaired Student's t-test was used as a post-hoc analysis to identify differences in intergroup comparisons, the Mann-Whitney test, respectively, with a Benjamini-Hochberg correction for multiple hypothesis testing. The results were considered significant at p ≤0.05.

RESULTS

To form representative groups of experimental and control animals synchronized by age, first the number of related sires corresponding to the objectives of the experiment were received. Crossing of homozygous mice with a mutation was performed with mice of the same genotype against the same genetic background obtained in the previous crosses. The offspring were genotyped by conventional PCR using three primers, one of which is specific for the mutation.

A schematic representation of the primers position for the amplification of the inserted retrotranspase is shown in Fig. 1.

In mutant mice, a retrotransposon larger than 6k bps was inserted into the fourth intron of the DYSF gene, which made it possible to use a system of three primers to identify a localized mutation in the allele. DYSF-F is homologous to the genomic sequence area

of the intron located before the insertion sequence of the retrotransposon. Due to this, in case of the primer annealing on the mutant allele, the synthesized chain will not have time to amplify to the area homologous to the reverse primer – an amplicon with a size of more than 6 thousand bps will not form and accumulate in large numbers during PCR. ETn-oR is homologous to the retrotransposon area in the long terminal repeats (on the 3' LTR side). In combination with the reverse primer DYSF-F, which is homologous to the area of the intron genomic sequence that makes it possible for 193 nucleotide pairs to be flanked. This arrangement of primers led to the successful separation of mutant and wild type animals because of conventional PCR (Fig. 2) [28, 29].

Ho M. et al showed the insertion of a retrotransposon into a certain area of intron 4 (495 base pairs from exon 4 and about 4400 base pairs (bps) to exon 5) with a substitution of 6 bps [30]. The results of the genotyping confirmed the presence of the mutation in the homozygous form of the studied animals.

As a result of the amplification of wild-type animals images, a fragment of 204 bps was formed. In Bla/J animals homozygous for the mutant allele, a fragment 237 bps long was formed after the amplification of the DYSF gene sequence (marker 100+bp DNA Ladder).

To study a motor function, representative groups of experimental animals (homozygous knockouts – Bla/J) (n=20) were formed, the groups were tested at two age points – of 12 and 24 weeks and control animals without a genome modification (WT) (n=10 and n=13, respectively).

In the Grip Strength test, forelimb strength was significantly reduced in control mice compared to Bla/J mice at both age points (Fig. 3 A and B). In the Weight-loaded swimming test (Fig. 3 C and D), a difference was found out between the control and experimental mice at the age of 24 weeks and 12 weeks, respectively. This indicated a decrease in the endurance of mice at the age of 24 weeks with developing pathology.

The following physical performance tests were carried out: "Wire Hanging test" (Fig. 3 E and F) and "Vertical Pole test" (Fig. 3 G and H). As a result of the tests, it was found out that at the age of 24 weeks, there was a decrease in the physical performance of the Bla/J line mice compared to the C57BL/6J line.

In the "Inverted grid test" in the animals of both groups (Fig. 3 K and L), the coordination of movements and muscle strength of the limbs did not differ statistically significantly. Thus, in these age marks, the studied indicators did not change.

When setting up immunofluorescent reactions with antibodies to the dysferlin protein in the samples of

mutant animals, this protein was not detected; in the control tissues, sarcolemmal localization of dysferlin was detected, which corresponds to the canonical descriptions for skeletal muscle tissue (Fig. 4).

Histopathologically studied muscle tissue in the research of transverse sections was characterized by an age-related increase in the myopathic pattern and a violation of the tissue architecture. In contrast to the transverse sections of the WT mice muscle tissue, the fibers of the evaluated animals were characterized by polymorphism in cross sections and different sizes. In addition, compared to the WT mice, the cross section of Bla/J had a larger diameter: the so-called round muscle fibers were present in a significant amount. The muscle tissue of the studied animals was characterized by necrosis of single muscle fibers, the number of which increased by the age of 24 weeks. Around focal necrosis, accumulation of leukocytes can be notified, as well as invasion of macrophages under the basement membrane of the fiber and phagocytosis of the anesthetized part of the sarcoplasm. An important diagnostic criterion was a pronounced number of fibers with centrally located nuclei (central muscle fibers), which is interpreted in the scientific literature as a cytoskeleton destruction of the muscle fibers and/or an active regeneration process with the appearance of muscle tubules.

Attention is drawn to the edema of the endomysium and perimysium, as well as mild lymphomacrophage infiltration (Fig. 5). With an increase in the life expectancy of mutant animals, hyperplasia of the endomysium and perimysium was notified, which was expressed in an increase in the proportion of connective tissue in the composition of the muscular organ (Fig. 6).

A morphometric evaluation and statistical processing of the main tissue parameters revealed significant differences in the number of necrotic muscle fibers in WT mice, both when comparing the index at 12 and 24 weeks of age, and between the animal lines. Significant intra- and intergroup differences were established in terms of indicators: the proportion of central nuclear muscle fibers, the average cross-sectional area of the muscle fibers and the proportion of connective tissue (Fig. 6). As shown by the previous studies, an increase in the cross section of the muscle fibers should be considered as compensatory working hypertrophy due to the death of some of the structural units of the muscle. With a longer period of the animals observation, a breakdown of this process and a gradual atrophy of the muscle were established, which was later accompanied by a decrease in this indicator.

DISCUSSION

The identification of a representative *in vivo* model of dysferlinopathy is important for the search for new therapeutic targets and the study of the pharmacological activity of new drugs aimed at treating this pathology. Major mouse strains of dysferlinopathy with a complete lack of a dysferlin expression include the A/J$^{dysf-/-}$ (A/J), SJL/J$^{dysf-/-}$ (SJL/J), and BLA/J$^{dysf-/-}$ (BLAJ; B6.A) animal strains. (Dysf^{prmd}/GeneJ), which have similar, with minor changes, phenotypic manifestations of the disease [31] and pronounced histopathology [32].

The studies examining a muscle function in the mice lacking a dysferlin (Dysf$^{-/-}$) expression, have shown conflicting results. The lack of a sufficient repeatability and reproducibility of preclinical studies characterizing diferlinopathic mouse strains, may be partly due to the differences in a disease severity and phenotypic manifestations in specific strains of Dysf$^{-/-}$ mice of different origins and/or the lack of suitable control colonies of wild-type mice for their comparison [33].

In the course of this study, representative groups of experimental (homozygous Dysf$^{-/-}$ – Bla/J knockouts) and control animals (C57Bl/6), age-synchronized, which were further genotyped by conventional PCR, were formed. The authors used primer sequences from the JAX protocol (Protocol 26095), which simultaneously amplify the retrotranspason area (if present) and the animals' genomic DNA area. The absence of a DYSF gene expression in Bla/J mice led to muscular dystrophy, as a result of which the disease began to develop from the 12th week of life of the animal, and the peak of phenotepic manifestations could be observed at the 24th week.

When conducting behavioral testing, the authors showed that a physical activity and endurance of the studied animals decreases with age in comparison with the control group. This is confirmed by the "Grip Strength test", in which the indicators decreased in comparison with the control by 22.2% at 12 weeks, by 25.1% at 24 weeks and by 9.5% between the experimental groups at two age points (54.47±2.659 and 49.27±1.157, respectively). When conducting the "Weight-loaded swimming test", a difference was revealed in comparison with the control by 32.3% at 12 weeks, by 50.5% at 24 weeks and by 53.3% between the experimental groups at two age points (393.6±59.26 and 183.8±24.94). The preservation of physical performance was checked using the following tests: The "Wire Hanging test" (68.00± 8.809; 31.81±3.637) and the "Vertical Pole test" (13.67 ±1.875), which showed a decrease in results of the studied animals at 24 weeks compared with the control by 64.4% and 82.9%, respectively. The data on the criteria for the coordination of movements and muscle strength of the limbs, studied in the "Inverted Grid test", did not change at these ages.

The results obtained in the course of behavioral testing, i.e., a decrease in the grip strength of the forelimbs and a decrease in physical endurance with age, reflect the progression of the underlying muscle disease in the studied animals. Based on this, it can be concluded that the studied experimental model describes the clinical picture of dysferlinopathy in patients with this disease.

The histological study also showed that with an increase in the life expectancy of mutant animals, hyperplasia of endomysium and perimysium was notified. That was expressed in an increase in the proportion of connective tissue in the composition of the muscular organ. Significant intra- and intergroup differences were established in terms of indicators: the proportion of central nuclear muscle fibers; the average cross-sectional area of muscle fibers; the proportion of connective tissue. As shown by the previous studies, an increase in the cross section of muscle fibers should be considered as compensatory working hypertrophy due to the death of some of the structural units of the muscle. With a longer period of observation, a breakdown of this process and gradual muscle atrophy were established, which was subsequently accompanied by a decrease in this indicator.

CONCLUSION

Using such tests, like: "Inverted Grid", "Grip strength", "Wire Hanging test", "Weight-loaded swimming", "Vertical Pole test", it was found out that the lack of $Dysf^{-/-}$ gene expression in the mice subline Bla/J B6.A-Dysf^{prmd}/GeneJ (Bla/J), can lead to muscular dystrophy. This pathology had been manifesting itself from the beginning of the disease development of phenotypic manifestations since the 12th week of life. The peak of phenotypic manifestations occurred at the 24th week of the animals' life. Histopathological phenotypic manifestations of the disease are generally non-specific and consistent with the data of intravital pathological examination in patients with diferlinopathy.

B6.A-Dysf^{prmd}/GeneJ (Bla/J) subline mice are a representative model of dysferlinopathy and can be used to evaluate new therapeutic agents for this disease treatment.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHORS' CONTRIBUTION

Mikhail V. Korokin – article writing, research design development; Elena V. Kuzubova – assessment and conduct of behavioral tests, results interpretation; Alexandra I. Radchenko – evaluation and conduct of behavioral tests, article writing; Kirill D. Chaprov – article writing, results interpreting; Alexey V. Deikin – literature analysis; Nikita S. Zhunusov – preparation of animals cohorts, gene therapy; Anastasia M. Krayushkina – preparation of animals cohorts, gene therapy; Natalya V. Ekimova – formalization of references list, observation and care of animals, animals handling; Olesya A. Puchenkova – histological examination sampling; Roman V. Deev – consultation on planning, methodology and experiment implementation; Sergey N. Bardakov – literature analysis; Olga N. Chernova – sample preparation for histological examination, morphological description of muscle tissue sections; Vladimir M. Pokrovsky – research planning, stages of experimental work planning; Ivan A. Yakovlev – design development and research program writing; Alexey M. Emelin – sample preparation for histological examination, morphological description of muscle tissue sections; Igor S. Limaev – sample preparation of histological sections, working with graphic materials.

REFERENCES

1. Reash NF, James MK, Alfano LN, Mayhew AG, Jacobs M, Iammarino MA, Holsten S, Sakamoto C, Tateishi T, Yajima H, Duong T, de Wolf B, Gee R, Bharucha-Goebel DX, Bravver E, Mori-Yoshimura M, Bushby K, Rufibach LE, Straub V, Lowes LP; Jain COS Consortium. Comparison of strength testing modalities in dysferlinopathy. Muscle Nerve. 2022 Aug;66(2):159–66. DOI: 10.1002/mus.27570

2. Contreras-Cubas C, Barajas-Olmos F, Frayre-Martínez MI, Siordia-Reyes G, Guízar-Sánchez CC, García-Ortiz H, Orozco L, Baca V. Dysferlinopathy misdiagnosed with juvenile polymyositis in the pre-symptomatic stage of hyperCKemia: a case report and literature review. BMC Med Genomics. 2022;15(1):139. DOI: 10.1186/s12920-022-01284-y

3. Bardakov SN, Tsargush VA, Carlier PG, Nikitin SS, Kurbatov SA, Titova AA, Umakhanova ZR, Akhmedova PG, Magomedova RM, Zheleznyak IS, Emelyantsev AA, Berezhnaya EN, A Yakovlev I, Isaev AA, Deev RV. Magnetic resonance imaging pattern variability in dysferlinopathy. Acta Myol. 2021 Dec 31;40(4):158–71. DOI: 10.36185/2532-1900-059

4. Seo K, Kim EK, Choi J, Kim DS, Shin JH. Functional recovery of a novel knockin mouse model of dysferlinopathy by readthrough of nonsense mutation. Mol Ther Methods Clin Dev. 2021 May 1;21:702–9. DOI: 10.1016/j.omtm.2021.04.015

5. Kokubu Y, Nagino T, Sasa K, Oikawa T, Miyake K, Kume A, Fukuda M, Fuse H, Tozawa R, Sakurai H. Phenotypic Drug Screening for Dysferlinopathy Using Patient-Derived Induced Pluripotent Stem Cells. Stem Cells Transl Med. 2019 Oct;8(10):1017–29. DOI: 10.1002/sctm.18-0280

6. Korokin MV, Soldatov VO, Gudyrev OS, Koklin IS, Taran EI, Mishenin MO, Korokina LV, Kochkarov AA, Pokrovsky MV, Varaksin MV, Chupakhin ON. The role of cortisol metabolism in the realization of pathogenetic links in the development of osteoporosis – the rationale for the search for new pharmacotherapeutic targets (review). Research Results in Biomedicine. 2022;8(4):457–73. DOI: 10.18413/2658-6533-2022-8-4-0-5. Russian

7. Fanin M, Angelini C. Progress and challenges in diagnosis of dysferlinopathy. Muscle Nerve. 2016 Nov;54(5):821–35. DOI: 10.1002/mus.25367

8. Kuzubova EV, Radchenko AI, Pokrovsky VM, Patrakhanov EA, Novikova AA, Stepenko YuV, Deikin AV. Pathological conditions associated with tau protein: mechanisms of development and possible biological targets for pharmacological correction of tau proteinopathy (review). Research Results in Biomedicine. 2022;8(4):474–94. DOI: 10.18413/2658-6533-2022-8-4-0-6. Russian

9. Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M, Ashida A, Sakamoto C, Tateishi T, Yajima H, Canal A, Ollivier G, Decostre V, Mendez JB, Sánchez-Aguilera Praxedes N, Thiele S, Siener C, Shierbecker J, Florence JM, Vandevelde B, DeWolf B, Hutchence M, Gee R, Prügel J, Maron E, Hilsden H, Lochmüller H, Grieben U, Spuler S, Tesi Rocha C, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Harms M, Pestronk A, Krause S, Schreiber-Katz O, Walter MC, Paradas C, Hogrel JY, Stojkovic T, Takeda S, Mori-Yoshimura M, Bravver E, Sparks S, Díaz-Manera J, Bello L, Semplicini C, Pegoraro E, Mendell JR, Bushby K, Straub V; Jain COS Consortium. Assessment of disease progression in dysferlinopathy: A 1-year cohort study. Neurology. 2019 Jan 9;92(5):e461–74. DOI: 10.1212/WNL.0000000000006858

10. Harris E, Bladen CL, Mayhew A, James M, Bettinson K, Moore U, Smith FE, Rufibach L, Cnaan A, Bharucha-Goebel DX, Blamire AM, Bravver E, Carlier PG, Day JW, Díaz-Manera J, Eagle M, Grieben U, Harms M, Jones KJ, Lochmüller H, Mendell JR, Mori-Yoshimura M, Paradas C, Pegoraro E, Pestronk A, Salort-Campana E, Schreiber-Katz O, Semplicini C, Spuler S, Stojkovic T, Straub V, Takeda S, Rocha CT, Walter MC, Bushby K; Jain COS Consortium. The Clinical Outcome Study for dysferlinopathy: An international multicenter study. Neurol Genet. 2016 Aug 4;2(4):e89. DOI: 10.1212/NXG.0000000000000089

11. Jacobs MB, James MK, Lowes LP, Alfano LN, Eagle M, Muni Lofra R, Moore U, Feng J, Rufibach LE, Rose K, Duong T, Bello L, Pedrosa-Hernández I, Holsten S, Sakamoto C, Canal A, Sanchez-Aguilera Práxedes N, Thiele S, Siener C, Vandevelde B, DeWolf B, Maron E, Guglieri M, Hogrel JY, Blamire AM, Carlier PG, Spuler S, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Pestronk A, Walter MC, Paradas C, Stojkovic T, Mori-Yoshimura M, Bravver E, Díaz-Manera J, Pegoraro E, Mendell JR; Jain COS Consortium, Mayhew AG, Straub V. Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale. Ann Neurol. 2021 May;89(5):967–78. DOI: 10.1002/ana.26044

12. Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013;9(381):845-60. DOI: 10.1016/S0140-6736(12)61897-2

13. Crudele JM, Chamberlain JS. AAV-based gene therapies for the muscular dystrophies. Hum Mol Genet. 2019 Oct 1;28(R1):R102–R107. DOI: 10.1093/hmg/ddz128

14. Niewiadomski W, Palasz E, Skupinska M, Zylinski M, Steczkowska M, Gasiorowska A, Niewiadomska G, Riedel G. TracMouse: A computer aided movement analysis script for the mouse inverted horizontal grid test. Sci Rep. 2016 Dec 16;6:39331. DOI: 10.1038/srep39331

15. Lysikova EA, Chaprov KD. Knock-out of α-, β-, and γ-synuclein genes in mice leads to changes in the distribution of several lipids in the liver and blood plasma. Research Results in Biomedicine. 2022;8(4):448–56. DOI: 10.18413/2658-6533-2022-8-4-0-4. Russian

16. Chaprov KD, Teterina EV, Roman AY, Ivanova TA, Lysikova EA, Lytkina OA, Koroleva IV, Ovchinnikov RK, Kukharsky MS, Goloborshcheva VV, Kucheryanu VG, Morozov SG, Popova NI, Antohin AI. Comparative analysis of MPTP neurotoxicity in mice with a constitutive knockout of the α-synuclein gene. Molecular Biology. 2021;55(1):133–42. DOI: 10.31857/S0026898421010031. Russian

17. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, Van Der Meulen JH, Cha HJ, Pistilli EE, Partridge TA, Hoffman EP, Nagaraju K. Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve. 2009 May;39(5):591–602. DOI: 10.1002/mus.21211

18. Reeves SL, Fleming KE, Zhang L, Scimemi A. M-Track: A New Software for Automated Detection of Grooming Trajectories in Mice. PLoS Comput Biol. 2016 Sep 16;12(9):e1005115. DOI: 10.1371/journal.pcbi.1005115

19. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, Danning C, Wada R, Thompson C, Bahtiyar G, Craft J, Hooft Van Huijsduijnen R, Plotz P. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9209–14. DOI: 10.1073/pnas.97.16.9209

20. García-Campos P, Báez-Matus X, Jara-Gutiérrez C, Paz-Araos M, Astorga C, Cea LA, Rodríguez V, Bevilacqua JA, Caviedes P, Cárdenas AM. N-Acetylcysteine Reduces Skeletal Muscles Oxidative Stress and Improves Grip Strength in Dysferlin-Deficient Bla/J Mice. Int J Mol Sci. 2020 Jun 16;21(12):4293. DOI: 10.3390/ijms21124293

21. Veniaminova E, Oplatchikova M, Bettendorff L, Kotenkova E, Lysko A, Vasilevskaya E, Kalueff AV, Fedulova L, Umriukhin A, Lesch KP, Anthony DC, Strekalova T. Prefrontal cortex inflammation and liver pathologies accompany cognitive and motor deficits following Western diet consumption in non-obese female mice. Life Sci. 2020 Jan 15;241:117163. DOI: 10.1016/j.lfs.2019.117163

22. Spasov AA, Maltsev DV, Miroshnikov MV, Skripka MO, Sultanova KT, Zhukovskaya ON, Morkovnik AS. Anxiolytic activity of 11H-2,3,4,5-tetrahydro[1,3] diazepino[1,2-A]benzimidazole and 2-mercaptoben-zimizadole derivatives. Russian Journal of Bioorganic Chemistry. 2020;46(1):107–14. DOI: 10.31857/S0132342320010145. Russian

23. Polyakova LV, Zhukova ES, Irkaeva AM, Chugunova VV, Shcherbatyuk TG, Pozdnyakova MA, Umnyagina IA. The concept of using the test "forced swimming with a load" for experimental modeling of the labor process on laboratory animals. Abstracts of the Ninth Conference of Specialists in Laboratory Animals Rus-LASA, Laboratory animals for science. 2021; 4. DOI: 10.29296/2618723X-RusLASA2021-06. Russian

24. Zaytseva MS, Ivanov DG, Alexandrovskaya NV The rat work capacity in forced swimming test with load and causes it variability. Journal Biomed. 2015;1(4):30–42. (In Russian)

25. Shustov EB, Novikov VS, Berzin IA, Kim AE, Bolotova VT. Functional sports nutrition for martial athletes: design and performance criteria. Journal Biomed. 2017;(1):10–23. Russian

26. Chernova ON, Chekmareva IA, Mavlikeev MO, Yakovlev IA, Kiyasov AP, Deev RV. Structural and ultrastructural changes in the skeletal muscles of dysferlin-deficient mice during postnatal ontogenesis. Ultrastruct Pathol. 2022 Jul 4;46(4):359–67. DOI: 10.1080/01913123.2022.2105464

27. Chernova ON, Mavlikeev MO, Kiyasov AP, Bozo IY, Deev RV. Reactive Changes in Elements of Stromal-Vascular Differons of Dysferlin-Deficient Skeletal Muscles after Procaine Injection. Bull Exp Biol Med. 2021 Mar;170(5):677–81. DOI: 10.1007/s10517-021-05131-5

28. Chakravorty S, Nallamilli BRR, Khadilkar SV, Singla MB, Bhutada A, Dastur R, Gaitonde PS, Rufibach LE, Gloster L, Hegde M. Clinical and Genomic Evaluation of 207 Genetic Myopathies in the Indian Subcontinent. Front Neurol. 2020 Nov 5;11:559327. DOI: 10.3389/fneur.2020.559327

29. Khukharevaa DD, Gusevaa KD, Sukhanovaa IuA, Sebentsovab EA, Levitskaya NG. Physiological effects of acute neonatal normobaric hypoxia in C57BL/6 mice IP Pavlov Journal of Higher Nervous Activity. 2020;70(4): 515–27. DOI: 10.31857/S0044467720040048

30. Ho M, Post CM, Donahue LR, Lidov HG, Bronson RT, Goolsby H, Watkins SC, Cox GA, Brown RH Jr. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet. 2004 Sep 15;13(18):1999-2010. DOI: 10.1093/hmg/ddh212

31. Hornsey MA, Laval SH, Barresi R, Lochmüller H, Bushby K. Muscular dystrophy in dysferlin-deficient mouse models. Neuromuscul Disord. 2013 May;23(5):377-87. DOI: 10.1016/j.nmd.2013.02.004

32. Grounds MD, Terrill JR, Radley-Crabb HG, Robertson T, Papadimitriou J, Spuler S, Shavlakadze T. Lipid accumulation in dysferlin-deficient muscles. Am J Pathol. 2014 Jun;184(6):1668–76. DOI: 10.1016/j.ajpath.2014.02.005

33. Lloyd EM, Xu H, Murphy RM, Grounds MD, Pinniger GJ. Dysferlin-deficiency has greater impact on function of slow muscles, compared with fast, in aged BLAJ mice. PLoS One. 2019 Apr 10;14(4):e0214908. DOI: 10.1371/journal.pone.0214908

AUTHORS

Mikhail V. Korokin – Doctor of Sciences (Medicine), Associate Professor of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University. ORCID ID: 0000-0001-5402-0697. E-mail: korokin@bsu.edu.ru

Elena V. Kuzubova – Junior Researcher, Laboratory of Genetic Technologies and Gene Editing for Biomedicine and Veterinary Medicine, Belgorod State National Research University. ORCID ID: 0000-0003-2425-5027. E-mail: 1015artek1015@mail.ru

Alexandra I. Radchenko – Junior Researcher of Laboratory of Genetic Technologies and Gene Editing for Biomedicine and Veterinary Medicine, Belgorod State National Research University. ORCID ID: 0000-0002-4554-2116. E-mail: sandrinkaradchenko@gmail.com

Roman V. Deev – Candidate of Sciences (Medicine), Associate Professor, Acting Head of the Department of Pathological Anatomy, North-Western State Medical University named after I.I. Mechnikov; Director for Science, PJSC Human Stem Cell Institute. ORCID ID: 0000-0001-8389-3841. E-mail: romdey@gmail.com

Ivan A. Yakovlev – General Director of LLC "Genotarget". ORCID ID: 0000-0001-8127-4078. E-mail: ivan@ivan-ya.ru

Aleksey V. Deikin – Candidate of Sciences (Biology), Associate Professor of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University. ORCID ID: 0000-0001-9960-0863. E-mail: alexei@deikin.ru

Nikita S. Zhunusov – Assistant of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University. ORCID ID: 0000-0002-1969-3615. E-mail: nzhunu@mail.ru

Anastasia M. Krayushkina – Assistant of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University. ORCID ID: 0000-0002-6830-3820. E-mail: krayushkina_2016@mail.ru

Vladimir M. Pokrovsky – Assistant of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University. ORCID ID: 0000-0002-1493-3376. E-mail: pokrovskiy@bsu.edu.ru

Olesya A. Puchenkova – Resident of the Medical Institute, Belgorod State National Research University. ORCID ID: 0000-0002-7657-0937. E-mail: lesya759@yandex.ru

Kirill D. Chaprov – Junior Researcher of Laboratory for Modeling and Gene Therapy of Human Diseases, Belgorod State National Research University; Junior Researcher of Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian

Academy of Sciences (IPAC RAS). ORCID ID: 0000-0002-0258-1879. E-mail: chapkir@gmail.com

Natalya V. Ekimova – Assistant of the Department of Pharmacology and Clinical Pharmacology, Belgorod State National Research University. ORCID ID: 0000-0002-3629-048X. E-mail: ekimova@bsu.edu.ru

Sergey N. Bardakov – Neurologist, Lecturer of the Department of Nervous Diseases, S.M. Kirov Military Medical Academy. ORCID ID: 0000-0002-3804-6245. E-mail: epistaxis@mail.ru

Olga N. Chernova – Assistant of the Department of Human Morphology, North-Western State Medical University named after I.I. Mechnikov. ORCID ID: 0000-0001-6310-9319. E-mail: olgachernova92@yandex.ru

Aleksey M. Emelin – Assistant of the Department of Pathological Anatomy, North-Western State Medical University n. a. I.I. Mechnikov; Postgraduate Student of the Department of Pathological Anatomy, Belgorod State National Research University. ORCID ID: 0000-0003-4109-0105. E-mail: eamar40rn@gmail.com

Igor S. Limaev – Senior Assistant of the Department of Pathological Anatomy, North-Western State Medical University n. a. I.I. Mechnikov. ORCID ID: 0000-0002-0994-9787. E-mail: ig.limaev@gmail.com